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Abstrat
In this thesis a new randomisation designs for linial trials, alled patient-oriented ran-
domisation design, is introdued. This design was developed to ounter problems of `las-
sial' randomised ontrolled trials omparing strategies (onsisting of dierent treatments
in eah strategy) in presene of heterogeneity in patient-drug-interations. The disrep-
anies between daily linial pereption and results of randomised ontrolled trials lead to
the onvition that the methodologial approah of `lassial' randomised ontrolled trials,
suh as the blok randomisation design, is appropriate in this set-up. The patient-oriented
approah of the `CUtLASS' design reets everyday linial pratie, by allowing for a
patient-oriented hoie of one treatment of eah strategy. The alloation for a strategy is
random. However, the results are highly dependent on the physiians' preferenes. The
goal of the design desribed here is to take an intermediate path between randomised on-
trolled trials and the `CUtLASS' design. The idea of the new trial design is to randomise
two treatment pairs eah onsisting of one treatment of the one strategy and one treat-
ment of the other strategy in a rst step and subsequently, to involve the investigators
in deiding for a pair most appropriate to the patients' needs and then to randomise the
alloation to one treatment of that hosen pair.
After a short introdution, in Chapter 2 basi denitions and notations are given. The
onsiderations onentrate on the properties of the patient-oriented randomisation design
whih depend mainly on the number of treatments of eah strategy. An advantage of
the patient-oriented randomisation design (ompared to lassial randomisation designs)
is that in some ases a lear patient-oriented treatment deision of the physiian an be
seen and investigated.
The patient-oriented deision in the `CUtLASS' and the patient-oriented randomisation
design an lead to unbalaned treatment sample size in eah strategy. Chapter 3 investi-
gates the hanges of the alloation probability of eah treatment and determines the min-
imum and the maximum alloation probability in both designs. The investigation shows
that the interval of possible values of alloation probabilities is lager in the `CUtLASS'
design. However, the patient-oriented randomisation design ensures that eah treatment is
in fat administered in the study. Hene, it is possible to ompute the number of patients
needed to avoid poorly represented treatments and poorly powered omparisons.
After this, the pratial implementation of the patient-oriented randomisation design
are looked at and methods to estimate the probability of imbalane are presented. The
blok length of the patient-oriented randomisation design is large, hene, modiation for
the reation for the random list are possible and eetive to redue the probability of
imbalane.
Finally, Chapter 5 deals with a statistial model to ompare two strategies onsisting
of dierent treatments. Basi denitions and notations are given for unbalaned one-way
lassiation with xed eets and the onept of ontrasts. Additionally, the required
sample size alulation is presented. The power of the assoiated ontrast test depends
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partiularly on the alloation of sample size in eah treatment and the expeted eet
between both strategies. The nal onsideration shows that heterogeneity of patient-drug-
interation lead to no eet in the `Blok' design. Randomisation designs suh as the
`CUtLASS' design and the patient-oriented randomisation design only work as well as the
physiians seleting the treatments. In a patient-oriented randomisation design, it an
be distinguished between patients reeiving the treatment not only due to randomisation
but due to a patient-oriented deision of the physiian (patient-oriented treated patients)
and patients reeiving the treatment due to randomisation's reasons (randomised hoie
treated patients). Therefore, the patient-oriented randomisation design allows to test the
dierene in treatment means between patient-oriented treated patients and randomised
hoie treated patients in eah treatment, eah strategy, or overall. In partiular, the
possibility to analyse the dierene between strategies for subgroups onsisting of only
randomised hoie treated patients or only patient-oriented hoie treated patients help
to test the assumptions about the heterogeneity of patient-drug-interation in the patient-
oriented randomisation design. In the `CUtLASS' design, it is not possible to answer this
important question.
The onlusion onsists of a disussion of the results as well as important ndings. An
outlook on possible future work is also presented.
Zusammenfassung
In dieser Arbeit wird ein neues Randomisierungsverfahren für klinishe Studien einge-
führt, die patienten-orientierte Randomisierung bzw. im englishen patient-oriented ran-
domisation design. Dieses Verfahren wurde entwikelt, um dem Problem von klassis-
hen randomisierten, kontrollierten klinishen Studien entgegen zu wirken, die bei het-
erogener Patienten-Behandlungs-Wehselwirkung auftritt, wenn Strategien bestehend aus
vielen Therapiemöglihkeiten verglihen werden. Die Diskrepanz zwishen der täglihen
klinishen Wahrnehmung und den Ergebnissen von randomisierten und kontrollierten klin-
ishen Studien führt zu der Überzeugung, dass der methodishe Ansatz der klassishen
Randomisierungverfahren, wie der Blokrandomisierung, niht das geeignete Mittel für
die Untersuhung dieser Fragestellung ist. Es gibt bereits patienten-orientierte Ansätze,
wie das CUtLASS-Verfahren, um die täglihe klinishe Praxis wiederzuspiegeln. Hierbei
kann der Arzt innerhalb jeder Strategie eine Behandlung wählen und die Strategie, die
der Patient bekommen soll, wird anshlieÿend randomisiert. Jedoh hängen bei diesem
Verfahren die Resultate stark von der Arztentsheidung ab. Das Ziel des hier vorgestellten
Randomisierungsverfahrens ist ein Mittelweg zwishen dem Wunsh nah Randomisierung
wie in den randomisierten kontrollierten Studien und der ärztlihen Entsheidung wie im
CUtLASS-Design zu nehmen. Die Idee des neuen Randomisierungsverfahrens ist zwei
Behandlungspaare jeweils bestehtend aus einer Behandlung aus jeder Strategie im ersten
Shritt zu randomisieren. Anshlieÿend entsheidet der Arzt, welhes Paar zur Behandlung
des Patienten aufgrund seiner Krankengeshihte besser geeignet ist. Im zweiten Shritt
wird der Patient zu einer der zwei Behandlungen des gewählten Paars und damit zu einer
der beiden Strategien randomisiert.
Nah der Einleitung, werden in Kapitel 2 die wesentlihen Denitionen und Nota-
tionen gegeben, um im Weiteren die Eigenshaften des patienten-orientierten Ran-
domisierungsverfahrens zu untersuhen. Die Eigenshaften hängen hauptsählih von der
Anzahl der Behandlungen in beiden Strategien ab, daher sollte deren Festlegung bei der
Studienplanung wohlüberlegt sein. Ein Vorteil der patienten-orientierten Randomisierung
gegenüber den klassishen Randomisierungsverfahren ist, das in einigen Fällen eine klare
patienten-orientierte Entsheidung des Arztes zwishen zwei Behandlungen einer Strategie
beobahtet und untersuht werden kann.
Die patienten-orientierte Entsheidung im CUtLASS-Verfahren und im patienten-
orientierten Randomisierungsverfahren führt zu unbalanierten Behandlungsfallzahlen in
jeder Strategie. In Kapitel 3 werden die Veränderungen in der Allokationswahrshein-
lihkeit der einzelnen Behandlungen untersuht und die minimale und die maximale
Allokationswahrsheinlihkeit in beiden Verfahren bestimmt. Die Untersuhungen zeigen,
dass die Spannweite der möglihen Allokationswahrsheinlihkeiten im CUtLASS-
Verfahren breiter ist als im patienten-orientierten Randomisierungsverfahren. Dahingegen
sihert das patienten-orientierte Randomisierungsverfahren ab, dass jede Behandlung auh
tatsählih mit einem gewissen Prozentsatz in der Studie angewendet wird. Damit ist man
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bei der Planung der Studie in der Lage, die Fallzahl zu berehnen, um unterpresentierte
Behandlungen und unterpowerte Vergleihe zu vermeiden.
Shlieÿlih wird in Kapitel 5 ein statistishes Model vorgestellt, um zwei Strategien zu
vergleihen. Wesentlihe Denitionen und Notationen werden zur unbalanierten Ein-
fahklassikation und dem Konzept der Kontraste gegeben. Auÿerdem wird die er-
forderlihe Fallzahlplanung vorgestellt. Die Power des zugehörigen Kontrasttests hängt
unter anderem von der Gröÿe der Behandlungsfallzahlen und dem erwarteten Eekt zwis-
hen den Strategien ab. Die abshlieÿenden Betrahtungen zeigen, dass die Hetero-
genität in der Patienten-Behandlungs-Wehselwirkung dazu führen kann, das kein Ef-
fekt in der Blokrandomisierung zu beobahten ist. Die Untersuhungen zeigen aber
auh, dass die patienten-orientierten Verfahren, wie das CUtLASS-Verfahren oder das
patienten-orientierte Randomisierungsverfahren nur so gut sind, wie die Qualität der
patienten-orientierten Wahl es zulassen. Zusätzlih kann im patienten-orientierten Ran-
domisierungsverfahren zwishen Patienten untershieden werden, die die Behandlung nur
aufgrund des Randomisierungsprozesses erhalten (randomisiert behandelte Patienten) und
jenen, die die Behandlung neben dem Randomisierungsprozesses auh aufgrund der Arzt-
wahl erhalten haben (patienten-orientiert behandelte Patienten). Daher erlaubt das
patienten-orientierte Randomisierungsverfahren den Untershied zwishen randomisiert be-
handelten Patienten und patienten-orientiert behandelten Patienten in jeder Behandlung,
in jeder Strategie und in insgesamt zu testen. Insbesondere ist es möglih die Unter-
shiede zwishen den Strategien innerhalb von Subgruppen bestehend aus randomisiert
behandelten Patienten oder patienten-orientiert behandelten Patienten zu analysieren.
Damit können die Annahmen über die heterogene Patienten-Behandlungs-Wehselwirkung
im patienten-orientierten Randomisierungverfahren überprüft werden. Im CUtLASS-
Verfahren ist es niht möglih, diese wihtige Frage zu klären.
Die Arbeit shlieÿt mit einer Disskussion über die Resulte und einem Ausblik auf möglihe
weiterführende Forshungsthemen ab.
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CHAPTER 1
Introdution
1.1 Introdution
`The gold standard for linial studies is a randomised ontrolled trial (RCT) usually
omparing spei treatments, for example a new drug, a omparator drug or plaebo.
This omparison is espeially appropriate when eay and safety of new drugs are being
investigated. The proedure beomes more ompliated if the sienti problem expands
to strategy omparison, in whih eah strategy inludes various treatments.'(Shulz et al.,
2016a) Firstly, we desribe in the following setion the bakground and problems involving
strategy omparison in the psyhiatri researh eld to motivate the development of a
new linial trial design. Some parts of this setion have already been introdued in the
publiations Shulz et al. (2016a) and Shulz et al. (2016b) whih ontain an example of
the below presented trial design. These ontents are marked aordingly. Afterwards, we
have a general look at the problems and the onsequenes if we use other trial designs. In
the last setion of this hapter, we introdue the idea of a new linial trail design to solve
the problems and desribe the goal of this thesis.
1.2 Motivation and bakground
`The starting point for the development of this design is a debate in the psyhiatri om-
munity. Based on everyday pratie it is widely aepted that seond-generation antipsy-
hotis [...℄ are onsidered to be the treatment of hoie in the therapy of shizophreni dis-
orders (Gaebel et al., 2006, p. 82). However, the general superiority of [seond-generation
antipsyhotis℄ over the rst-generation antipsyhotis [...℄ ould not be learly demon-
strated in reent ontrolled linial trials suh as the European First Episode Shizophrenia
Trial (EUFEST), Clinial Antipsyhoti Trials of Intervention Eetiveness (CATIE) and
Cost Utility of the Latest Antipsyhoti drugs in Shizophrenia Study (CUtLASS)(Kahn
et al., 2008; Lieberman et al., 2005; Jones et al., 2006).'(Shulz et al., 2016a) The questions
why do the linial trials show results ontraditing pratial experiene and are either the
pratial experienes or the results of linial trials wrongly interpreted immediately arose.
No denite fault has been found with either. The methodologial problems of those trials
have been disussed by Naber and Lambert (2009) and Constantine and Tandon (2007). As
bakground, we onsider the advantages and disadvantages for a strategy deision (to use
seond-generation or rst-generation antipsyhotis) to see the problems of the suitability
of the methologial approah.
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`EUFEST is an open, randomised trial [omparing the eetiveness of haloperidol
to seond-generation antipsyhotis℄ in rst-episode shizophrenia. CATIE Phase 1 is a
double-blind trial omparing perphenazine with four [seond-generation antipsyhotis℄.
One disadvantage of both studies is that only one representative was hosen in the group
of [rst-generation antipsyhotis℄ to ompare both strategies. The overall CATIE study
design is more omplex and allowed for patients who had disontinued one antipsyhoti
study drug to enter subsequent phases (2 and later 3) of the study and reeive another
antipsyhoti study drug (Lieberman et al., 2005). Thus, the CATIE study is a repre-
sentative of the Sequential Multiple Assignment Randomised Trials (Dawson and Lavori,
2012; Lavori et al., 2000; Murphy, 2005), whose primary goal is to yield information for the
development of adaptive intervention strategies. A further goal is to ollet information on
andidate tailoring variables (Lei et al., 2012). This diers slightly from the goal of ompar-
ing two one-step strategies (whether to use [rst-generation℄ or to use [seond-generation
antipsyhotis℄). Thus, the CATIE study provided no lear answer to the question of
strategy omparison. It does, however, provide more evidene to liniians, patients, and
poliy makers that response to antipsyhoti drug treatment is heterogeneous. The indi-
vidual variations in response to mediations are likely due to multiple fators that may be
diult to eluidate (Stroup et al., 2007). [The problem is more omplex than a simple
randomised strategy omparison.℄ This diulty underlines an additional ondition im-
portant for [the new℄ design: the treatments even in one strategy perform dierently for
dierent patients, but subgroups whih might aount for these dierenes are not iden-
tiable. This implies that in a design with simple blok randomisation, suh as EUFEST
and CATIE Phase 1, the results from the responders and non-responders may anel eah
other out.
To measure the atual strategy eet [in pratie℄, the physiian should be involved
in the deision onerning trial treatment within eah strategy, taking risks and healing
opportunities of dierent drugs for eah patient into aount. This means using a design
lose to everyday pratie. Despite these points of ritiism, however, we must not re-
turn to mere observational studies, beause, in fat, randomisation is the only way that
eetively deals with the risk of bias by seletion and onfounding (Kleijnen et al., 1997).
The hallenge is to ombine the advantages of an RCT approah with the advantage of
taking the physiians' expertise appropriately into aount. [A℄ patient-oriented, straight-
forward RCT design for omparing two strategies in heterogeneous patient olletives was
implemented in the CUtLASS study (Jones et al., 2006).
The CUtLASS study is an open-label trial, in whih eah psyhiatrist hooses one
of 13 [rst-generation antipsyhotis℄ and one of four [seond-generation antipsyhotis℄
before randomisation to one of these drugs. This patient-oriented approah for treatment
seletion and without blinding is very lose to everyday pratie. However, the fat that
the physiian an freely hoose from a large number of mediations an lead to several
problems partly visible in the CUtLASS study. For an ideal situation, every physiian
should be as thoroughly knowledgeable and experiened as possible with all 17 drugs to be
able to deide objetively on the best treatment in eah strategy. In pratie however, the
physiians' preferenes are often based on previous positive experiene with a ertain drug
or on information gathered from ourses, literature or advertising. Thus the physiian may
miss the most eetive drug of a strategy olletion beause he has never used it or has
reeived misleading information (see also Korn and Baumrind (1998)). This seletion bias
will inuene the study.
A related problem is the distribution of patients to the drugs tested, espeially for the
[rst-generation antipsyhotis℄. Half of the patients in the [rst-generation antipsyhoti℄
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group reeived just one drug and only zero to three patients reeived any of the other nine
out of 13 drugs. The question arises why aren't the physiians using the full range of drugs
available. Theoretially, the drugs within both strategies should reet the real market
distribution. This is obviously not the ase. In the worst ase senario of the CUtLASS
design, however, only one treatment in one strategy may be seleted, resulting in a one-to-
many drug omparison suh as in EUFEST and CATIE, and not in a real omparison of
strategies with patient-oriented treatment. Thus, the physiians' preferenes may lead to
poorly represented and thus underpowered omparisons, espeially for new drugs or drugs
with hanged dosage or indiations. With studies of the CUtLASS design, the study yields
no evidene for drugs provided in the study design but not used. Furthermore, blinding
is an issue. In the CUtLASS study the physiians [knew℄ if they had given a drug not
belonging to their favoured strategy. This ourred in about 50% of ases.
In onlusion, the CUtLASS design already took a great step towards a more patient-
oriented approah to testing, while EUFEST and CATIE ontinue to represent the lassi-
al RCT approah, ensuring systemati omparisons independent of the physiian's pref-
erene.' Shulz et al. (2016a)
1.3 Problem
The previous setion desribes the motivation and bakground of the development of the
new linial trial design in ontext of the debate in the psyhiatri ommunity. However, we
will onentrate on the ore of our issue and asking what happens to strategy omparison
in presene of heterogeneity, if not all patients respond to the same drug equally well. Let
us onsider a hypothetial linial trial in whih we ompare two dierent strategies A and
B. Eah strategy onsists of two dierent treatments A1, A2 ∈ A and B1, B2 ∈ B. We also
suppose that we have two dierent population types P1 and P2 whose response behaviour
is given by Table 1.1.
Strategy Treatment
Response rate by
population
P1 P2
A A1 60% 20%
A2 20% 60%
B B1 40% 40%
B2 40% 40%
Table 1.1: Hypothetial response behaviour of two dierent populations P1 and P2 with
two strategies A (with treatments A1 and A2) and B (with treatments B1 and
B2).
In pratie, we don not know how many population types we have and how the treatments
perform in the dierent population types. In our example, the treatments of strategy
A work dierently in dierent populations. For the rst hypothetial implementation to
investigate the question of strategy omparison, we use a randomised trial with a blok
randomisation as used in EUFEST or CATIE. The blok length should be a multiple of four
and we assume that all treatments in all populations are balaned. The patients treated
with treatment A1 from strategy A have an average response rate of 40% and also the
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patients treated with treatment A2 have an average response rate of 40%. In total strategy
A has an average response rate of 40%. In the same way, we get an average response
rate of 40% for patients treated with treatments of strategy B. Finally, there are no
dierenes between both strategies, even though in both populations, there is a treatment
in A whih is superior to all treatments from B. Therefore, under an ideal patient- or
population-oriented treatment alloation (disregarding randomisation), one would expet
a better average response rate for A than for B. This is quite an artiial example, but
it demonstrates the danger of misleading results from randomised trials if heterogeneity is
not arefully onsidered.
For this reason, the introdutory question is how should we design a trial that is foused
on a strategy omparison in the presene of suh a heterogeneity of patient-drug-interation
if the relevant riteria in whih the patients dier are not yet identied.
If we investigate the same strategy omparison as before, but hange the randomisation
proess in suh a way that the physiians deide between the therapy within eah strategy
and randomise patients to one strategy as was done in CUtLASS, the result of the trial
depends on the physiians' deisions. Though the relevant riteria in whih the patients
dier are not yet identied, the physiians' deisions take the many partiular harater-
istis of their patients into aount. If we assume the best ase that physiians alloate
eah patient to the right population, all patients treated with treatment A1 ome from
population P1 and have a response rate of 60%. In the same way, patients treated with A2
will also have a response rate of 60%. In this trial, strategy A has an average response rate
of 60% in total. Sine we have no hanges in response of patients treated with strategy
B, we obtain the superiority of strategy A over B. This example shows that the idea of
patient-oriented deisions an handle heterogeneity. However, it has some disadvantages
when being implemented in the same way as in the CUtLASS study, e.g. seletion bias, no
representation of some treatments/omparisons and no progress of evidene, as mentioned
in the previous setion. Designs suh as CUtLASS only perform as well as the physiians
seleting the treatments. But the questions arise what are the hallenges to its internal
and external validity and how do we ritially evaluate the results of suh a trial (Shulz
et al., 2016b).
1.4 Idea and goal
In this thesis, we dene a new linial trial design to solve the problems outlined above.
`The goal of the new design desribed here is to take an intermediate path ombining the
advantages of both study types [(RCT and CUtLASS)℄ by randomising treatment pairs in
a rst step, involving the investigators in deiding for a pair most appropriate to the pa-
tients' needs (desribed below) and then randomising the alloation [double-blinded℄ to one
drug ([rst-generation℄ or [seond-generation antipsyhoti℄) of that hosen pair. Through
this proedure, the new design should reet everyday pratie better than EUFEST and
CATIE studies, as well as yielding more systemati omparisons than CUtLASS.'(Shulz
et al., 2016a) To emphasise the ombination of randomisation and patient-oriented deision,
we alled the new linial trial design 'patient-oriented randomisation'. This study design
ompares strategies based on patient-oriented hoie of physiians within eah strategy to
deal with the problem of heterogeneity. We assume that the knowledge of the physiian
about the patient and his medial history will lead to hoies of a more eetive treat-
ment than purely randomised alloation within eah strategy. Thus, the design reets
the daily linial therapy pratie without negleting the basi methods to avoid bias
randomisation and blinding.
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`The new design was implemented in the linial trial The Neurolepti Strategy Study
(NeSSy) omparing eay and safety of the strategies using either rst-generation or
seond-generation antipsyhotis in patients suering from shizophrenia. NeSSy was a
multi-entre, double-blind study in whih two rst-generation antipsyhotis and three
seond-generation antipsyhotis were used. It was onduted from April 2010 to August
2013 at 20 linial sites in Germany and was funded by the German Federal Ministry of
Eduation and Researh (BMBF).'(Shulz et al., 2016a)
The goal of this thesis is to investigate the new lass of trial designs introdued rstly
in the NeSSy study and to dedue general properties of this lass. Only in a few setions,
the NeSSy study is mentioned as an example.

CHAPTER 2
Patient-oriented randomisation
2.1 Introdution
In the following setion, the new trial design to ompare strategies onsisting of dierent
treatments will be introdued. We start with a general denition of the randomisation
proess and desribe every step with a random variable. Therefore, the onsiderations in
this setion onentrate on the properties of the design and the inuene of the number
of treatments on these properties. The deision how many treatments are seleted in
eah strategy has far-reahing onsequenes and should be arefully onsidered during the
planning phase of a linial trial with this patient-oriented randomisation design.
2.2 Denition
Denition 2.2.1 (Patient-oriented randomisation design for two strategies
PORk, l). Let A and B be two dierent therapy strategies with any number of treat-
ments k in strategy A and l in strategy B. A patient-oriented randomisation design for two
strategies PORk, l is dened as study design ontaining two steps of randomisation and one
patient-oriented deision of the physiian in the following order:
• In the rst step of randomisation, eah patient is assigned two pairs of treatment,
eah pair onsisting of one treatment of eah strategy.
• In the patient-oriented step, the physiian hooses one of the two previously ran-
domised pairs.
• In the seond step of randomisation, eah patient is randomised to one of the two
strategies A or B, i.e. to the respetive treatment of the seleted pair.
Remark.
• Thus, to enable the physiian to take a patient-oriented deision, at least two treat-
ments must be presented in one strategy. This design is symmetri in k and l. Hene,
without loss of generality, we assume 2 ≤ l and k ≤ l.
• The PORk, l design was rst implemented in the NeSSy study. The assoiated POR2, 3
design is therefore alled NeSSy design throughout this thesis.
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Notation.
• The treatments in strategy A are denoted by A1, A2, . . . , Ak and the treatments in
strategy B by B1, B2, . . . , Bl.
• A = {Ai | 1 ≤ i ≤ k} and B = {Bj | 1 ≤ j ≤ l, max(2,k) ≤ l} are non-empty and
ountable sets. Therefore, the power sets P(A) and P(B) are σ-elds and the tuples
(A,P(A)) and (B,P(B)) are measurable spaes.
Example (Pratial implementation). For a better understanding of the pratial im-
plementation, we onsider the ase k, l = 2 as an example. Sine we want to ompare two
dierent strategies, eah treatment in A is ompared to eah treatment in B. From the
four treatments A1, A2, B1 and B2 the pairs
(A1, B1), (A1, B2), (A2, B1) and (A2, B2)
an be formed. In the rst step of randomisation, two of these four pairs are randomly
seleted (random pair 1 and random pair 2). At this point, the physiian hooses the most
suitable of these two seleted pairs for his patient aording to eay and safety aspets.
In the seond randomisation step, the treatment strategy the patient is assigned to is
hosen randomly. Consequently, the spei treatment for the patient is now determined.
Neither patient nor physiian know the result of the seond randomisation step suh that
we have a double-blind randomisation. The randomisation proess is illustrated by Figure
2.1.
A1 B1
A1 B2
A2 B1
A2 B2
1
2
3
4
Pairs
1
A1 B1
4
A2 B2
Random Random
Pair 1 Pair 2
4
A2 B2
Random
Pair 2
A2
Random I
in mediation
pairs
Physiian
patient-oriented
deision
Random II
in strategy
(blinded)
Figure 2.1: Randomisation sheme desribed by a hypothetial example for the POR2,2
design.
2.3 Properties of PORk, l
Some of the following properties are results from set theory and ombinatoris and require
no proof (see for example Georgii (2009)). For the other properties the proofs are given.
2.3.1 Pairs
Property 2.3.1. Consider a PORk, l design and let A× B = {(Ai, Bj) | Ai ∈ A, Bj ∈ B}
be the artesian produt between the two sets A and B. If we denote the number of elements
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in A× B by |A × B|, then the number of pairs (Ai, Bj) with i = 1, . . . , k, j = 1, . . . , l and
l ≥ 2 in A× B is
|A × B| = |A| · |B| = k · l.
Remark. A×B is a non-empty and ountable set. Therefore, (A×B, P(A×B)) desribes
a measurable spae.
2.3.2 Two-pair ombination
Denition 2.3.2 (Two-pair ombination TPC). A two-pair ombination
TPC = [(Ai, Bj),(Ai′ , Bj′)] is dened as unordered pair of two randomly seleted
dierent pairs (Ai, Bj) ∈ A×B and (Ai′ , Bj′) ∈ A×B\{(Ai, Bj)}. The set of all two-pair
ombinations is referred to as
T PCk,l :=(A× B) ×
k, l
(A× B)
={[ω1, ω2] | ωn ∈ A× B, n = 1, . . . , |A × B|;ω1 < ω2, . . . , ω|A×B|}.
The operator '
×
k, l ' denotes the unordered artesian produt of A×B and A×B without the
set of pairs with equal elements (drawing without replaement, unordered result).
Property 2.3.3. The number of all distint two-pair ombinations |T PCk,l| in a PORk, l
design an be omputed by
|T PCk,l| :=
(|A × B|
2
)
=
kl(kl − 1)
2
.
Remark.
• T PCk,l is a non-empty and ountable set. Therefore, (T PCk,l, P(T PCk,l)) desribes
a measurable spae.
• The number of two-pair ombinations is also symmetri but the sequene is
quadratially inreasing with the number of pairs. Therefore, it is not pratiable to
reommend a high number of therapies in both strategies. In Figure 2.2, the number
of two-pair ombinations are illustrated for dierent numbers of k and l.
For a better understanding of what happened during the randomisation proess, we
dene three dierent random variables, one for eah of the step of Denition 2.2.1. All
three random variables are disrete. The rst random variable Γ desribes the rst step of
randomisationthe seletion of one two-pair ombination for eah patient. The patient-
oriented step is not really random, but we do not know all reasons the physiians take
into aount when hoosing one pair of the two-pair ombination based on the respetive
patient. We only see the distribution whih desribes the deision of the physiians between
the two dierent pairs. The random variable Θ desribes the distribution of the two
dierent pairs in eah two-pair ombination. The third random variable Ψ represents the
seond step of randomisationthe randomisation between the two dierent strategies A
and B.
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Figure 2.2: Number of two-pair ombinations in a PORk, l design.
Denition 2.3.4 (Randomisation random variables).
1. Let P : T PCk,l → [0, 1] be the probability measure on (T PCk,l, P(T PCk,l)) with
P({TPCm}) = |T PCk,l|−1 = 2/(kl(kl − 1)) for m = 1, . . . , |T PCk,l|.
Then the funtion
Γ : (T PCk,l, P(T PCk,l)) −→ (T PCk,l, P(T PCk,l))
with the law PΓ of Γ under P is a random variable, whih desribes the randomisation
in T PCk,l. {TPC1, . . . , TPC|T PCk,l|} is the support of PΓ and
PΓ({TPCm}) = P ({TPCm | Γ(TPCm) = TPCm}) = P(Γ = TPCm) = 2
kl(kl − 1)
are the single portabilities for m = 1, . . . , |T PCk,l|.
2. The funtion
Θ : (T PCk,l, P(T PCk,l)) −→ (A× B, P(A× B))
with
PΘ({ωn}) = P ({(ω1, ω2) | Θ(ω1, ω2) = ωn, ωn ∈ A× B for n = 1, 2})
= P(Θ−1(ωn), ωn ∈ A× B for n = 1, 2)
=
{
pmΘ if Θ = ω1 = (Ai, Bj)
qmΘ = (1− pmΘ ) if Θ = ω2 = (Ai′ , Bj′)
for pmΘ ∈ [0, 1] is a random variable whih desribes the distribution of the patient-
oriented step of the randomisation proedure for eah TPCm, m = 1, . . . , |T PCk,l|.
pmΘ desribes the probability of the physiian's deision for random pair 1 if the patient
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reeives the two-pair ombination m.
Ψ : (A× B, P(A× B)) −→ (A ∪ B, P(A ∪ B))
with
PΨ({C}) = P({(Ai, Bj) | Ψ((Ai,Bj)) = C, C ∈ A ∪ B})
= P(Ψ−1(C), C ∈ A ∪ B})
=
{
pΨ if Ψ = C ∈ A
qΨ = (1− pΨ) if Ψ = C ∈ B
for pΨ ∈ [0, 1] is a random variable whih randomises eah pair (Ai, Bj) ∈ A × B to
one strategy (either strategy A with treatment Ai or strategy B with treatment Bj).
pΨ desribes the probability for a patient reeiving a treatment of strategy A.
Remark.
1. The random variable Ψ is independent of Θ.
2. The superposition of the three random variables Γ, Ψ and Θ desribes all possible
outomes of the randomisation proess.
3. The probability of Ψ resulting as an element of A or B is depending on the sampling
strategy. In most ases it will be hosen as pΨ = 1/2, whih is impliitly assumed in
the ourse of this thesis. Of ourse in general sampling for strategies like one-to-two
are possible if the study goal demands suh unequal randomisation.
Notation.
• To reeive a better understanding of the possibilities of the physiians' deision
we onsider the realisation of the rst and seond randomisation step without the
patient-oriented deision step. That means that if we have one two-pair ombination
[(Ai, Bj),(Ai′ , Bj′)], we only onsider the orresponding A-pair (Ai, Ai′) and the or-
responding B-pair (Bj , Bj′). Sine we are not interested in the order of this pairs we
summarise all pairs with the same elements in one equivalene lass of unordered pairs
[Ai, Ai′ ] = {(Ai, Ai′),(Ai′ , Ai)} and analogous for [Bj , Bj′ ] = {(Bj , Bj′),(Bj′ , Bj)}.
The set of all unordered equivalene lasses of A-pairs is denoted by
A ⊗
k, l
A := {[Ai, Ai′ ] | Ai, Ai′ ∈ A }
and analogous the set of all unordered equivalene lasses of B-pairs by
B ⊗
k, l
B := {[Bi, Bi′ ] | Bi, Bi′ ∈ B}.
The operator '
⊗
k, l ' denotes the unordered artesian produt of A and A as well as B
and B.
• Therefore, we also dene two random variables ΨA and ΨB to reeive all orrespond-
ing unordered A-pairs and B-pairs and the probabilities of pairs with equal and mixed
elements. The funtion ΨA is dened as
ΨA : (T PCk,l, P(T PCk,l)) −→ (A ⊗
k, l
A, P(A ⊗
k, l
A))
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with
PΨA({[Ai, Ai′ ]}) = P(Ψ−1A ([Ai, Ai′ ]), Ai, Ai′ ∈ A})
=
{
pA if Ai = Ai′
qA if Ai 6= Ai′
for pA, qA ∈ [0, 1] and the funtion ΨB is dened as
ΨB : (T PCk,l, P(T PCk,l)) −→ (B ⊗
k, l
B, P(B ⊗
k, l
B))
with
PΨB({[Bj , Bj′ ]}) = P(Ψ−1B ([Bj , Bj′ ]), Bj, Bj′ ∈ B})
=
{
pB if Bj = Bj′
qB if Bj 6= Bj′ .
for pB, qB ∈ [0, 1]. We will determine the probabilities pA, pB and qA, qB in the
following Subsetions 2.3.3 and 2.3.4.
Remark. To show how the dierent random variables introdued above are onneted,
we give a graphial representation in the following diagram (Figure 2.3).
A ⊗
k, l
A
T PCk,l Γ // T PCk,l
ΨA
::✉✉✉✉✉✉✉✉
Θ
//
ΨB
$$
■■
■■
■■
■■
■■
A× B Ψ // A∪ B
B ⊗
k, l
B
Figure 2.3: Interation of random variables involved in the PORk, l design.
Example. In Table 2.1, we nd all possible two-pair ombinations from the POR2,2 design.
The physiian reeives one of these two-pair ombinations at random, for example two-pair
ombination 3 for one patient. Let us assume that this patient does not tolerate the drug
B2. Hene, the physiian hooses random pair 1. This underlines that the PORk, l design
oers the opportunity for patient-oriented hoies.
The alloation of eah patient to one of the strategies is random and independent of the
physiian's hoie. However, the physiian takes the onsideration about what happens if
the patient is randomised to strategy A as well as B into aount. For example, onsider the
rst two-pair ombination of Table 2.1 above. If the patient is randomised to strategy A,
he reeives treatment A1 independent of the hoie of the physiian. Hene, the physiian
is foused on the treatments of strategy B. He has to deide whether treatment B1 or B2
is better for the respetive patient. In this ase, the physiian's seletion of one random
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Number of two-pair
ombination
T PC2, 2 Equivalene lass in
Random pair 1 Random pair 2
A ⊗
2, 2
A B ⊗
2, 2
B
1 (A1, B1) (A1, B2) [A1, A1] [B1, B2]
2 (A1, B1) (A2, B1) [A1, A2] [B1, B1]
3 (A1, B1) (A2, B2) [A1, A2] [B1, B2]
4 (A1, B2) (A2, B1) [A1, A2] [B2, B1]
5 (A1, B2) (A2, B2) [A1, A2] [B2, B2]
6 (A2, B1) (A2, B2) [A2, A2] [B1, B2]
Table 2.1: Two-pair ombinations of the POR2,2 design. The idential treatments in a
two-pair ombination are highlighted.
pair an be interpreted as a lear deision for either treatment B1 or treatment B2. The
last two olumns of Table 2.1 desribe this onsideration for all two-pair ombinations
A ⊗
2, 2
A = {[A1, A1],[A1, A2],[A2, A2]}
B ⊗
2, 2
B = {[B1, B1],[B1, B2],[B2, B2]}.
In four out of all six two-pair ombinations, we have either an idential treatment in
strategy A or B. Suh two-pair ombinations are alled informative ombinations. These
informative ombinations are of partiular interest. We an onlude from the physiian's
deision whih onrete treatment he prefers for the respetive patients. Therefore, we
take a loser look at these two-pair ombinations in the next setion.
2.3.3 Informative ombination
Denition 2.3.5 (Idential and mixed pairs). A orresponding unordered pair of a
two-pair ombination is alled
1. idential, if the treatments in the unordered pair are the same, i.e. [Ci, Ci] for Ci ∈ A
or Ci ∈ B;
2. mixed, if the treatments in the unordered pair are not the same, i.e. [Ci, Ci′ ] for i 6= i′
and Ci, Ci′ ∈ A or Ci, Ci′ ∈ B.
Denition 2.3.6 (Informative ombination). An informative ombination is dened
as a two-pair ombination where either the orresponding unordered A-pair or B-pair is
idential. To illustrate in whih strategy treatments are idential and in whih strategy
we found the information, the informative ombinations are alled A-informative ombi-
nation if the orresponding B-pair is idential as well as B-informative ombination if the
orresponding A-pair is idential.
Property 2.3.7.
• In a PORk, l design, there are k distint idential A-pairs and for k > 1 there are l
distint idential B-pairs.
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• For eah idential A-pair [Ai, Ai] in A ⊗k, lA the pre-image Ψ−1A ([Ai, Ai]) onsists of
l(l− 1)/2 two-pair ombinations and for eah idential B-pairs [Bj , Bj ] in B ⊗k, lB the
pre-image Ψ−1B ([Bj , Bj ]) onsists of k(k − 1)/2 two-pair ombinations.
Remark.
• For k = 1, A ⊗1, lA = {[A1, A1]} onsist of one idential A-pair. In B ⊗1, lB there is no
idential B-pair.
• For k 6= 1, the number of pre-images of idential A-pairs for one treatment Ai depends
on the number of treatments in B and vie versa.
• The probability pA for two-pair ombinations with one idential A-pair is alulated
by the ratio of the number of pre-images of the idential A-pair and the number of
two-pair ombinations, i.e.
pA = P
(
Ψ−1A ([Ai, Ai])
)
=
|Ψ−1A ([Ai, Ai])|
|T PCk,l| =
l − 1
k(kl − 1) (2.1)
for i = 1, . . . , k, and the probability pB for two-pair ombinations with one idential
B-pair is alulated by
pB = P
(
Ψ−1B ([Bi,Bi])
)
=
|Ψ−1B ([Bj , Bj])|
|T PCk,l| =
k − 1
l(kl − 1) (2.2)
for j = 1, . . . , l.
Notation. The proofs of the following properties often use a sequene indexed by two
parameters. In the appliations one of them is onstant. Therefore, we introdue an
abbreviation for the sequene (ak, l)k∈N\{1}, l∈N\{1} with k or l onstant. If the number
of treatments in one strategy is xed, the assoiated parameter is replaed by a dot, i.e.
(ak,.)k∈N\{1} for l = const. and (a.,l)l∈N\{1} for k = const.
Property 2.3.8.
1. Consider the probability for idential A-pairs as a sequene
(ak, l)k∈N\{1}, l∈N\{1} :=
l − 1
k(kl − 1) ,
in k and l. Then the sequene (a.,l)l∈N\{1} is monotonially inreasing for k = const.
and onvergent to 1/k2. For l = const., the sequene (ak,.)k∈N\{1} is monotonially
dereasing and onvergent to 0.
2. Similarly, onsider the probability for idential B-pairs as a sequene
(bk, l)k∈N\{1} l∈N\{1} :=
k − 1
l(kl − 1) .
Then, the sequene (b.,l)l∈N\{1} is monotonially dereasing for k = const. and on-
vergent to 0. For l = const., the sequene (bk,.)k∈N\{1} is monotonially inreasing
and onvergent to 1/l2.
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Example. In Figure 2.4, we an see the probabilities for idential A-pairs and for idential
B-pairs for dierent numbers of treatments k and l.
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Figure 2.4: Probability for idential a) A-pairs and b) B-pairs in a PORk, l design.
The properties of the patient-oriented randomisation design depend on k and l. In
order to not always hek the monotoniity and the onvergene of the resulting sequenes
of probabilities we onsider the general ase in the following lemma.
Lemma 2.3.9. Let
(an)n∈N\{1} :=
αn+ β
γn2 + δn+ ε
a real valued sequene with α, β, γ, δ, ε ∈ R and α, γ ≥ 0. Let also αn+ β ≥ 0 as well as
γn2 + δn + ε > 0 for all n ∈ N \ {1}. Then
1. For γ = 0, δ > 0, the sequene is onvergent to α/δ.
1.1 If βδ < αε, then (an)n∈N\{1} is stritly monotonially inreasing.
1.2 If βδ > αε, then (an)n∈N\{1} is stritly monotonially dereasing.
2. For γ 6= 0,
2.1 α = 0 and β > 0, (an)n∈N\{1} is onvergent to 0 and stritly monotonially
dereasing for all n > max(1,− 1/2 − δ/γ).
2.2 α 6= 0, (an)n∈N\{1} is onvergent to 0 and is stritly monotonially dereasing
for n ≥ max(−β/α, N(α, β, γ, δ, ε)) with
N(α, β, γ, δ, ε) = −1
2
− β
α
+
√
1
4
+
β2
α2
− βδ
αγ
+
ε
γ
(2.3)
if N exists, (i.e. the disriminant is greater than or equal zero), and otherwise
for n ≥ −β/α.
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Proof (of Lemma 2.3.9).
1. Let γ = 0. Consider
an − α
δ
=
αn+ β
δn + ε
− α
δ
=
βδ − αε
δ2n+ δε
−→
n→∞
0. (2.4)
Therefore, the sequene (an)n∈N\{1} is onvergent to α/δ.
1.1 Suppose βδ < αε. To show that (an)n∈N\{1} is stritly monotonially inreasing,
we establish an+1 > an for all n ∈ N \ {1}. From Equation (2.4), we obtain
an < an+1
⇔ an − α
δ
< an+1 − α
δ
⇔ βδ − αε
δ2n+ δε
<
βδ − αε
δ2(n+ 1) + δε
.
Whih is a true statement, sine βδ −αε < 0 and δ2n+ δε < δ2(n+1) + δε for
δ > 0 and δn + ε > 0. Hene, (an)n∈N\{1} is stritly monotonially inreasing.
1.2 If βδ > αε, it an be shown analogously to 1.1 that (an)n∈N\{1} is stritly
monotonially dereasing.
2. First, we prove the monotoniity of (an)n∈N\{1}. The sequene is stritly monotoni-
ally dereasing if an > an+1 for all n ∈ N \ {1}.
an > an+1
⇔ αn + β
γn2 + δn + ε
>
α(n + 1) + β
γ(n + 1)2 + δ(n + 1) + ε
⇔ (αn+ β)(γn2 + 2γn + γ + δn+ δ + ε) > (αn + α+ β)(γn2 + δn+ ε)
⇔ αγn3 + 2αγn2 + αγn+ αδn2 + αδn + αεn > αγn3 + αδn2 + αεn + αγn2 + αδn
+βγn2 + 2βγn+ βγ + βδn + βδ + βε + αε+ βγn2 + βδn + βε
⇔ αγn2 + (αγ + 2βγ)n + βγ + βδ − αε > 0. (2.5)
2.1 Let α = 0. Then Equation (2.5) beomes
2βγn + βγ + βδ > 0
⇔ n > −1
2
− δ
γ
, (2.6)
for β > 0. Hene, the sequene is stritly monotonially dereasing for all
n > max(1,− 1/2 − δ/γ).
Sine both the numerator and the denominator of (an)n∈N\{1} are positive, the
sequene is learly bounded from below by 0. The sequene is onvergent be-
ause we have proved that (an)n∈N\{1} is monotonially dereasing and bounded
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from below. Finally, the limit an be omputed by
lim
n→∞
β
γn2 + δn + ε
= lim
n→∞
β
n2
γ + δn +
ε
n2
= 0.
2.2 Let α 6= 0, then the left side of inequality (2.5) is a quadrati polynomial in n
with a positive leading oeient. Therefore, the inequality (2.5) is always true
if the quadrati equation has no roots, or when n is greater or equal than the
largest root N(α, β, γ, δ, ε) given by (2.3).
To prove onvergene, it sues again to show that the sequene is bounded
from below by 0.
an ≥ 0
⇔ αn + β
γn2 + δn + ε
≥ 0
⇔ αn+ β ≥ 0, sine γn2 + δn + ε > 0
⇔ n ≥ −β
α
.
Hene, the sequene (an)n∈N\{1} is onvergent and the limit is
lim
n→∞
αn+ β
γn2 + δn + ε
= lim
n→∞
α
n +
β
n2
γ + δn +
ε
n2
= 0. 
Proof (of Property 2.3.8).
1. Let us onsider the sequene
(a.,l)l∈N\{1} =
l − 1
k2l − k
whih an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 1, β =
−1, γ = 0, δ = k2 and ε = −k. To show the laim, we only have to prove the
ondition βδ < αε. Sine
βδ < αε ⇔ −k2 < −k,
the sequene inreases stritly monotonially and onverges to α/δ = 1/k2.
For l = const. we onsider the sequene (ak,.)k∈N\{1} with a quadrati denominator
in k and α = 0,
(ak,.)k∈N\{1} =
l − 1
lk2 − k ,
whih an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = k,
β = l − 1, γ = l, δ = −1 and ε = 0. Sine −1/2 − δ/γ = −1/2 + 1/l ≤ 0 < k
and β = l − 1 ≥ 0, the ondition (2.6) in the proof of Lemma 2.3.9 is satised and
the sequene (ak,.)k∈N\{1} is stritly monotonially dereasing and onvergent to 0.
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2. Analogously to strategy A we an onsider the sequene (b.,l)l∈N\{1} and (bk,.)k∈N\{1}
and prove the onditions in Lemma 2.3.9. 
Example.
1. For the POR2,2 design, the B-informative ombinations an be seen in line 1 and
6 of Table 2.1 with the orresponding idential A-pairs [A1, A1] and [A2, A2]. The
A-informative ombinations an be seen in line 2 and 5 of Table 2.1 with the orre-
sponding idential B-pairs [B1, B1] and [B2, B2]. Eah idential pair has a probability
of pA = pB = 1/6.
2. Suppose k = 2. Then the probability for idential A-pairs inreases and onverges
to 1/k2 = 1/4 and the probability for idential B-pairs dereases for inreasing l and
onverges to 0 (see Figure 2.5). In general, the probability of idential pairs in one
strategy an be inreased when the number of treatments in this strategy is onstant
while the number of treatments in the remaining strategy inreases. This onnetion
is important for later onsiderations.
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Figure 2.5: Probability for idential A-pairs pA and for idential B-pairs pB in a
POR2, l design.
2.3.4 Mixed ombination
Denition 2.3.10 (Mixed ombination). A mixed ombination is dened as a two-
pair ombination [(Ai, Bj),(Ai′ , Bj′)] where the orresponding unordered A-pair and the
orresponding unordered B-pair are mixed, i.e. Ai 6= Ai′ and Bj 6= Bj′.
Notation. An A-pair with two dierent treatments or a B-pair with two dierent treat-
ments are denoted by mixed A-pair or mixed B-pair respetively.
Property 2.3.11.
• In a PORk, l design, there are k(k−1)/2 distint mixed A-pairs and l(l−1)/2 distint
mixed B-pairs.
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• In the ase of a PORk, l design with k 6= 1, the number of pre-images of a mixed
A-pair Ψ−1A ([Ai, Ai′ ]) is equal to l2 and the number of pre-images of a mixed B-pair
Ψ−1B ([Bj , Bj′ ]) is equal to k
2
. For the speial ase k = 1, there are no mixed A-
pairs and the number of pre-images of a mixed B-pair orresponds to the number of
two-pair ombinations l(l − 1)/2.
Remark.
• For k 6= 1, the number of mixed A-pairs depends on the number of treatments in B
and the number of mixed B-pairs depends on the number of treatments in A.
• The probability qA for mixed A-pairs is
qA = P
(
Ψ−1A ([Ai, Ai′ ])
)
=
|Ψ−1A ([Ai, Ai′ ])|
|T PCk,l| =
{
2l
k(kl−1) if k > 1
0 if k = 1
(2.7)
for i, i′ = 1, . . . , k and i 6= i′, and the probability qB for mixed B-pairs is
qB = P
(
ΨB−1([Bj , Bj′ ])
)
=
|Ψ−1B ([Bi,Bi′ ])|
|T PCk,l| =
{
2k
l(kl−1) if k > 1
1 if k = 1
(2.8)
for j, j′ = 1, . . . , l and j 6= j′.
Property 2.3.12.
1. We onsider the probability for mixed A-pairs as a sequene
(ak, l)k∈N\{1}, l∈N\{1} :=
2l
k(kl − 1) ,
in k and l. Then the sequene (a.,l)l∈N\{1} is stritly monotonially dereasing to 2/k
2
when k is onstant. For l = const., the sequene (ak,.)k∈N\{1} is stritly monotonially
dereasing and onvergent to 0.
2. Analogously, we onsider the probability for mixed B-pairs as sequene
(bk, l)k∈N\{1}, l∈N\{1} :=
2k
l(kl − 1) .
Then the sequene (b.,l)l∈N\{1} the is stritly monotonially dereasing for k = const.
and onvergent to 0. For l = const., the sequene (bk,.)k∈N\{1} is stritly monotoni-
ally dereasing and onvergent to 2/l2.
Proof.
1. For k = const., the denominator of the sequene
(a.,l)l∈N\{1} =
2l
k2l − k
whih an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 2, β = 0,
γ = 0, δ = k2 and ε = −k is ane linear in l. With the help of Lemma 2.3.9, we
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know that (a.,l)l∈N\{1} is onvergent to α/δ = 2/k
2
. For the monotoniity behaviour
we prove the relationship of βδ = 0 and αε = −2k and reeive βδ > αε. Hene,
(a.,l)l∈N\{1} is stritly monotonially dereasing.
For l = const., the denominator of the sequene is a quadrati polynomial in k
and an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = k, α = 0, β = 2l,γ =
l, δ = −1 and ε = 0. Sine β > 0, we only have to prove that k > max(1,−1/2−δ/γ).
With γ = 2l and δ = −1, we obtain −1/2 + 1/(2l) < 1 < k. By Lemma 2.3.9, the
sequene is stritly monotonially dereasing and onvergent to 0.
2. The results are obtained by symmetry from 1, beause
(ak, l)k∈N\{1}, l∈N\{1} =
2k
l(lk − 1) = (bl, k)l∈N\{1}, k∈N\{1} . 
Example.
1. In Figure 2.6, we an see the probabilities for mixed A-pairs and for mixed B-pairs
for dierent numbers of treatments k and l.
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Figure 2.6: Probability for mixed a) A-pairs and b) B-pairs in a PORk, l design.
2. For a POR2,2 design, the number of pre-images of the only mixed A-pair [A1, A2]
is four. Analogously, we nd one mixed B-pair [B1, B2] for whih the number of
pre-images is also four. Therefore, the probability for mixed A-pairs or B-pairs is
qA = qB = 4/6 = 2/3 in a POR2, 2 design.
3. Consider k = 2, the probability for mixed A-pairs dereases and onverges to 1/2 and
the probability for mixed B-pairs dereases and onverges to 0 (see Figure 2.7). As
we have also seen in Figure 2.5, the probabilities hange muh more in the strategy
where we add one or more treatments as in the other strategy with a onstant number
of treatments.
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Figure 2.7: Probability for mixed A-pairs qA and B-pairs qB in a POR2, l design.
2.3.5 Clear patient-oriented deision
In eah informative ombination, the physiian has only the hoie within treatments of
the assoiated mixed pair for the respetive patient. For this reason, it is possible to see
the hoie of the physiian diretly, if we assume that he did not hoose the pair at random.
Denition 2.3.13 (Clear patient-oriented deision POD). The hoie of the physi-
ian between the two random pairs of one two-pair ombination is alled a lear patient-
oriented deision (POD), if the two-pair ombination is an informative ombination. The
set of all informative ombinations is dened as PODk, l.
Property 2.3.14. The number of lear patient-oriented deisions |PODk, l| in a PORk, l
design is
|PODk, l| = kl(l + k − 2)
2
.
Proof. From Setion 2.3.3, we know that here are k dierent idential A-pairs with l(l−1)/2
pre-images for eah A-pair and l dierent idential B-pairs with k(k − 1)/2 pre-images in
T PCk,l. We also know that no informative ombination with two idential pairs exists,
otherwise we would have seleted two idential pairs from the set of possible pairs. Hene
the number of lear patient-oriented deisions an be alulated from (2.1) and (2.2) as
∣∣Ψ−1A ([Ai, Ai])∣∣ · k + ∣∣Ψ−1B ([Bj , Bj ])∣∣ · l = l(l − 1)2 · k + k(k − 1)2 · l = kl(l + k − 2)2 .

Property 2.3.15. The probability for a lear patient-oriented deision is equal to
P
(
Ψ−1A
( k⋃
i=1
[Ai, Ai]
))
+ P
(
Ψ−1B
( l⋃
j=1
[Bj , Bj]
))
=
l + k − 2
kl − 1 .
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Proof. Sine [Ai, Ai] for i = 1, . . . , k and [Bj, Bj ] for j = 1, . . . , l are disjoint, we have
P
(
Ψ−1A
( k⋃
i=1
[Ai, Ai]
))
+ P
(
Ψ−1B
( l⋃
j=1
[Bj , Bj ]
))
=
k∑
i=1
P
(
Ψ−1A ([Ai, Ai])
)
+
l∑
j=1
P
(
Ψ−1B ([Bj , Bj ])
)
=
k∑
i=1
∣∣Ψ−1A ([Ai, Ai])∣∣
|T PCk,l| +
l∑
j=1
∣∣Ψ−1B ([Bj , Bj ])∣∣
|T PCk,l|
(2.1)(2.2)
=
k∑
i=1
l − 1
k(kl − 1) +
l∑
j=1
k − 1
l(kl − 1)
= k · l − 1
k(kl − 1) + l ·
k − 1
l(kl − 1)
=
l − 1
kl − 1 +
k − 1
kl − 1
=
l + k − 2
kl − 1 . 
Remark. For k = 1, the probability for a lear patient-oriented deision is equal to 1.
Property 2.3.16. The sequene
(ck, l)k∈N\{1}, l∈N\{1} :=
l + k − 2
kl − 1 ,
in k and l desribes the probability for a lear patient-oriented deision. For k = const.,
(c.,l)l∈N\{1} is stritly monotonially dereasing and onvergent to 1/k. For l = const., the
sequene (ck,.)k∈N\{1} is stritly monotonially dereasing and onvergent to 1/l.
Proof. The denominators of (c.,l)l∈N\{1} and (ck,.)k∈N\{1} are ane linear in k respetively
in l. Let k = const., then the sequene (c.,l)l∈N\{1} an be obtained from (an)n∈N\{1} of
Lemma 2.3.9 with n = l, α = 1, β = k− 2, γ = 0, δ = k and ε = −1. Hene the sequene
is onvergent to α/δ = α/δ = 1/k. To show the monotoniity, we only have to prove
ondition βδ > αε. To this end onsider
βδ > αε ⇔ (k − 2)k > −1 ⇔ (k − 1)2 > 0,
whih is true.
Let l = const., then the results are obtained by symmetry, by simply interhanging of
k and l in (ck, l)k∈N\{1}, l∈N\{1}, beause
(cl, k)k∈N\{1}, l∈N\{1} =
k + l − 2
lk − 1 = (ck, l)k∈N\{1}, l∈N\{1} . 
Example.
• In Table 2.2 and Figure 2.8, the probabilities of lear patient-oriented deisions for
dierent numbers of treatments k and l are presented.
• For a POR2,2 design, the number of lear patient-oriented deisions is |POD2,2| = 4.
Sine the number of two-pair ombinations is 6, we obtain a probability of 2/3 for
lear patient-oriented deisions.
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k\l 2 3 4 5 6 7 8 9 10
1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2 0.67 0.60 0.57 0.56 0.55 0.54 0.53 0.53 0.53
3 0.50 0.45 0.43 0.41 0.40 0.39 0.38 0.38
4 0.40 0.37 0.35 0.33 0.32 0.31 0.31
5 0.33 0.31 0.29 0.28 0.27 0.27
6 0.29 0.27 0.26 0.25 0.24
7 0.25 0.24 0.23 0.22
8 0.22 0.21 0.20
9 0.20 0.19
10 0.18
Table 2.2: Probability for a lear patient-oriented deision depending on the numbers of
treatments k in strategy A and l in strategy B.
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Figure 2.8: Probability for lear patient-oriented deision in a PORk, l design.
2.3.6 Exampels the POR2, 3, POR3, 3 and POR2, 4 design
Example. As we have seen in Setion 2.3.2, the number of two-pair ombinations inreases
quadratially with the number of pairs. Hene ertain values of k, l are pratiable only
for large sample sizes. Therefore, in addition to the presented example POR2, 2 design, the
designs POR2, 3, POR2, 4 and POR3, 3 are of pratial interest. Table 2.3 summarises the
theoretial properties of these designs.
PORk, l Pairs |T PCk,l| |PODk, l| pA qA pB qB PODk l
POR2, 2 4 6 4 1/6 2/3 1/6 2/3 2/3
POR2, 3 6 15 9 1/5 3/5 1/15 4/15 3/5
POR2, 4 8 28 16 3/14 4/7 1/28 1/7 4/7
POR3, 3 9 36 18 1/12 1/4 1/12 1/4 1/2
Table 2.3: Theoretial properties of POR2, 2, POR2, 3, POR2, 4 and POR3, 3 design.
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Tables 2.42.6 provide an overview on the patient-oriented deisions within the two-
pair ombinations. Table 2.4 illustrates the NeSSy design. In 9 out of the 15 two-pair
ombinations, the physiian has a lear hoie between two treatments of one strategy. In
the rst three lines, there is a lear hoie in the A strategy between A1 and A2 (20%
of all two-pair ombinations). In the B strategy, there are three kinds of lear treatment
deision: [B1, B2], [B1, B3] and [B2, B3]. For eah of these pairs, there are two two-pair
ombinations (13.3% of all two-pair ombinations) with a patient-oriented deision.
Number of two-pair
ombination
T PC2, 3 Equivalene lass in
Random pair 1 Random pair 2
A ⊗
2, 3
A B ⊗
2, 3
B
Clear deision between A1 ↔ A2
1 (A1, B1) (A2, B1) [A1, A2] [B1, B1]
2 (A1, B2) (A2, B2) [A1, A2] [B2, B2]
3 (A1, B3) (A2, B3) [A1, A2] [B3, B3]
Clear deision between B1 ↔ B2
4 (A1, B1) (A1, B2) [A1, A1] [B1, B2]
5 (A2, B1) (A2, B2) [A2, A2] [B1, B2]
Clear deision between B1 ↔ B3
6 (A1, B1) (A1, B3) [A1, A1] [B1, B3]
7 (A2, B1) (A2, B3) [A2, A2] [B1, B3]
Clear deision between B2 ↔ B3
8 (A1, B2) (A1, B3) [A1, A1] [B2, B3]
9 (A2, B2) (A2, B3) [A2, A2] [B2, B3]
Non lear deision
10 (A1, B1) (A2, B2) [A1, A2] [B1, B2]
11 (A1, B1) (A2, B3) [A1, A2] [B1, B3]
12 (A1, B2) (A2, B1) [A1, A2] [B2, B1]
13 (A1, B2) (A2, B3) [A1, A2] [B2, B3]
14 (A1, B3) (A2, B1) [A1, A2] [B3, B1]
15 (A1, B3) (A2, B2) [A1, A2] [B3, B2]
Table 2.4: There are 15 possibilities of two-pair ombinations for the POR2, 3 design. The
idential pairs in strategy A and strategy B are highlighted.
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Number of two-pair
ombination
T PC2, 4 Equivalene lass in
Random pair 1 Random pair 2
A ⊗
2, 4
A B ⊗
2, 4
B
Clear deision between A1 ↔ A2
1 (A1, B1) (A2, B1) [A1, A2] [B1, B1]
2 (A1, B2) (A2, B2) [A1, A2] [B2, B2]
3 (A1, B3) (A2, B3) [A1, A2] [B3, B3]
4 (A1, B4) (A2, B4) [A1, A2] [B4, B4]
Clear deision between B1 ↔ B2
5 (A1, B1) (A1, B2) [A1, A1] [B1, B2]
6 (A2, B1) (A2, B2) [A2, A2] [B1, B2]
Clear deision between B1 ↔ B3
7 (A1, B1) (A1, B3) [A1, A1] [B1, B3]
8 (A2, B1) (A2, B3) [A2, A2] [B1, B3]
Clear deision between B1 ↔ B4
9 (A1, B1) (A1, B4) [A1, A1] [B1, B4]
10 (A2, B1) (A2, B4) [A2, A2] [B1, B4]
Clear deision between B2 ↔ B3
11 (A1, B2) (A1, B3) [A1, A1] [B2, B3]
12 (A2, B2) (A2, B3) [A2, A2] [B2, B3]
Clear deision between B2 ↔ B4
13 (A1, B2) (A1, B4) [A1, A1] [B2, B4]
14 (A2, B2) (A2, B4) [A2, A2] [B2, B4]
Clear deision between B3 ↔ B4
15 (A1, B3) (A1, B4) [A1, A1] [B3, B4]
16 (A2, B3) (A2, B4) [A2, A2] [B3, B4]
Non lear deision
17 (A1, B1) (A2, B2) [A1, A2] [B1, B2]
18 (A1, B1) (A2, B3) [A1, A2] [B1, B3]
19 (A1, B1) (A2, B4) [A1, A2] [B1, B4]
20 (A1, B2) (A2, B1) [A1, A2] [B2, B1]
21 (A1, B2) (A2, B3) [A1, A2] [B2, B3]
22 (A1, B2) (A2, B4) [A1, A2] [B2, B4]
23 (A1, B3) (A2, B1) [A1, A2] [B3, B1]
24 (A1, B3) (A2, B2) [A1, A2] [B3, B2]
25 (A1, B3) (A2, B4) [A1, A2] [B3, B4]
26 (A1, B4) (A2, B1) [A1, A2] [B4, B1]
27 (A1, B4) (A2, B2) [A1, A2] [B4, B2]
28 (A1, B4) (A2, B3) [A1, A2] [B4, B3]
Table 2.5: There are 28 possibilities of two-pair ombinations for the POR2, 4 design. The
idential pairs in strategy A and strategy B are highlighted.
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Number of two-pair
ombination
T PC3, 3 Equivalene lass in
Random pair 1 Random pair 2
A ⊗
3, 3
A B ⊗
3, 3
B
Clear deision between A1 ↔ A2
1 (A1, B1) (A2, B1) [A1, A2] [B1, B1]
2 (A1, B2) (A2, B2) [A1, A2] [B2, B2]
3 (A1, B3) (A2, B3) [A1, A2] [B3, B3]
Clear deision between A1 ↔ A3
4 (A1, B1) (A3, B1) [A1, A3] [B1, B1]
5 (A1, B2) (A3, B2) [A1, A3] [B2, B2]
6 (A1, B3) (A3, B3) [A1, A3] [B3, B3]
Clear deision between A2 ↔ A3
7 (A2, B1) (A3, B1) [A2, A3] [B1, B1]
8 (A2, B2) (A3, B2) [A2, A3] [B2, B2]
9 (A2, B3) (A3, B3) [A2, A3] [B3, B3]
Clear deision between B1 ↔ B2
10 (A1, B1) (A1, B2) [A1, A1] [B1, B2]
11 (A2, B1) (A2, B2) [A2, A2] [B1, B2]
12 (A3, B1) (A3, B2) [A3, A3] [B1, B2]
Clear deision between B1 ↔ B3
13 (A1, B1) (A1, B3) [A1, A1] [B1, B3]
14 (A2, B1) (A2, B3) [A2, A2] [B1, B3]
15 (A3, B1) (A3, B3) [A3, A3] [B1, B3]
Clear deision between B2 ↔ B3
16 (A1, B2) (A1, B3) [A1, A1] [B2, B3]
17 (A2, B2) (A2, B3) [A2, A2] [B2, B3]
18 (A3, B2) (A3, B3) [A3, A3] [B2, B3]
Non lear deision
19 (A1, B1) (A2, B2) [A1, A2] [B1, B2]
20 (A1, B1) (A2, B3) [A1, A2] [B1, B3]
21 (A1, B1) (A3, B2) [A1, A3] [B1, B2]
22 (A1, B1) (A3, B3) [A1, A3] [B1, B3]
23 (A1, B2) (A2, B1) [A1, A2] [B2, B1]
24 (A1, B2) (A2, B3) [A1, A2] [B2, B3]
25 (A1, B2) (A3, B1) [A1, A3] [B2, B1]
26 (A1, B2) (A3, B3) [A1, A3] [B2, B3]
27 (A1, B3) (A2, B1) [A1, A2] [B3, B1]
28 (A1, B3) (A2, B2) [A1, A2] [B3, B2]
29 (A1, B3) (A3, B1) [A1, A3] [B3, B1]
30 (A1, B3) (A3, B2) [A1, A3] [B3, B2]
31 (A2, B1) (A3, B2) [A2, A3] [B1, B2]
32 (A2, B1) (A3, B3) [A2, A3] [B1, B3]
33 (A2, B2) (A3, B1) [A2, A3] [B2, B1]
34 (A2, B2) (A3, B3) [A2, A3] [B2, B3]
35 (A2, B3) (A3, B1) [A2, A3] [B3, B1]
36 (A2, B3) (A3, B2) [A2, A3] [B3, B2]
Table 2.6: There are 36 possibilities of two-pair ombinations for the POR3, 3 design. The
idential pairs in strategy A and strategy B are highlighted.
CHAPTER 3
Alloation probability of a speifi
treatment
3.1 Introdution
In the PORk, l design disussed in this thesis both strategies are assumed to be balaned
(see Remark 3 following Denition 2.3.4). However, due to the seletion or deseletion of
one random pair, it an happen that the treatments in eah strategy are unbalaned. The
question we like to study in this hapter is how the probability of eah treatment to be
represented in this study is hanged by the physiian's hoie. To this end, we dene the
onept of alloation probability of a spei treatment.
Denition 3.1.1 (Alloation probability). The alloation probability for one treatment
C is the proportion of patients treated with C of the total number of patients treated in this
study.
In the rst setions of this hapter, we analyse the extreme ases of alloation probabil-
ities whih may our when one treatment is avoided or one treatment is seleted whenever
possible. These extreme ases are dened as minimum alloation probability and maximum
alloation probability. Obviously, the alloation probability of one treatment depends on
the alloation probabilities of the other treatments: If the alloation probability inreases
for a treatment of one strategy, the alloation probability dereases in at least one of the
remaining treatments of this strategy.
In the introdutory setion, we laimed that the patient-oriented randomisation design
onstitutes an intermediate path between a blok randomisation and the CUtLASS design,
where, ompared to the PORk, l design, the rst step of systemati omparison is missing.
The minimum alloation probabilities as well as the maximum alloation probabilities dier
between these three designs. Therefore, we dene in the last part of this setion the two
dierent study designs 'Balaned blok randomisation design for two dierent strategies'
and the 'CUtLASS design' and ompare their alloation probabilities to the alloation
probabilities of the patient-oriented randomisation design.
3.2 Minimum alloation probability of a spei treatment
The physiian's deision an be seen as deseletion of a spei treatment. If the physiian
would be fully free to deide about the treatments in a linial trial, it might happen that
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non-popular treatments or treatments not meeting personal preferenes are unfoundedly
omitted and thus not represented in the trial. However, an advantage of the PORk, l design
is that any treatment is administered with a minimum alloation probability, regardless
of any physiian's preferenes. Even if a spei treatment is generally deseleted (i.e.
physiians always pik the random pair where said treatment is not inluded, if they have
the hoie) it is not possible to avoid that treatment ompletely: the idential pairs ensure
that in 50% of the outomes of this pair, the doubled treatment will be the treatment to
be applied (due to the seond randomisation step) independent of the physiian's hoie,
even if he had preferred to deselet it.
Example. For the POR2, 2 design, we rearrange Table 2.1 and onsider the informative
ombinations. We study what happens if the physiian deselets for example treatment A1
Number of two-pair
ombination
T PC2, 2 Equivalene lass in
Random pair 1 Random pair 2
A ⊗
2, 2
A B ⊗
2, 2
B
Clear deision between A1 ↔ A2
2 (A1, B1) (A2, B1) [A1, A2] [B1, B1]
5 (A1, B2) (A2, B2) [A1, A2] [B2, B2]
Clear deision between B1 ↔ B2
1 (A1, B1) (A1, B2) [A1, A1] [B1, B2]
6 (A2, B1) (A2, B2) [A2, A2] [B1, B2]
No lear deision
3 (A1, B1) (A2, B2) [A1, A2] [B1, B2]
4 (A1, B2) (A2, B1) [A1, A2] [B2, B1]
Table 3.1: Rearranged two-pair ombinations of the POR2, 2 design. The idential pairs in
strategy A and strategy B are highlighted.
whenever possible, independent from the spei patient. Given the two-pair ombinations
2 to 5 the physiian an avoid treatment A1 by hoosing random pair 2 (see Table 3.1). In
two-pair ombination 6, there is no treatment A1 either in random pair 1 or in random pair
2 thus treatment A1 is avoided automatially. The only ritial two-pair ombination we
onentrate on is two-pair ombination 1. If the patient reeives this two-pair ombination,
he will get treatment A1 with 50% probability independent of whether the physiian has
hosen random pair one or two. This is due to the seond random step implemented in
the PORk, l design (see Denitions 2.2.1 and 2.3.4). This results in a minimum alloation
probability, whih onsists of the probability for idential A-pairs whih is 1/6 and the
probability to be randomised into strategy A (pΨ = 1/2). Thus, treatment A1 is adminis-
tered at least with probability 1/12 for eah patient in this study. If we were in a study
with 120 randomised patients, the minimum expeted number of patients with A1 was 10.
Denition 3.2.1 (Minimum alloation probability). Let ΘC¯ be a speial ase of
Θ whih desribes the deseletion behaviour (deseletion of random pairs ontaining C
whenever possible) of the physiian against treatment C in the patient-oriented step of
randomisation. Then the minimum alloation probability for treatment C is dened as the
probability that this treatment ours, in ase that it is deseleted by the physiian whenever
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possible, i.e.
PΨ◦ΘC¯ ({C}) = P
(
(Ψ ◦ΘC¯)−1(C)
)
.
Notation. To emphasise that treatment C is deseleted, we denote the funtion ΘC¯ with
the omplement of C as subsript.
Property 3.2.2. The minimum alloation probability for any treatment Ai ∈ A is given
by
P
(
(Ψ ◦ΘA¯i)−1(Ai)
)
=
l − 1
2k(kl − 1) for i = 1, . . . , k
where ΘA¯i desribes the deseletion behaviour of the physiian against treatment Ai. Sim-
ilarly, the minimum alloation probability for any treatment Bj ∈ B is given by
P
(
(Ψ ◦ΘB¯j)−1(Bj)
)
=
k − 1
2l(kl − 1) for j = 1, . . . , l,
where ΘB¯j desribes the deseletion behaviour of the physiian against treatment Bj .
Proof. Sine the two random steps are independent, we obtain
P
(
(Ψ ◦ΘA¯i)−1(Ai)
)
= pΨ P
(
Θ−1
A¯i
([Ai, Bj]), j = 1, . . . , l
)
.
Beause of the deseletion behaviour of ΘA¯i we have
Θ−1
A¯i
([Ai, Bj ]) =
{
[(Ai, Bj),(Ai, Bj′ ] | 1 ≤ j, j′ ≤ l
}
= Ψ−1A ([Ai, Ai]) .
Consequently,
P
(
Θ−1
A¯i
([Ai, Bj ]), j = 1, . . . , l
)
= P
(
Ψ−1A ([Ai, Ai])
)
= pA.
Hene we have
P
(
(Ψ ◦ΘA¯i)−1(Ai)
)
= pΨ · pA (2.1)= l − 1
2k(kl − 1) .
Analogously, we obtain the result for Bj by using Equation (2.2). 
Remark. The minimum alloation probability diers between the strategies if k and l are
dierent. In this ase we determine the average minimum alloation probability to reeive
a partiular treatment Ci regardless of the strategy for PORk, l by the weighted average
P
(
(Ψ ◦ΘC¯i)−1(Ci)
)
=
1
k + l
(
k · P((Ψ ◦ΘA¯i)−1(Ai))+ l · P((Ψ ◦ΘB¯j)−1(Bj)))
=
1
k + l
(
k(l − 1)
2k(kl − 1) +
l(k − 1)
2l(kl − 1)
)
=
k + l − 2
2(kl − 1)(k + l) .
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Property 3.2.3.
1. For k = 1, the minimum alloation probability for the only A-treatment A1 is P
(
(Ψ ◦
ΘA¯1)
−1(A1)
)
= 1/2. For k 6= 1, we onsider the minimum alloation probability for
any treatment Ai from strategy A as a sequene
(ak, l)k∈N\{1}, l∈N\{1} :=
l − 1
2k(kl − 1) ,
in k and l. Then, the sequene (a.,l)l∈N\{1} is stritly monotonially inreasing for
k = const. and onvergent to 1/k2. For l = const., the sequene (ak,.)k∈N\{1} is
stritly monotonially dereasing and onvergent to 0.
2. The minimum alloation for any B-treatment Bj is P
(
(Ψ ◦ΘB¯j)−1(Bj)
)
= 0 for
k = 1. For k > 1, we onsider the minimum alloation probability for any treat-
ment Bj from strategy B as a sequene
(bk, l)k∈N\{1}, l∈N\{1} :=
k − 1
2l(kl − 1) .
Then, the sequene (b.,l)l∈N\{1} is stritly monotonially dereasing for k = const. and
onvergent to 0. For l = const., the sequene (bk,.)k∈N\{1} is stritly monotonially
inreasing and onvergent to 1/l2.
3. The average minimum alloation probability is given by
P
(
(Ψ ◦ΘC¯i)−1(Ci)
)
= 1/(2(l + 1)) for k = 1. For k 6= 1, the sequene
(ck, l)k∈N\{1},l∈N\{1} :=
k + l − 2
2(kl − 1)(k + l)
desribes the average minimum alloation probability. (c.,l)l∈N\{1} is monotonially
dereasing for k = const. and onvergent to 0. For l = const., (ck,.)k∈N\{1} is also
monotonially dereasing and onvergent to 0.
Proof.
1.-2. Sine the sequenes of the minimum alloation probabilities for Ai and Bj math up
to a fator of 1/2 (see Remark 3 to Denition 2.3.4) with the probabilities of the
idential pairs, we refer to the proof of Property 2.3.8.
3. The sequene (ck, l)k∈N\{1}, l∈N\{1} is symmetri in k and l. Therefore, we only prove
the properties for k = const. Consider
(c.,l)l∈N\{1} =
l + k − 2
2kl2 + (2k2 − 2)l − 2k .
The denominator of the sequene is a quadrati polynomial in l and the sequene
an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 1, β = k − 2,
γ = 2k, δ = 2k2 − 2 and ε = −2k. With the help of Lemma 2.3.9, we know that
the sequene (c.,l)l∈N\{1} is monotonially dereasing and onvergent to 0 for all
l > max(−β/α,N(α, β, γ, δ, ε)). The single terms are given by
−β
α
=
2− k
1
= 2− k ≤ 0
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and
N(1, k − 2, 2k, 2k2 − 2, − 2k) = −1
2
− k + 2
+
√
1
4
+ k2 − 4k + 4− (k − 2)(2k
2 − 2)
2k
− 1
=
3
2
− k +
√
13
4
− 2k
3 − 4k2 − 2k + 4
2k
+ k2 − 4k
=
3
2
− k +
√
13
4
− k2 + 1 + 2k − 2
k
+ k2 − 4k
=
3
2
− k +
√
17
4
− 2k − 2
k
≤ 1.
For k > 1 the disriminant is smaller than zero and N exists only for k = 1. There-
fore,
−β
α
≤ 0 < l.

Remark. To inrease the minimum alloation probability of one treatment in one strategy,
the number of treatments in the other strategy should be inreased.
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The physiian's deision an also be seen as seletion of a spei treatment, whih an
inrease the probability to reeive this treatment in the assoiated strategy.
Example. If the physiian prefers one spei treatment for a ertain patient, for example
A1 in the POR2, 2 design, he an hoose one random pair ontaining treatment A1 in the
majority of ases, i.e. ve of the six two-pair ombination ontain treatment A1 in at least
one random pair. In two-pair ombination 1 from Table 3.1, there is always the hane
that the patient reeives treatment A1 in ase he is randomised to strategy A. In two-pair
ombination 2 to 5 the physiian an always hose random pair 1 to obtain a hane of
50% for the patient to reeive treatment A1. The random pairs of two-pair ombination 6
both ontain no treatment A1.
To onentrate only on the hoie of the physiian in strategy A, we onsider all lasses
of A-pairs of the POR2, 2 design
A ⊗
2, 2
A = {[A1, A1],[A1, A2],[A2, A2]}.
Assuming that the physiian always hooses a random pair with A-treatment A1 when
possible, the patient will reeive treatment A1 with probability 1/2 (seond randomisation
step), when the rst randomisation step yield a two-pair ombination whose A-pair belongs
to either [A1, A1] or [A1, A2]. There are ve pre-images of these A-pairs, eah of whih
has a probability of 1/6 to be hosen in the rst randomisation step. Hene, when the
physiian is seleting treatment A1 whenever possible, patients will reeive this treatment
with probability 5/6 · 1/2 = 5/12. Obviously, this is the maximum value for the alloation
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probability of treatment A1. If we were in a study with 120 randomised patients, the
maximum expeted number of treated patients with A1 would be 50. Within strategy A,
the expeted proportion of patients with treatment A1 would be 5/6.
Denition 3.3.1 (Maximum alloation probability). Let ΘC be a speial ase of Θ
whih desribes the distribution of the seletion behaviour of the physiian for treatment C
in the patient-oriented step of randomisation with
ΘC : (T PCk,l, P(T PCk,l)) −→ (A× B, P(A× B)).
Then the maximum alloation probability for treatment C is dened as the probability that
this treatment ours, when it is seleted by the physiian whenever possible i.e.
PΨ◦ΘC ({C}) = P
(
(Ψ ◦ΘC)−1(C)
)
.
Property 3.3.2. The maximum alloation probability for any treatment Ai ∈ A is given
by
P
(
(Ψ ◦ΘAi)−1(Ai)
)
=
2kl − l − 1
2k(kl − 1) for i = 1, . . . , k.
Analogously, the maximum alloation probability for any treatment Bj ∈ B is given by
P
(
(Ψ ◦ΘBj)−1(Bj)
)
=
2kl − k − 1
2l(kl − 1) for j = 1, . . . , l.
Proof. Beause the two randomisation steps are independent, we obtain
P
(
(Ψ ◦ΘAi)−1(Ai)
)
= pΨ P
(
Θ−1Ai ([Ai,Bj ]), j = 1, . . . , l
)
. (3.1)
Beause of the seletion behaviour of ΘAi we have
Θ−1Ai ([Ai,Bj ]) =
{
[(Ai, Bj),(Ai′ , Bj′)] | 1 ≤ i′ ≤ k; 1 ≤ j, j′ ≤ l; i 6= i′ ∧ j 6= j′
}
= Ψ−1A
(
[Ai, Ai] ∪
k⋃
j=1
j 6=i
[Ai, Aj ]
)
.
Consequently,
P
(
Θ−1Ai ([Ai, Bj ]), j = 1, . . . , l
)
= Ψ−1A
(
[Ai, Ai] ∪
k⋃
j=1
j 6=i
[Ai, Aj ]
)
= Ψ−1A ([Ai, Ai]) + Ψ
−1
A
( k⋃
j=1
j 6=i
[Ai, Aj ]
)
= pA + (k − 1)qA. (3.2)
Combining Equations (3.1) and (3.2) we obtain
P
(
(Ψ ◦ΘAi)−1(Ai)
)
= pΨ · (pA + (k − 1)qA)
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(2.1)(2.7)
=
1
2
(
(l − 1)
k(kl − 1) + (k − 1)
2l
k(kl − 1)
)
=
l − 1 + 2l(k − 1)
2k(kl − 1)
=
2lk − l − 1
2k(kl − 1) .
Analogously, we obtain the result for Bj with Equations (2.2) and (2.8). 
Remark. The maximum alloation probability for a spei treatment is equal for eah
treatment within eah strategy. However, the probability diers in both strategies if k
and l are dierent. In this ase, we dene the average maximum alloation probability to
reeive a partiular treatment Ci of any strategy for PORk, l by the weighted averages.
P
(
(Ψ ◦ΘCi)−1(Ci)
)
=
1
k + l
(
k · P ((Ψ ◦ΘAi)−1(Ai))+ l · P ((Ψ ◦ΘBi)−1(Bi)))
=
1
k + l
(
k(2lk − l − 1)
2k(kl − 1) +
l(2kl − k − 1)
2l(kl − 1)
)
=
4kl − l − k − 2
2(kl − 1)(k + l) .
Property 3.3.3.
1. For k = 1, the maximum alloation probability for the only A-treatment A1 is equal
to P
(
(Ψ ◦ΘA1)−1(A1)
)
= 1/2. For k 6= 1, we onsider the maximum alloation
probability for Ai as a sequene
(ak, l)k∈N\{1}, l∈N\{1} :=
2kl − l − 1
2k(kl − 1) ,
in k and l. The sequene (a.,l)l∈N\{1} is stritly monotonially dereasing for
k = const. and onvergent to (2k−1)/(2k2). For l = const., the sequene (ak,.)k∈N\{1}
is monotonially dereasing and onvergent to 0.
2. For k = 1, the maximum alloation probability for the treatment Bj is equal to
P
(
(Ψ ◦ΘBj )−1(Bj)
)
= 1/l. Let the maximum alloation probability for Bj onsidered
as a sequene
(bk, l)k∈N\{1}, l∈N\{1} :=
2kl − k − 1
2l(kl − 1)
for k 6= 1. Then, the sequene (b.,l)l∈N\{1} is stritly monotonially dereasing for
k = const. and onvergent to 0. For l = const., the sequene (bk,.)k∈N\{1} is stritly
monotonially dereasing and onvergent to (2l − 1)/(2l2).
3. For k = 1, the average maximum alloation probability for a partiular treatment Ci
of any strategy is equal to P
(
(Ψ ◦ΘCi)−1(Ci)
)
= 1/(2(l+1)). For k 6= 1, the sequene
(ck, l)k∈N\{1}, l∈N\{1} :=
4kl − l − k − 2
2(kl − 1)(k + l)
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desribes the average maximum alloation probability. (c.,l)l∈N\{1} is stritly mono-
tonially dereasing and onvergent to 0 for k = const. and for all l > l0 ≥ 2 with
l0 = max
(
k + 2
4k − 1 ,
−2k + 5
2(4k − 1) +
√
−3
4
− 4k
4 + 8k3 − 2k2 − 3k + 2
k(4k − 1)2
)
.
For l = const., (ck,.)k∈N\{1} is stritly monotonially dereasing and onvergent to 0
and for all k > k0 ≥ 2 with
k0 = max
(
l + 2
4l − 1 ,
−2l + 5
2(4l − 1) +
√
−3
4
− 4l
4 + 8l3 − 2l2 − 3l + 2
l(4l − 1)2
)
.
Proof.
1. For k = const., the denominator of the sequene
(a.,l)l∈N\{1} =
(2k − 1)l − 1
2k2l − 2k
is ane linear in l. The sequene an be obtained from (an)n∈N\{1} of Lemma 2.3.9
with n = l, α = 2k − 1, β = −1, γ = 0, δ = 2k2 and ε = −2k. With Lemma 2.3.9,
we know that (a.,l)l∈N\{1} is onvergent to α/δ = (2k−1)/2k2. For the monotoniity
we investigate the relationship of βδ = −2k2 and αε = (2k − 1)(−2k)
βδ > αε ⇔ −2k2 > −4k2 + 2k ⇔ k2 > k.
Hene, (a.,l)l∈N\{1} in stritly monotonially dereasing by Lemma 2.3.9.
For l = const., the sequene
(ak,.)l∈N\{1} =
2lk − l − 1
2lk2 − 2k
an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = k, α = 2l, β = −l − 1,
γ = 2l, δ = −2 and ε = 0 and the denominator of this sequene is a quadrati poly-
nomial in k. With the help of Lemma 2.3.9, we know that the sequene (ak,.)l∈N\{1}
is stritly monotonially dereasing for all k > max(−β/α,N(α, β, γ, δ, ε)) and on-
vergent. We have
−β
α
= −−l− 1
2l
=
1
2
+
1
2l
≤ 1
and
N(2l, − l − 1, 2l, − 2, 0) = −1
2
+
1
2
+
1
2l
+
√
1
4
+
l2 + 2l + 1
4l2
− −2(−l − 1)
4l2
=
1
2l
+
√
2l2 − 1
4l2
≤ 1.
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From this follows
max
(
−β
α
,N(α, β, γ, δ, ε)
)
= max
(
1
2
+
1
2l
,
1
2l
+
√
2l2 − 1
4l2
)
≤ 1 < k.
Hene, the sequene is stritly monotonially dereasing for all k ∈ N \ {1} and
onvergent to 0.
2. The result follows from 1. by symmetry:
(ak, l)k∈N\{1}, l∈N\{1} =
2kl − l − 1
2k(lk − 1) = (bl,k)l∈N\{1},k∈N\{1} .
3. The sequene (ck, l)k∈N\{1}, l∈N\{1} is symmetri in k and l. Hene, we need to prove
the properties only for k = const. Consider
(c.,l)l∈N\{1} =
(4k − 1)l − k − 2
2kl2 + (2k2 − 2)l − 2k .
The denominator of the sequene is a quadrati polynomial in l and the se-
quene an be obtained from (an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 4k − 1,
β = −k − 2, γ = 2k, δ = 2k2 − 2 and ε = −2k. With Lemma 2.3.9, we
know that the sequenes (c.,l)l∈N\{1} is stritly monotonially dereasing for all
l > l0 := max(−β/α,N(α, β, γ, δ, ε)) and onvergent. We have
−β
α
=
k + 2
4k − 1 ≤ 1
as well as
N(4k − 1, − k − 2, 2k, 2k2 − 2, − 2k) = −1
2
− −k − 2
4k − 1
+
√
1
4
+
k2 + 4k + 4
(4k − 1)2 +
(k + 2)(2k2 − 2)
2k(4k − 1) − 1
=
−4k + 1 + 2k + 4
2(4k − 1)
+
√
−3
4
− 4k
4 + 8k3 − 2k2 − 3k + 2
k(4k − 1)2
=
−2k + 5
2(4k − 1)
+
√
−3
4
− 4k
4 + 8k3 − 2k2 − 3k + 2
k(4k − 1)2 .
For
l > l0 = max
(
−β
α
, N(α, β, γ, δ, ε)
)
= max
(
k + 2
4k − 1 ,
−2k + 5
2(4k − 1) +
√
−3
4
− 4k
4 + 8k3 − 2k2 − 3k + 2
k(4k − 1)2
)
,
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the sequene (c.,l)l∈N\{1} is stritly monotonially dereasing and onvergent to 0. 
Example. At the end of eah study, all physiians' deisions lead to a ertain alloation
ratio for eah treatment. Here, the bounds of this alloation probabilities are given by
the minimum and the maximum probability alloations. For example, Table 3.2 lists the
minimum and the maximum alloation probabilities to reeive a spei treatment and
the orresponding average alloation probabilities for the patient-oriented randomisation
designs POR2, 2, POR2, 3, POR2, 4 and POR3, 3.
PORk, l
Alloation probability of
Ai Bi Ci
min max min max min max
POR2, 2 0.08 0.42 0.08 0.42 0.08 0.42
POR2, 3 0.10 0.40 0.03 0.30 0.06 0.34
POR2, 4 0.11 0.39 0.02 0.23 0.05 0.29
POR3, 3 0.04 0.29 0.04 0.29 0.04 0.29
Table 3.2: The minimum and maximum alloation probability for a spei treatment in
strategy A, B and the orresponding average minimum and average maximum
alloation probabilities for the patient-oriented randomisation designs POR2, 2,
POR2, 3, POR2, 4 and POR3, 3.
In the NeSSy design POR2, 3, the maximum and the minimum alloation probabilities
are dierent for the treatments of strategy A and B. In the study, neither the maximum nor
the minimum alloation probabilities were reahed for one treatment, so that no treatment
was totally seleted or deseleted. The alloation probabilities of the A-treatments amount
18% and 28% and of the B-treatments amount 17%, 25% and 21%.
Remark. For k 6= 1, only one treatment in one strategy an ahieve the maximum
alloation probability, respetively the minimum alloation probability. Simultaneously,
the minimum and the maximum alloation probability an be ahieved only in one strategy.
For k = 2 or l = 2, the following relation applies: If one treatment has the maximum
alloation probability, the remaining treatment in this strategy has the minimum alloation
probability. Furthermore, if a treatment of one strategy reahes one of the alloation
probability bounds, the treatments in the other strategy ahieve neither the maximum nor
the minimum alloation probability.
In order to assess the maximum and the minimum alloation probability of the PORk, l
design, we will dene a kind of blok randomisation design in the next setion, whih also
follows the aim of strategy omparison, and ompare the alloation probabilities for spei
treatments between both designs.
3.4 Patient-oriented randomisation design versus balaned
blok randomisation design
Denition 3.4.1 (Balaned blok randomisation design for two strategies
Blockk, l). Let A and B be two strategies with k respetively l treatments. A balaned
blok randomisation design for two strategies Blockk, l is a random alloation of patients
whih after every h patients (where h is a predened number alled blok length), has the
following properties:
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1. The number of assignments is the same for all treatments within eah strategy, i.e.
|Ai| = |Ai′ | and |Bj | = |Bj′ | for i, i′ = 1, . . . , k and j, j′ = 1, . . . , l.
2. The number of assignments to eah strategy is equal, i.e.
∑k
i=1 |Ai| =
∑l
j=1 |Bj|.
Denition 3.4.2 (Minimum blok length of a Blockk, l design). The minimum
blok length of a balaned blok randomisation design for two strategies Blockk, l is dened
as the smallest number h that an be hosen in Denition 3.4.1.
Notation. The minimum blok length of a Blockk, l design is denoted by H
Block
k, l .
Example. To get a feeling for Denitions 3.4.1 and 3.4.2, we onsider two balaned blok
designs Block2, 2 and Block2, 3. In the rst example, we have two treatments in eah
strategy A = {A1, A2} and B = {B1, B2}. To full the properties from Denition 3.4.1, it
is suient to take all four treatments at one. The minimum blok of Block2, 2 onsists of
A1 A2 B1 and B2
and the minimum blok length HBlock2, 2 = 4.
In the seond example Block2, 3, the number of treatments of strategy B = {B1, B2, B3}
inreases to three. If we take all treatments one like in the rst example, we see that
property one of Denition 3.4.1 is fullled but not the seond one. Sine we have to
maintain the rst property, we an only use multiples of the numbers of treatments in eah
strategy. The least ommon multiple of two and three is six, so that the minimum blok
onsists of
A1 A2 B1 B2 B3
A1 A2 B1 B2 B3
A1 A2
.
Both strategies are equally often represented and also the treatments are equally often
represented within eah strategy. The minimum blok length HBlock2, 3 of Block2, 3 is 12.
This leads us to the following property.
Property 3.4.3 (Size of minimum blok length of Blockk, l). Let LCMk, l be the
least ommon multiple of k and l. For the minimum blok length HBlockk, l of the balaned
blok randomisation design for two strategies Blockk, l, we have
HBlockk, l = 2 · LCMk, l.
Proof. From the two properties of Denition 3.4.1 we obtain that
k∑
i=1
|Ai| =
l∑
j=1
|Bj |
Prop. 1
⇔
k∑
i=1
|A1| =
l∑
j=1
|B1| ⇔ k · |A1| = l · |B1|.
Hene, k · |A1| and l · |B1| are multiples of both k and l. Sine we are searhing for the
minimum blok length, they should both equal to LCMk, l. Consequently
|A1| = LCMk, l
k
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and
|B1| = LCMk, l
l
.
Beause of Property one of Denition 3.4.1 this also applies to the other treatments in A
and B. The minimum blok length is therefore given by
HBlockk, l =
k∑
i=1
|Ai|+
l∑
j=1
|Bj |
=
k∑
i=1
LCMk, l
k
+
l∑
j=1
LCMk, l
l
= k · LCMk, l
k
+ l · LCMk, l
l
= 2 · LCMk, l. 
Remark. From this, we an also ompute an alloation probability for the appearane of
the treatments Ai and Bj . Let Υ be a random variable whih indiates to whih treatment
the patient is randomised, then we obtain for the alloation probability for treatment Ai
P(Υ = Ai) =
|Ai|
HBlockk, l
=
LCMk, l
k · 2LCMk, l =
1
2k
and for the alloation probability to reeive treatment Bj
P(Υ = Bj) =
|Bj |
HBlockk, l
=
LCMk, l
l · 2LCMk, l =
1
2l
.
Sine this probabilities are dierent for strategies with dierent numbers of treatments, we
alulate the average alloation probability to reeive treatment Ci ∈ A ∪ B
P(Υ = Ci) =
1
k + l
(k · P(Υ = Ai) + l · P(Υ = Bj))
=
1
k + l
(
k
2k
+
l
2l
)
=
1
k + l
.
Property 3.4.4.
1. The ratio between the average maximum alloation probability of a PORk, l design and
the average alloation probability of a Blockk, l design to reeive a partiular treatment
Ci is
P
(
(Ψ ◦ΘCi)−1(Ci)
)
P(Υ = Ci)
=
4kl − l − k − 2
2(kl − 1) > 1.
If we onsider the ratio as a sequene (ck, l)k∈N\{1}, l∈N\{1}, then the sequene
(c.,l)l∈N\{1} is stritly monotonially inreasing and onvergent to (4k − 1)/(2k) for
3.4 Patient-oriented randomisation versus blok randomisation 39
k = const. The sequene (ck,.)l∈N\{1} is stritly monotonially inreasing and onver-
gent to (4l − 1)/(2l) for l = const.
2. The ratio between the average minimum alloation probability of a PORk, l design and
the average alloation probability of a Blockk, l design to reeive a partiular treatment
Ci is
P
(
(Ψ ◦ΘC¯i)−1(Ci)
)
P(Υ = Ci)
=
k + l − 2
2(kl − 1) < 1.
If we onsider the ratio as a sequene (dk, l)k∈N\{1}, l∈N\{1}, then the sequene
(d.,l)l∈N\{1} is stritly monotonially dereasing and onvergent to 1/(2k) for
k = const. The sequene (dk,.)l∈N\{1} is stritly monotonially dereasing and on-
vergent to 1/(2l) for l = const.
Proof.
1. We an easily prove the rst statement of the inequality
4kl − l − k − 2
2(kl − 1) > 1 ⇔ 2kl − l − k > 0 ⇔ k(l − 1)︸ ︷︷ ︸
>0
+ l(k − 1)︸ ︷︷ ︸
≥0
> 0.
For the other properties, we prove only the ase k = const, sine the sequene
(ck, l)k∈N\{1}, l∈N\{1} is symmetri in k and l. Consider
(c.,l)l∈N\{1} =
(4k − 1)l − k − 2
2kl − 2 .
The denominator of the sequene is ane linear in l and the sequene an be obtained
from (an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 4k − 1, β = −k − 2, γ = 0, δ = 2k
and ε = −2. With Lemma 2.3.9, we know that (c.,l)l∈N\{1} is onvergent to
α/δ = (4k − 1)/(2k) = 2− 1/(2k). For the monotoniity we investigate the relation-
ship of βδ = −2k2 − 4k and αε = −8k − 2 and reeive
βδ < αε ⇔ −2k2 − 4k < −8k + 2
⇔ 2k2 − 4k + 2 > 0
⇔ k(k − 2) + 2 > 0, true statment.
Hene, (c.,l)l∈N\{1} is stritly monotonially inreasing.
2. The rst statement we an also easily proof by transposing the inequality
k + l − 2
2(kl − 1) < 1 ⇔ −2kl + l + k < 0 ⇔ 2kl − l − k > 0,
true statement. See ase 1 above. The further laims for the sequene
(dk, l)k∈N\{1}, l∈N\{1} are veried only for k = const. due to symmetri reasons. The
denominator of the sequene is ane linear in l and the sequene an be obtained from
(an)n∈N\{1} of Lemma 2.3.9 with n = l, α = 1, β = k − 2,γ = 0, δ = 2k and ε = −2.
With Lemma 2.3.9, we know that (d.,l)l∈N\{1} is onvergent to α/δ = 1/(2k). For the
monotoniity we investigate the relationship between βδ = 2k2 − 4k and αε = −2
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and reeive
βδ > αε ⇔ 2k2 − 4k > −2
⇔ k2 − 2k + 1 > 0
⇔ (k − 1)2 > 0, true statement.
Hene, (d.,l)l∈N\{1} is stritly monotonially dereasing. 
Conlusion 3.4.5. The following inequality applies
P
(
(Ψ ◦ΘC¯i)−1(Ci)
)
< P(Υ = Ci) < P
(
(Ψ ◦ΘCi)−1(Ci)
)
.
Remark.
• For k = 1, the ratio of the average maximum alloation probability of a POR1, l
design and the average alloation probability of a Block1, l design for treatment Ci is
equal to 3/2 for all number of treatments l in strategy B.
• For k = 1, the ratio of the average minimum alloation probability of a POR1, l
design and the average alloation probability of a Block1, l design for treatment Ci is
equal to 1/2 for all number of treatments l in strategy B.
• In Figure 3.1, we see that the alloation probability of a treatment an be almost
doubled by a patient-oriented randomisation design in some ases ompared to a
given balaned blok randomisation design for two strategies due to the fat that
P
(
(Ψ ◦ΘCi)−1(Ci)
)
P(Υ = Ci)
=
4kl − l − k − 2
2(kl − 1) −→k,l→∞ 2.
Furthermore, the following applies
P
(
(Ψ ◦ΘC¯i)−1(Ci)
)
P(Υ = Ci)
=
k + l − 2
2(kl − 1) −→k,l→∞ 0.
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Figure 3.1: Range of the average minimum and the average maximum alloation probability
(AP) of a PORk, l design and the average alloation probability of a Blockk, l
design depending on k and l.
3.5 Patient-oriented randomisation design versus CUtLASS
design
In Setion 1.2 'Motivation and bakground' we introdued the patient-oriented, straight-
forward RCT design for omparing two strategies in heterogeneous patient olletives im-
plemented in the CUtLASS study (Jones et al., 2006).
Denition 3.5.1 (CUtLASS design for two strategies). Let A and B two dier-
ent strategies with any number of k treatments in strategy A and l treatments B with
l ≥ max(2,k). Then, the CUtLASS design for two strategies CUtLASSk, l is dened as a
study design whih
• allows in the rst step for physiians a patient-oriented hoie for one treatment of
eah strategy and
• randomises in the seond step the patient to one strategy A or B.
Notation.
• Sine the random proess is the same as the seond random proess in
the PORk, l design, we maintain the denition of our randomisation funtion
Ψ : (A× B, P(A× B)) −→ (A ∪ B, P(A ∪ B)). We also assume here a one-to-one
randomisation between strategies as in the PORk, l design (pΨ = 1/2). Of ourse in
general other pΨ are possible if the study goal demands suh unequal randomisation.
• We dene a new random variable ΘCUtLASS
ΘCUtLASS :
(
Ak × Bl, P(Ak × Bl)
)
−→ (A× B, P(A×B))
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with
P
(
(ΘCUtLASS)−1 ((Ai,Bj))
)
= pijΘ
for pijΘ ∈ [0, 1] whih desribes the distribution of the patient-oriented step of the
physiian in CUtLASS design CUtLASSk, l.
• We also dene analogous to the PORk, l design two random variables desribing the
distribution of the two extreme ases where the physiian always deselets or selets
one treatment (denoted by C here). That is,
ΘCUtLASSC¯ :
(
Ak × Bl, P(Ak ×Bl)
)
−→ (A× B, P(A× B))
with
P
((
ΘCUtLASSC¯
)−1
((Ai,Bj))
)
=


0 if C = Ai for j = 1, . . . , l
0 if C = Bj for i = 1, . . . , k
pijΘC¯
if C 6= Ai and C 6= Bj
desribes the distribution of the deseletion behaviour of the physiian against treat-
ment C ∈ A ∪ B and
ΘCUtLASSC :
(
Ak × Bl, P(Ak × Bl)
)
−→ (A× B, P(A× B))
with
P
(
(ΘCUtLASSC )
−1((Ai,Bj))
)
=


0 if C 6= Ai for j = 1, . . . , l
0 if C 6= Bj for i = 1, . . . , k
p.jΘC if C = Ai
pi.ΘC if C = Bj
desribes the seletion of a physiian who hooses always the treatment C ∈ A ∪ B.
Remark.
• In the CUtLASS design CUtLASSk, l the physiian has k · l dierent pairs (Ai, Bj),
for i = 1, . . . , k and j = 1, . . . , l, whih he an hoose from. Sine there is no restri-
tions for the physiian's deision, it is possible that some pairs are unrepresented.
Consequently, also some treatments may be unrepresented.
• Sine the randomisation step and the patient-oriented step are independent in the
CUtLASSk, l design we obtain as the minimum alloation probability for any treat-
ment Ai ∈ A
P
((
Ψ ◦ΘCUtLASSA¯i
)−1
(Ai)
)
= pΨ P
((
ΘCUtLASSA¯i
)−1 ( l⋃
j=1
(Ai,Bj)
))
= pΨ · 0
= 0 for i = 1, . . . , k
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and analogously as the minimum alloation probability for any treatment Bj ∈ B
P
((
Ψ ◦ΘCUtLASSB¯j
)−1
(Bj)
)
= 0 for j = 1, . . . , l.
• The maximum alloation probability for any treatment Ai ∈ A is given by
P
((
Ψ ◦ΘCUtLASSAi
)−1
(Ai)
)
=pΨ P
((
ΘCUtLASSAi
)−1 ( l⋃
j=1
(Ai,Bj)
))
=pΨ
l∑
j=1
p.jΘAi︸ ︷︷ ︸
=1
=
1
2
for i = 1, . . . , k,
sine all other probabilities for Ai′ 6= Ai are zero. Analogously, the alloation prob-
ability for any treatment Bj ∈ B is given by
P
((
Ψ ◦ΘCUtLASSBj
)−1
(Bj)
)
=
1
2
for j = 1, . . . , l.
• Sine these probabilities are not dierent for strategies with dierent numbers of
treatments, the average minimum alloation probability for any Ci ∈ A ∪ B orre-
sponds to the minimum alloation probability for any treatment Ai ∈ A or Bj ∈ B.
Also the average maximum alloation probability for any Ci ∈ A∪B orresponds to
the maximum alloation probability for any treatment Ai ∈ A or Bj ∈ B.
If we add the average minimum and the average maximum alloation probabilities of
a CUtLASSk, l design in Figure 3.1, they will be loated in the parallel planes limited
by the uboid up- and downwards.

CHAPTER 4
Balane behaviour and pratial
implementation
4.1 Introdution
In this setion, we deal with the pratial implementation of the patient-oriented ran-
domisation design. `Randomisation depends primarily on two interrelated but separate
proesses, i.e. generation of an unpreditable randomised alloation sequene and on-
ealment of that sequene until assignment ours (alloation onealment)'(Shulz and
Grimes, 2002). We look at how these separate proesses are realised in the NeSSy study
and we look beyond at possible ways to reate the randomisation list to avoid imbalanes
in strategies A and B as well as in the frequenies of two-pair ombinations. `This is im-
portant beause treatment imbalanes may aets statistial power' (Lahin, 1988). We
onsider the eets in the NeSSy study to disuss possible problems and have a look at
models whih ompute the overall imbalanes for dierent numbers of entres and dierent
types of PORk, l designs.
4.2 Randomisation - applied in the NeSSy study
Example. Figure 4.1 illustrates the basi sequene of the randomisation proess in one
entre as implemented in the NeSSy study. The patients entered the study one by
one, and the treatment for eah patient had to be known soon after entry. `The allo-
ation proedure must not be too omplex or time-onsuming' (White and Freedman,
1978). Therefore, at the beginning of the study the biometri entre reated a ran-
dom list with the omplete information about the total proess [Z1℄. For eah random
number, the appropriate mediation had been entrally paked in two pakages [Z4℄ and
sent to the entres together with the information envelope [Z2℄. These pakages were
labelled with the orresponding random number and orresponding enoded information
(X and Y) for the rst or the seond pair hoie. When a patient presenting symptoms ap-
peared in the entre, the physiian started the sreening proedure. If eligible, he informed
the patient and asked for onsent. After written onsent, the patient was admitted and re-
eived a random number [1℄. The physiian reported inlusion of the patient with random
number and reeived [2℄ an envelope with the information about the two-pair ombination
for this random number [3℄. The physiian seleted the most suitable pair from this two-
pair ombination for this patient and justied his hoie in the CRF [4℄. Afterwards, the
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Figure 4.1: Flow hart of the pratial implementation of the study design (f. Shulz et al.
(2016a)).
mediation administration (study nurse) of the entre was informed about the deision and
the random number [5℄. On this basis, the physiian reeived the prepared parel for this
random number with the mediation provided by the entral randomisation [Z3℄ (double
blinded drug A or drug B out of the seleted pair). He stiked the ontrol label in the
CRF and handed over the rst drugs for the rst weeks ontained in the pakage.
For the ontrol of drug logistis [Z4℄, a ontrol system had been set up in terms of
durability during the whole study period. The demand for mediation of patients and
entres had been alulated in advane, monitored with speial respet to expiry dates,
prepared the neessary mediation and exhange-planned the return delivery of expired /
unused mediation from the entres. The spei design aused a greater amount of study
drugs to be provided as for eah random number two parels with mediation had to be
delivered. Mediation logistis management tried to reyle the returned unused pakages
but this proedure was limited espeially by expiry dates and rates of reruitment (f.
Shulz et al. (2016a)).
Example. In the NeSSy study, bloks were used in preparing randomisation assignments
to ensure an equal number of patients in eah strategy and of eah two-pair ombination.
The randomisation used a blok length of 30 whih arised from the number of two-pair
ombinations and the possibility of randomisation into both strategies (15×2). Aording
to the sample size alulations, 630 patients should be reruited into the NeSSy study.
For eah of the 10 partiipating entres a randomisation list was reated before the trial
started, using the method of stratied bloked randomisation in whih `entre' was the
prognosti variable (Pook and Simon, 1975; Lahin, 1988). The randomisation list was
ompletely balaned, i.e. in this list, eah of the 15 two-pair ombinations was represented
42 times and 315 patients had to be treated with strategy A and 315 with strategy B.
Following internal planning eah of the 10 entres should reruit about 60 patients. Thus
in the beginning eah entre was assigned to two bloks eah of length 30.
Remark. Following the argumentation in planning the NeSSy study, we assume through-
out that patients enter the study one by one, generally over some period of time and the
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treatment for eah patient will need to be known soon after entry. Therefore, we assume
that a total randomisation list is prepared at the beginning of the trial. As there is a
risk in some researh eld that the randomisation list is not fully proessed, a blok ran-
domisation is used to ensure that there are no large imbalanes in the number of patients
in eah strategy and also in the frequenies of two-pair ombinations. `Further, sine a
lini frequently may withdraw (or be dropped) from a study, it is desirable that suh
withdrawal not aet the validity of the overall randomization plan. For these reasons, it
is also generally advoated that randomization in a multienter trial should be stratied
by lini.' (Lahin, 1988)
Denition 4.2.1 (Minimum blok length of a PORk, l design). Let eah entry
in the randomisation list be a tuple onsisting of one two-pair ombination TPCm, for
m = 1, . . . , |TPC| and one strategy, either A or B. Then, the minimum blok length of
a patient-oriented randomisation design PORk, l is dened as smallest blok length whih
fulls the two following properties:
1. Eah two-pair ombination is randomised with the same frequeny for strategy A as
for strategy B, i.e.
|(TPCm,A)| = |(TPCm,B)| for all m = 1, . . . , |TPC|.
2. Eah two-pair ombination ours an equal amount of times, i.e.
|(TPCm,.)| = |(TPCm′ ,.)| for all m,m′ ∈ {1, . . . , |TPC|}.
Notation. The minimum blok length of a PORk, l design is denoted by H
POR
k,l .
Property 4.2.2 (Size of minimum blok length of a PORk, l design). For the
minimum blok length HPORk,l of a patient-oriented randomisation design PORk, l, we have
HPORk,l = 2 · |T PCk,l| = kl(kl − 1).
Proof. In general, we have
HPORk,l = min
|T PCk,l|∑
m=1
(|(TPCm,A)|+ |(TPCm,B)|) .
From property one of Denition 4.2.1 we know that
HPORk,l = min
|T PCk,l|∑
m=1
(2 · |(TPCm,A)|) .
Property two of Denition 4.2.1 gives that eah TPC ours with the same frequeny,
HPORk,l = min (2 · |(TPCm,A)| · |T PCk,l|) .
The only parameter we an minimize in this term is |(TPCm,A)|. Sine the blok length
should be greater than zero, eah tuple |(TPCm,A)|, for m = 1, . . . , |TPC|, ours only
one and onsequently also eah tuple |(TPCm,B)|, for m = 1, . . . , |TPC|. 
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Example. The minimum blok length of the patient-oriented randomisation designs for
the examples of Setion 2.3.6 would be 12 for the POR2, 2 design, 30 for the POR2, 3 design,
56 for the POR2, 4 design and 72 for the POR3, 3 design. The minimum blok length of a
patient-oriented randomisation design inreases very fast. Also for small numbers of k and
l, the minimum blok length for a patient-oriented randomisation design HPORk,l is large.
Remark. The minimum number of patients to be reruited should be at least HPORk,l to
insure that eah TPCm is randomised in eah strategy. Sine the minimum blok length
HPORk,l is very large even for small numbers of treatments in eah strategy, this is a drawbak
of a PORk, l design.
Example. During the NeSSy trial, reruiting problems ourred. As a onsequene, the
large pre-planned sample size of the NeSSy study was redued to a goal of 150 ases in
order to meet the apaities of the entres and the time lines of the study. At the end of
the study, 149 patients were randomised. The results of randomisation step 1 (two-pair
ombinations assigned) are doumented in Figure 4.2. As a result of the seond step of
randomisation 69 (46%) patients were assigned to strategy A and 80 (54%) patients to
strategy B. The partiipating entres diered in apaities for reruiting patients. Figure
4.3 illustrates the number of patients per entre. Sine the pre-planned sample size was
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Figure 4.2: Frequenies of two-pair ombi-
nations in the NeSSy study.
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Figure 4.3: Frequenies of patients per
entre in the NeSSy study.
not reahed, many of the randomisation bloks (eah of length 30) were not ompletely
proessed due to the large blok length and little numbers of reruited patients per entre.
Only two entres reruited almost two full bloks with 40% of the patients. Therefore,
the observed number of patients per strategy and per two-pair ombination diered from
the expeted numbers. In 149 patients, one would expet that eah strategy is overed
74.5 times and every two-pair ombination is overed 10 times. However, the observed
alloation to strategies was 69 : 80. Although the imbalanes are not very large, this shows
a disadvantage of the outlined randomisation proess.
With the stratied bloked randomisation, there is no imbalane between two-pair om-
bination frequenies, as long as all bloks are lled within eah stratum. However, if some
or all bloks are not lled as in the NeSSy study, there may our dierenes in patient
numbers between the strategies or two-pair ombination frequenies. In order to assess the
problem of imbalane, a mathematial model is built in the next setion, whih allows us
to investigate the relationship between blok length, number of strata and the probability
distribution of dierenes in sample sizes between the strategies.
4.3 Probability of strategy imbalane 49
4.3 Probability of strategy imbalane
4.3.1 Unstratied randomisation
As mentioned in the previous setion, we aim to develop a mathematial model whih
allows us to ompute the probability of strategy imbalanes. At rst, we onsider the ase
where we have only one entre and no stratum otherwise dened. In this ase of unstratied
randomisation, imbalanes in patient numbers between strategies emerge from the fat that
one blok is not lled ompletely. Later, we will transfer the idea developed to the stratied
bloked randomisation ase. The ontent of this setion is based on Kundt (2002). The
following proposition an be seen in general with a xed blok length h. Espeially in
the ontent of the patient-oriented randomisation design, we are mostly interested in the
imbalane in bloked randomisation with blok length equal to the minimum blok length
of the PORk, l design, i.e. h := H
POR
k,l . In pratie, it ould be also possible that a multiple
of the minimum blok length is used; then h := b · HPORk,l with b ∈ N (every possible blok
length is a multiple of the minimum blok length).
Proposition 4.3.1 (Strategy imbalanes in bloked randomisation). Assume N
patients should be randomised with equal probability to strategy A and B in one en-
tre. Let NA and NB be the number of patients assigned to strategy A respetively B and
AD := |D| := |NB −NA| be the absolute dierene of sample sizes. Then the probability
that the absolute dierene AD for a blok randomisation with xed blok length h is at
least e is given by
P(AD ≥ e) = 1− 2
h
e−1∑
i=1
h
2
−i∑
s=0
(h
2
s
)( h
2
s+i
)
( h
2s+i
) − 1
h
h
2∑
s=0
(h
2
s
)(h
2
s
)( h
2s
) .
Proof. Let R be the number of assignments issued in the last blok and r the realisation of
R, 1 ≤ r ≤ h. Furthermore, let S be the number of assignments to strategy A in the last
blok and s the realisation of S, 1 ≤ s ≤ h/2. Then the realisation of the absolute dier-
ene AD = |NB −NA| an take values between 0 and h/2. Conditional on R, S desribes
the draw of R items from a population of size h that has h/2 suess states in the popula-
tion. Hene, S onditional on R is hypergeometri distributed (S | R = r ∼ H(h, h/2, r)).
For R = r, this implies
P(S = s | R = r) =
(h
2
s
)( h
2
r−s
)
(
h
r
) .
Assumed R is uniform over the intergers 1 to h, then
P(R = r) =
1
h
.
Next, we alulate separately the probabilities P(AD = 0) and P(AD = e) for e ∈ N. This
results in
P(D = 0) = P(R = 2S)
=
h
2∑
s=0
P(S = s | R = r)P(R = 2s)
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=
h
2∑
s=0
(h
2
s
)( h
2
2s−s
)
( h
2s
) 1
h
=
1
h
h
2∑
s=0
(h
2
s
)(h
2
s
)(
h
2s
) . (4.1)
In a similar way, we alulate for e ∈ N
P(AD = e) = P(D = e ∨D = −e)
= 2P(D = e)
= 2P(R− 2S = e)
= 2
h
2
−e∑
s=0
P(S = s,R = 2S + e)
= 2
h
2
−e∑
s=0
P(S = s | R = 2s+ e)P(R = 2s + e)
= 2
h
2
−e∑
s=0
(h
2
s
)( h
2
2s+e−s
)
(
h
2s+e
) 1
h
=
2
h
h
2
−e∑
s=0
(h
2
s
)( h
2
s+e
)
( h
2s+e
) . (4.2)
Combining equations (4.1) and (4.2), we obtain
P(AD ≥ e) = 1− P(AD < e)
= 1−
e−1∑
i=0
P(AD = i)
= 1−
e−1∑
i=1
P(AD = i)− P(D = 0)
= 1− 2
h
e−1∑
i=1
h
2
−i∑
s=0
(h
2
s
)( h
2
s+i
)
(
h
2s+i
) − 1
h
h
2∑
s=0
(h
2
s
)(h
2
s
)(
h
2s
) . 
Example. Table 4.1 shows the probability of imbalane between the two strategies A and
B for dierent blok lengths. The extent of possible imbalanes is limited by the blok
length, i.e. the maximum imbalane in one enter is h/2. The assessment whether the
possible imbalane e is high depends on the total sample size of patients, e.g. an imbalane
of ten patients is high at a sample size of 50 patients but not at a sample size of 5000
patients.
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h\e 0 1 2 3 4 5 6 7 10
2 0.500 0.500 - - - - - - -
4 0.417 0.583 0.083 - - - - - -
6 0.367 0.633 0.150 0.016 - - - - -
8 0.332 0.668 0.204 0.039 0.004 - - - -
10 0.306 0.694 0.248 0.063 0.010 0.001 - - -
12 0.286 0.714 0.285 0.087 0.019 0.003 0.0002 - -
30 0.197 0.803 0.470 0.252 0.122 0.053 0.021 0.007 0.0001
56 0.150 0.850 0.583 0.383 0.239 0.142 0.079 0.042 0.004
72 0.134 0.866 0.624 0.434 0.291 0.188 0.116 0.069 0.011
Table 4.1: Probabilities for imbalanes between strategies in blok randomisation greater
or equal to e for dierent blok lengths h.
4.3.2 Stratied randomisation
In ontrast to the unstratifeid ase, K-strata randomisation harbours the risk of up to K
unlled bloks. We will see, that the probability of a strategy imbalane is greater in a
linial trial with stratied bloked randomisation than in a unstratied bloked randomi-
sation. Hallstrom and Davis (1988) desribe the probability of total imbalanes in a trial
using stratied bloked randomisation.
Lemma 4.3.2. Assume N patients should be assigned with equal probability to strategy A
and B, within K strata (entres). Eah of the K strata are balaned by using bloks, and
the blok size in eah stratum is h. Let Ri be the number of assignments issued in the last
blok of the ith stratum and ri the realisation of Ri, 1 ≤ ri ≤ h. Furthermore, let Si be the
number assigned to strategy A in that blok of the ith stratum and si the realisation of Si,
1 ≤ si ≤ h/2. Dene
Di := (Ri − Si)− Si = Ri − 2Si
to be the imbalane in the ith stratum. Summing over the independent strata, the total
imbalane between the strategies is given by
D =
K∑
i=1
Di.
We then have
E[Di] = 0, Var[Di] =
hE[Ri]− E[R2i ]
h− 1
and
E[D] = 0, Var[D] =
K∑
i=1
hE[Ri]− E[R2i ]
h− 1 . (4.3)
Proof. Conditional on Ri, Si obeys, similar to the ase with one entre, a hypergeometri
52 4 Balane behaviour and pratial implementation
distribution (Si | Ri = ri ∼ H(h,h/2,ri)), with
E[Si | Ri] = Ri
2
and Var[Si | Ri] = Ri(h−Ri)
4(h− 1) . (4.4)
For the expetations of Di | Ri and Di, we have
E[Di | Ri] = Ri − 2E[Si | Ri] = 0 and also E[Di] = E[E[Di | Ri]] = 0.
For the variane in the ith stratum we obtain
Var[Di] = E [Var[Di | Ri]] + Var [E[Di | Ri]]
= E
[
E[(Ri − 2Si)2 | Ri]
]
+ 0
= E
[
E[R2i − 4SiRi + 4S2i | Ri]
]
= E
[
R2i − 4RiE[Si | Ri] + 4E[S2i | Ri]
]
= E
[−R2i + 4 E[S2i | Ri]︸ ︷︷ ︸
=Var[Si|Ri]+(E[Si|Ri])
2=Var[Si|Ri]+R2i /4
]
with (4.4)
= E [4Var[Si | Ri]]
= E
[
hRi −R2i
h− 1
]
with (4.4)
=
hE[Ri]− E[R2i ]
h− 1 .
and for the sum of the independent dierenes in eah stratum follows
Var[D] = Var
[
K∑
i=1
Di
]
=
K∑
i=1
Var[Di] =
K∑
i=1
hE[Ri]− E[R2i ]
h− 1 . 
Remark.
• The absolute dierene of ADi = |Di| an take values between 0 and h/2. The
umulative dierene over all strata AD =
∑K
i=1ADi lies between 0 and Kh/2.
Before the probability of the imbalane is alulated, the dierene between treated
patients in eah strategies whih is not desired should be determined depending on
the sample size, e.g. a dierene of 50 patients are a lot in a total of 100 patients but
not in 10,000 patients.
• To use the variane formula (4.3) and to determine the probability of imbalanes
with blok size h and number of strata K, the rst two moments of Ri must be
known. Hallstrom and Davis (1988) onsider two speial ases that simplify these
formulas. We present these two dierent models in the next two lemmas. In the rst
model, we assume that Ri follows a disrete uniform distribution on the integers 1 to
h. In the seond ase, the number of assignments in the last blok of the ith stratum
Ri follows a binomial distribution with parameters h and pi. In general, the blok
length h is xed and hpi is the average number of assignments in the last blok.
Hallstrom and Davis (1988) and Kundt (2002) assume a binomial distribution for
the number of assignments in the last blok of ith stratum Ri with N and Pi, the
total number of randomised patients and the probability that a patient belongs to
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the ith stratum. If we assume that no blok is lled, this assumption of binomial
distribution an be used. Otherwise, this ontradits the denition of Ri as number
of assignments issued in the last blok of the ith stratum, 1 ≤ Ri ≤ h.
Example. Figure 4.4 shows the observed numbers of assignments in the last bloks ri
and the dierenes to the mean of all ri of eah entre in the NeSSy study. Based on
this database, it is diult to estimate the rst and seond moment of Ri for eah en-
tre, sine we have only one value for one entre. However, if we assume that all Ri are
independent and identially distributed, we an estimate the moments with the empirial
moment estimators from the 14 entres. We obtain a mean value of 6.36 and a seond
moment of 77.43 and in total an estimation of Var[D] with 54.69 (
√
Var[D] = 7.40).
In the same way, we an also estimate Var[Di] diretly with the imbalanes of strate-
gies di from all entres (d1 = 0, d2 = −1, d3 = −2, d4 = 1, d5 = 2, d6 = 6,
d7 = 0, d8 = −1, d9 = 1, d10 = 1, d11 = 2, d12 = 1, d13 = 1 and d14 = 0). We obtain an
empirial standard deviation for D of 7.07.
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Figure 4.4: Observed numbers of assignments issued in the last blok ri in the NeSSy study,
by entre. The striped areas (red and light grey) show the dierenes to the
mean number of patients in eah entre.
Lemma 4.3.3 (First model  uniform distribution). Let Ri be uniformly distributed
over {1, . . . , h}. Then we have
Var[D] =
K(h+ 1)
6
. (4.5)
Proof. Under the uniform distribution assumption, we have
E[Ri] =
h+ 1
2
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and
E[R2i ] = Var[Ri] + (E[Ri])
2
=
h2 − 1
12
+
(
h+ 1
2
)2
=
h2 − 1 + 3h2 + 6h+ 3
12
=
2(2h2 + 3h+ 1)
12
=
(h+ 1)(2h + 1)
6
.
Thus, from Equation (4.3), we get
Var[D] =
1
h− 1
K∑
i=1
(
h
h+ 1
2
− (h+ 1)(2h + 1)
6
)
=
1
h− 1
K∑
i=1
(h− 1)(h + 1)
6
=
K(h+ 1)
6
. 
Lemma 4.3.4 (Seond model  binomial distribution). Let Ri be binomially dis-
tributed with parameter h and pi (Ri ∼ Bin (h, pi)). Then we have
Var[D] = h
K∑
i=1
pi(1− pi). (4.6)
Proof. Under the binomial distribution,
E[Ri] = hpi
and
E[R2i ] = Var[Ri] + (E[Ri])
2
= hpi(1− pi) + (hpi)2.
From (4.3), we an ompute
Var[D] =
K∑
i=1
hhpi −
(
hpi(1− pi) + (hpi)2
)
h− 1
=
K∑
i=1
hpi (h− (1− pi + hpi))
h− 1
= h
K∑
i=1
pi(h− 1 + pi − hpi)
h− 1
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= h
K∑
i=1
pi(h− 1)(−pi + 1)
h− 1
= h
K∑
i=1
pi(1− pi). 
Remark. To ompute the probability P(AD ≥ e), for e ≥ 0, a normal approximation
to the distribution of D an be used (Rosenberger and Lahin, 2004, page 57). Assume
D
A∼ N (0,Var[D]), then it follows that (Var[D])−1/2D is standard normally distributed
and
P(AD ≥ e) = P(|D| ≥ e)
= P
(∣∣∣∣∣ D√Var[D]
∣∣∣∣∣ ≥ e√Var[D]
)
≃ Φ
(
− e√
Var[D]
)
+ 1− Φ
(
e√
Var[D]
)
= 2
(
1− Φ
(
e√
Var[D]
))
.
The variane Var[D] as well as this probability depend on the number of strata (entres)
K and the blok length h. In the seond model onsidered above, the probabilities pi
additionally inuene P(AD ≥ e) through Var[D].
Example. In the NeSSy study, there was an imbalane of AD = 11 between the strategies.
With the newly derived models, we want to alulate the probability of an imbalane greater
than or equal to eleven for the originally planned study sample size and for the atual
one. It was planned to reruit 630 patients in K = 10 entres at blok length h = 30,
i.e. more than one blok was expeted to be lled in eah stratum. For the uniformly
distributed model, we reeive the probability P(AD ≥ 11) = 0.13. For the alulation of
the probability, we use the normal approximation of the remark above and the Equation
(4.5) for the variane of D in the rst model. For the seond model, we have to make
some assumptions on the probabilities pi of the distribution of eah number of assignments
issued in the last blok of the ith stratum Ri. For pi = 1/2, we reeive P(AD ≥ 11) = 0.20.
In the worst ase senario, eah blok is lled only half and all of the patients of this half
blok are randomised to one strategy.
In the study performed, 149 patients were reruited in 14 entres, i.e. on average,
eah entre has reruited 10.64 patients. In this ase, we an use the distribution of the
observed numbers of assignments in the last blok seen in Figure 4.4 for the binomially
distributed model. We take in eah enter the same probability pi =
∑
i ri/(14 ·30) = 0.21
for i = 1, . . . , 14 , the average relative frequeny of the number of assignments in the last
blok, and alulate the variane from Equation (4.6). Thus, we obtain P(AD ≥ 11) = 0.19.
With the uniformly distributed model, we reeive P(AD ≥ 11) = 0.20. To investigate how
well these models desribe the reality, we made simulation studies in whih the NeSSy
study onditions were used with their distribution of patients per enter (see Figure 4.5).
For the results, 10,000 simulation runs were performed. Figure 4.5 shows the histogram
and normal approximation with the mean 74.51 and standard deviation sd = 4.20 of the
number of patients in strategy A from the simulations.
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Figure 4.5: Histogram and normal approximation of the distribution of the patients treated
with one strategy from a simulation study with NeSSy onditions.
Although AD = 11 is a large dierene in a small sample size of 149, the probability to
reah this absolute dierene is larger than 19%. With the present distribution of patients
per entre, a worst ase dierene of AD = 75 was theoretially possible in the NeSSy
study. This number results from the following onsiderations: We have two full bloks in
two entres and these are balaned. Additionally, we have one inomplete blok where more
than the half of the patients (22 patients) are randomised. Therefore, at least 14 patients
are balaned in this blok and in total at least 74 patients are balaned in strategies. The
remaining patients (149 − 74 = 75) may be randomised to only one strategy. In Setion
4.5, we disuss modiations of the randomisation list whih derease the probability of
strategy imbalanes.
If we onsider the dierene of both strategies, the mean of the dierene is equal to zero
(see Equation 4.3) and we an onentrate on the standard deviation. Figure 4.6 shows the
histogram of dierene between both strategies in the simulation studies and the normal
approximation with standard deviation from the simulations, the uniform model and the
binomial model. The standard deviations from the uniform and binomial model are lose
to the empirial standard deviations. Hene the theoretial results are onsistent with the
simulation studies.
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Figure 4.6: Histogram and normal approximation (approx.) of the distribution of dier-
enes between both strategies. Normal approximations are alulated with
standard deviation from the simulations (data), the uniform model (uni) and
the binomial model (binom).
4.4 Probability of two-pair ombination imbalane
Example. To measure the imbalane in the number of appearanes of two-pair ombina-
tions, we need a parameter whih desribes the distanes of the frequenies of eah two-pair
ombination from the mean value of the frequenies of two-pair ombinations.
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Figure 4.7: Idea for measuring the imbalane in frequenies of two-pair ombinations. The
striped areas (red and light grey) show the deviations from the mean per two-
pair ombination.
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To introdue suh a parameter, we have a look at the NeSSy example with the dierent
frequenies of two-pair ombinations (see Figure 4.7). At a number of 149 patients, eah
of the 15 two-pair ombinations should our 149/15 ≈ 9.93 times. The striped areas in
Figure 4.7 show the deviations from the mean. If we average all squared deviations, we
obtain a standard deviation of 2.19.
Sine we do not have the frequenies of two-pair ombinations when planning a study, we
will design a model for the expeted variane. At rst, we have a look at the model for
only one entre with one blok. Later we will generalize this idea to the ase of one enter
with more bloks and to the stratied bloked randomisation ase with K > 1 entres.
Denition 4.4.1 (Variane estimator and average variane estimator). Let Xm,
for m = 1, . . . , τ , identially and independently distributed random variables with expeted
value E[Xm] <∞ and unknown variane Var[Xm] < ∞. ~X := (X1, . . . ,Xτ ) desribes the
vetor of all Xm. Then, we dene a variane estimator of Xm as
S2( ~X) :=
1
τ
τ∑
m=1
(Xm − E[Xm])2
and the average variane estimator of Xm as the expeted value of the variane estimator
of Xm
E[S2( ~X)] =
1
τ
τ∑
m=1
E
[
(Xm − E[Xm])2
]
.
4.4.1 Unstratied randomisation
Proposition 4.4.2 (Average variane estimator of the two-pair ombination fre-
quenies in one blok). Consider a PORk, l design with only one blok of minimum
blok length h := HPORk,l . We denote the number of two-pair ombinations in T PCk,l by τ .
Remember that between h and τ , we have the relation h/2 = τ , that means we have two
equal two-pair ombinations in eah blok. Let R be the number of assignments issued and r
the realisation of R, 1 ≤ r ≤ h, and let Xm, m = 1, . . . , τ the number of ourrenes of the
mth two-pair ombination. Then, ~X | R = r is multivariate hypergeometrially distributed
with H(h,2, . . . , 2, r) and the marginal distribution of Xm | R = r follows a hypergeometri
distribution with H(h, 2, r). Furthermore,
E[S2( ~X)] =
2(h− 2)
h2(h− 1)E[R](h− E[R]) +
2
h(h− 1)Var[R]. (4.7)
Proof. Conditional on R, eah Xm, m = 1, . . . , τ desribes the draw of R items from a
population of size h that has 2 suess states in the population. The marginal distribution
of Xm | R = r follows a hypergeometri distribution with H(h, 2, r), whih implies
E[Xm | R] = 2R
h
and Var[Xm | R] = 2R(h− 2)(h−R)
h2(h− 1) . (4.8)
For the average variane estimator of Xm we obtain
E[S2( ~X)] =
1
τ
τ∑
m=1
E
[
(Xm − E[Xm])2
]
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=
1
τ
τ∑
m=1︸ ︷︷ ︸
=1
Var[Xm], sine Xm i.i.d.
= Var[Xm].
With the variane deomposition, we ompute the variane of Xm
E[S2( ~X)] = E[Var[Xm | R]] + Var[E[Xm | R]]
= E
[
2R(h− 2)(h −R)
h2(h− 1)
]
+Var
[
2R
h
]
, with Equations (4.8)
=
2(h− 2)
h2(h− 1)(hE[R]− E[R
2]) +
4
h2
Var[R]
=
2(h− 2)
h(h− 1)E[R]−
2(h− 2)
h2(h− 1)E[R
2] +
4
h2
Var[R]
=
2(h− 2)
h(h− 1)E[R]−
2(h− 2)
h2(h− 1)Var[R]−
2(h− 2)
h2(h− 1)(E[R])
2 +
4
h2
Var[R]
=
2(h− 2)
h2(h− 1)E[R] (h− E[R]) +
2
h(h− 1)Var[R]. 
Conlusion 4.4.3 (First model  uniform distribution). If R is uniformly distributed
over the integers 1 to h, then
E[S2( ~X)] =
2h2 − h− 3
3h2
.
Proof. If we assume that R is uniformly distributed, we plug
E[R] =
h+ 1
2
and Var[R] =
(h+ 1)(h− 1)
12
into Equation (4.7)
E[S2( ~X)] =
2(h− 2)
h2(h− 1)
h+ 1
2
(
h− h+ 1
2
)
+
2
h(h− 1)
(h+ 1)(h − 1)
12
=
(h− 2)(h + 1)
2h2
+
h+ 1
6h
=
3(h2 − 2h+ h− 2) + h2 + h
6h2
=
4h2 − 2h− 6
6h2
=
2h2 − h− 3
3h2
. (4.9)

Conlusion 4.4.4 (Seond model  binomial distribution). Let R be binomially
distributed with parameters h and p (R ∼ Bin (h, p)). Then we have
E[S2( ~X)] = 2p(1− p). (4.10)
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Proof. If we assume that R is binomially distributed, we insert
E[R] = hp and Var[R] = hp(1− p)
into Equation (4.7)
E[S2( ~X)] =
2(h − 2)
h2(h− 1)hp(h− hp) +
2
h(h− 1)hp(1− p)
=
2p(1− p)
h− 1 (h− 2 + 1)
= 2p(1− p). 
Conlusion 4.4.5. Consider a PORk, l design with T bloks of length h and let
t ∈ {1, . . . , T − 1} be an arbitrary but xed number of lled bloks. Then
1. the average variane estimator of
~Xt+1 = (Xt+11 , . . . , X
t+1
τ ), where X
t+1
m desribes
the number of ourrenes of TPCm in the (t + 1)th blok, is equal to the average
variane estimator in Equation (4.7).
2. the average variane estimator of
~Xtot = (Xtot1 , . . . , X
tot
τ ), where X
tot
m is the number
of ourrenes of TPCm, is equal to the average variane estimator of ~X
t+1
.
Proof.
1. Obviously
~Xt+1 follows the same distribution as ~X from Proposition 4.4.2. Therefore
we have
E[S2( ~X)] = E[S2( ~Xt+1)].
2. Aording to the onditions, the rst t bloks are ompletely lled. Eah two-pair
ombination ours twie in a lled blok. Therefore, we have
Xtotm = X
t+1
m + 2t.
Consequently, we have
S2( ~Xtot) =
1
τ
τ∑
m=1
(
Xtotm − E[Xtotm ]
)2
=
1
τ
τ∑
m=1
(
Xt+1m + 2t− E[Xt+1m ]− 2t
)2
=
1
τ
τ∑
m=1
(
Xt+1m − E[Xt+1m ]
)2
= S2( ~Xt+1).
Thus, for the average variane estimators, we obtain the required equality
E[S2( ~Xtot)] = E[S2( ~Xt+1)]. 
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4.4.2 Stratied randomisation
In this setion, we onsider the average variane estimator of two-pair ombination frequen-
ies if we have K > 1 entres (strata). For this purpose, we have to extent the previous
onsiderations from one stratum of K strata.
Conlusion 4.4.6. Assume N patients should be assigned with equal probability to eah
two-pair ombination, within eah of the K strata (entres). The two-pair ombinations
are balaned in eah stratum, and the blok size in eah stratum is h := HPORk,l . Let Ri
be the number of assignments issued in the last blok of the ith stratum, and let ri be the
realisation of Ri, 1 ≤ ri ≤ h. Furthermore, let Xmi be the number of assignments to the
mth two-pair ombination in the last blok of the ith stratum and xmi the realisation of
Xmi, 0 ≤ xmi ≤ 2. Furthermore, let ~Xm = (Xm1, . . . ,XmK) be the vetor of random
variables desribing the number of assignments to the mthe two-pair ombinations in all
strata. Then we have for the average variane estimator of
~X1, . . . , ~XK
S2( ~X1, . . . , ~XK) :=
1
τ
τ∑
m=1
K∑
i=1
(Xmi − E[Xmi])2
of the two-pair ombinations
E[S2( ~X1, . . . , ~XK)] =
K∑
i=1
(
2(h− 2)
h2(h− 1)E[Ri](h− E[Ri]) +
2
h(h− 1)Var[Ri]
)
. (4.11)
Proof. In the same manner as before, we obtain with Xmi | Ri = ri ∼ H(h, 2, ri)
E[S2( ~X1, . . . , ~XK)] =
1
τ
τ∑
m=1︸ ︷︷ ︸
=1
K∑
i=1
E
[
(Xmi − E[Xmi])2
]
=
K∑
i=1
E
[
(X1i − E[X1i])2
]
=
K∑
i=1
(
2(h − 2)
h2(h− 1)E[Ri](h− E[Ri]) +
2
h(h − 1)Var[Ri]
)
.

Conlusion 4.4.7 (First model  uniform distribution). Let Ri be uniformly dis-
tributed over {1, . . . , h}. Then we have
E[S2( ~X1, . . . , ~XK)] =
K(2h2 − h− 3)
3h2
. (4.12)
Proof. Under the uniform distribution assumption, we have
E[Ri] =
h+ 1
2
and Var[Ri] =
(h+ 1)(h− 1)
12
.
Therefore, from Equations (4.11) and (4.9) follows that
E[S2( ~X1, . . . , ~XK)] =
K(2h2 − h− 3)
3h2
. 
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Conlusion 4.4.8 (Seond model  binomial distribution). Let Ri be binomially
distributed with parameters h and pi (Ri ∼ Bin (h, pi)). Then we have
E[S2( ~X1, . . . , ~XK)] = 2
K∑
i=1
pi(1− pi). (4.13)
Proof. Under the binomial distribution, we have
E[Ri] = hpi and Var[Ri] = hpi(1− pi).
From (4.11), we an ompute E[S2( ~X1, . . . , ~XK)]
E[S2( ~X1, . . . , ~XK)] =
K∑
i=1
(
2(h − 2)
h2(h− 1)hpi(h− hpi) +
2
h(h − 1)hpi(1− pi)
)
=
K∑
i=1
2pi(1− pi)
h− 1 (h− 2 + 1)
= 2
K∑
i=1
pi(1− pi). 
Remark. To ompute the probability P(|Xm − E[Xm]| ≥ e2), for e2 ≥ 0, the nor-
mal approximation an be used (Rosenberger and Lahin, 2004, page 57). Assume
Xm − E[Xm] A∼ N (0,σ2), in whih σ2 is estimated by the average variane of the two-pair
ombination frequenies. Then (E[S2( ~X1, . . . , ~XK)])
−1/2(Xm − E[Xm]) follows a standard
normal distribution and
P(|Xm − E[Xm]| ≥ e2) = P


∣∣∣∣∣∣ Xm − E[Xm]√E[S2( ~X1, . . . , ~XK)
∣∣∣∣∣∣ ≥ e2√E[S2( ~X1, . . . , ~XK)


≃ Φ

− e2√
E[S2( ~X1, . . . , ~XK)

+ 1− Φ

 e2√
E[S2( ~X1, . . . , ~XK)


= 2

1− Φ

 e2√
E[S2( ~X1, . . . , ~XK)
)



 .
The probability respetively the variane depend on the number of strata (entres) K
and the blok length h. In the seond model the probabilities pi additionally inuene
P(|Xm − E[Xm]| ≥ e2).
Example. In order to ompare the dierent models for the imbalanes between two-
pair ombination frequenies, we ome bak to our simulation studies in whih we used
the NeSSy study onditions inluding the same distribution of patients per enter (see
Figure 4.5). The simulation was run 10,000 times and yielded a mean of 9.93 and a
standard deviation 2.13 for the frequenies of two-pair ombinations. Figure 4.8 shows
the histogram and the normal approximations of the frequenies of ourrene of the two-
pair ombinations from the simulation study, the uniform model and the binomial model.
The standard deviation of the uniformly distributed model is approximately 3.03. For the
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seond model, we take the same probability pi =
∑
i ri/(14 · 30) = 0.21 for i = 1, . . . , 14 in
eah enter, the average relative frequeny of the number of assignments in the last blok.
Hene we reeive a standard deviation of the binomially distributed model of 2.16 whih
is lose to the empirial standard deviation.
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Figure 4.8: Histogram of the two-pair ombination frequenies and the normal approxima-
tion with standard deviation from a simulation study with NeSSy onditions,
uniform model (uni) and binomial model (binom).
Remark. The onept of two-pair ombination imbalane outlined above an not only
be onsidered in this ontext. Rather, it is the generalisation of imbalane between two
treatments to τ treatments. The only adjustment whih has to be made is the number of
treatments in one blok (here it is two).
4.5 Possible modiations of randomisation lists
4.5.1 Modiation I
As Pook (1982) desribed, `to ahieve suessful balanes [in the standard method of
stratiation, the blok randomisation within strata℄ the blok size should not to be too
large, say bloks of 4 or 6 with 2 treatments, and the number of strata should not to be too
great'. Usually, we do not have any inuene on the number of entres sine in pratie, a
ertain number of entres is needed to ahieve the preplanned sample size. Nevertheless,
attempts should be made to keep this number as low as possible. Likewise, we do not
have the possibility to hange the minimum blok length HPORk,l , beause it is determined
by the number of two-pair ombinations. Our main aim is to avoid imbalanes between
strategies beause this may aet the power of a statistial test. For example, the power
of the t-test for the dierene in means of two groups is maximised with equal sample sizes
(see Lahin (1988) and Appendix of White and Freedman (1978)). We an reah this aim
with one modiation to the randomisation list. For this we onsider the POR2, 2 design
as an example.
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Example. The POR2, 2 design has a minimum blok length of H
POR
2, 2 = 12. Eah blok
in the random list onsists of six tuples with strategy A and six tuples with strategy
B. If the entire blok is used, both strategies are balaned. But we ould even design a
randomisation list in whih both strategies are balaned after eah 6, 4 and 2 two-pair
ombinations. To this end, we dene the sub blok length hj with H
POR
2, 2 =
∑J
j=1 hj ,
j = 1, . . . , J , where J is the quotient of minimum blok length HPOR2,2 and sub blok length
hj . We assume that hj = hj′ for j 6= j′. Table 4.2 shows the possibilities of sub bloks in
the POR2, 2 design.
Possibility Number of sub bloks Sub bloks length
1 1 h1 = 12
2 2 h1 = 6, h2 = 6
3 3 h1 = 4, h2 = 4, h3 = 4
4 6 h1 = 2, h2 = 2, h3 = 2, h4 = 2, h5 = 2, h6 = 2
Table 4.2: Possibilities of sub bloks in the POR2, 2 design.
As may be seen in Table 4.1 for one entre P(AD ≥ e), e ≥ 1, is largest for hj = 12 and
beomes smaller with dereasing blok length.
With this approah, the minimum blok length is maintained. We arry an additional
restrition for the randomisation list, that we have a good balane between the strategies
in unlled bloks.
Denition 4.5.1 (Sub blok length). Consider a PORk, l design. Then a sub blok
length hj of H
POR
k,l is every even number in the set of divisors of the minimum blok length
HPORk,l . We have
HPORk,l =
J∑
j=1
hj = J · hj ,
where J is the quotient of minimum blok length HPORk,l and sub blok length hj .
Remark. For the distribution of the imbalane between the strategies, we use the theory
from Setion 4.3 and use instead of the minimum blok length, the sub blok length. The
suitability for the orresponding sub blok length should therefore be onsidered in advane.
It should be taken into aount that a small sub blok length has the disadvantage that the
physiian an predit at the end of eah blok what the next strategy will be if he knows
that there are balaned sub bloks. Although the risk of this is very low in double-blind
studies, one should avoid small blok sizes suh as two. Two standard proedures will also
be used in order to redue the preditability: rstly, the sub blok length an be hanged at
random from one minimum blok to the next and seondly, the physiian should preferably
not be informed that a sub bloking is being used in partiular they should not know the
sub blok size (Pook, 1979).
Example. Theoretially, the standard deviation of the dierene D between the two
strategies beomes smaller with smaller blok length. We performed dierent simulation
studies under the NeSSy onditions with dierent sub blok lengths. The results are shown
in Figure 4.9. We an onlude that by using a sub blok length smaller than the mini-
mum blok length, already a great improvement in the probability of strategy dierenes
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Figure 4.9: Histogram of frequenies of patients treated with strategy A and normal ap-
proximation (approx.) with standard deviations of strategy dierenes from
simulation studies with dierent sub blok lengths hj = 30, hj = 10, hj = 6
and hj = 2 used in the randomisation list.
is oneded. However, the dierene between the sub blok lengths hj = 10 and hj = 6
is not large. In order to prevent the preditability, we advoate for the sub blok length
hj = 10, in the POR2, 3 design used here.
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Figure 4.10: Histogram of the two-pair ombination frequenies and normal approximation
(approx.) of the two-pair ombination frequenies with standard deviation
from simulation studies with previous randomisation list and with randomi-
sation lists with modiation I.
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Figure 4.10 shows the results of the simulations desribed above for the frequenies of
two-pair ombinations. As we an see, also an improvement in the standard deviation of
the frequenies of ourrene of the two-pair ombinations was oneded by introduing
sub bloks in the randomisation. The improvement is the same for dierent sub blok
length hj .
4.5.2 Modiation II
Our seond aim is avoiding imbalanes between the frequenies of two-pair ombinations.
Ahieving this goal is muh more diult than balaning between strategies beause the
number of the dierent two-pair ombinations is larger ompared to the number of strate-
gies. This problem is not serious if we have one entre and exeute the minimum blok
length in suession. If the omplete blok is not used, the maximum dierenes between
the frequenies of two-pair ombinations an at most be two, e.g. if one two-pair om-
bination was assigned twie, one for strategy A and one for strategy B and the other
two-pair ombinations was not assigned. In the stratied ase, eah stratum an ahieve
a dierene of two between the two-pair ombination frequenies. In the worst ase se-
nario, the same two-pair ombinations are assigned, respetively unassigned, in eah of
the K strata. This results in the maximum imbalane possible between the frequenies of
two-pair ombinations of 2K. To redue the probability of great imbalanes between the
frequenies of two-pair ombinations, we perform a further modiation in the preparation
of the randomisation list that after a ertain number of randomised patients, the frequen-
ies of two-pair ombinations of all strata are balaned as in a Latin square. To make the
idea lear, we onsider the POR2, 2 design as an example.
Example. We onstrut a random list H with minimum blok length HPOR2, 2 = 12 for one
entre suh that H is divided into three sub bloks h1, h2 and h3 eah of blok length four
with the restrition that both strategies our equally often in eah sub blok. We assume
for the sake of simpliity that we have a number of three entres indiated by C1, C2 and
C3. Now we reate for eah of the three entres one random list with minimum blok
length HPOR2, 2 and rearrange the three sub bloks h1, h2 and h3 in suh a way that all sub
bloks of the three overall bloks result in a Latin square (see Table 4.3).
Centres C1 C2 C3
H
h1 h2 h3
h3 h1 h2
h2 h3 h1
Table 4.3: Modiation II: Latin square with sub bloks.
However, the two-pair ombinations in eah sub blok are also randomised and for this
reason, we have a dierent ordering in eah overall blok. The assignment of the overall
bloks H to the three entres may be random. By the arrangement of the sub bloks
in a Latin square, one overall blok is still lled although maybe only four patients are
randomised in eah entre.
Example. In the NeSSy simulation studies, we also used the modiation outlined here
with a sub blok length hj = 10 for one random list. Figure 4.11 shows the results of
the simulations studies with NeSSy onditions. The simulation studies with the original
randomisation list has the largest standard deviation. Introduing sub bloks (as was done
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in the previous setion, modiation I) leads to a smaller standard deviation than the
original randomisation list. The maximum redution of standard deviation is realised with
modiation II outlined here.
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Figure 4.11: Histogram of the two-pair ombination frequenies and normal approximation
(approx.) of the two-pair ombinations frequenies with standard deviation
from NeSSy simulation studies with previous randomisation list and with ran-
domisation lists with modiation I and II (hj = 10).
Remark.
• In order to prevent the preditability, the use of a Latin square should not be known
to the physiians.
• The balane behaviour between the strategies is not improved merely by the step
from introduing sub bloks (modiation I) to arranging these in a Latin square
(modiation II).
4.5.3 Summary modiation
The results of this setion should be kept in mind when planning a new trial. The prob-
ability of imbalanes should be heked under the given onditions (sample size, number
of treatments and entres, blok size) during the planning phase. If these theoretial on-
siderations raise no onerns for large imbalanes, there is no need for the use of one of
the two presented modiations. The assignments of treatments in both modiations of
the random list are fully random and the benets of randomisation (f. Shulz and Grimes
(2002)) still exist. However, both modiations restrit the randomisation list more than
the original one.
If the theoretial onsiderations demonstrate onerns for large imbalanes as well as
inuene on the results of the statistial analysis, one of the modiation methods should
be used. Both restrited randomisation modiations ontrol the probability of obtaining
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an alloation sequene with an undesirable sample size imbalane. Modiation I redues
the imbalane in the strategy groups as well as in the frequenies of two-pair ombina-
tions. Moving from modiation I to modiation II only leads to the improvement of
the imbalane in the two-pair ombination frequenies. Beause of the main fous in this
patient-oriented randomisation design is strategy omparison, modiation I is denitely
an option worth onsidering in the planning of a trial. To generate an unpreditable ran-
domised alloation sequene, the sub blok length should be seleted not too smallas
mentioned before. To evaluate the dierent sub blok lengths the presented onsiderations
ould be taken into aount.
CHAPTER 5
Statistial analysis
5.1 Introdution
The main goal of the PORk, l design is to ompare the strategies, but the design also allows
us to test the dierenes in treatment means of the outome between the patients who re-
eived the treatment solely due to randomisation (randomised hoie treated patients) and
those where the treatment hoie was patient-oriented (patient-oriented treated patients).
This test an be performed in eah treatment, eah strategy, or overall as well. Further-
more, the dierenes between strategies an be analysed for subgroups onsisting of only
randomised hoie treated patients or only patient-oriented hoie treated patients. In this
ase, we an test our assumptions about the eay of strategies, taking heterogeneity of
patient-drug-interation by physiian's deision into aount.
In order to be able to formulate the aording hypotheses and tests, we rst introdue a
suitable statistial model (one-way lassiation) as well as the onept of ontrast testing.
Both are well known, but are briey reviewed here, to speify the notation used in our
onsiderations for the PORk, l design. The ontent of this part is based on Kirk (1995) and
Winer et al. (1991). After the basi onepts and notation have been introdued we will
disuss whih ontrasts are of partiular interest in the PORk, l design. Primarily, we are
interested in a ontrast omparing two dierent strategies. Beside the main ontrast we
are also interested in ontrasts omparing the treatment eets of only randomised hoie
treated patients and patient-oriented hoie treated patients. Afterwards, we onsider the
sample size alulation and how the sample size hanges if the treatments' sample sizes
dier. In the last setion, we will examine the inuene of the physiians' patient-oriented
deision and of the heterogeneous populations on this main ontrast for the three dierent
study approahes (POR, Block and CUtLASS design) taking the ase of two strategies
and two treatments in eah strategy as example.
5.2 Model
In a linial trial, we often have a response Y depending on dierent fators like the
eetiveness of treatments or sex. A fator is a ategorial variable whih an realise in
several ategories (alled `levels' in the sequel). The goal is to analyse the eets of levels
of fators on the mean of Y . In this thesis, we assume that the response Y is normally
distributed. The ase of a disrete response is not onsidered here.
In our spei ase, the linial trial fouses on a strategy omparison A vs. B with
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dierent treatments A1, . . . , Ak respetively B1, . . . , Bl where the sample size per treatment
diers in the most ases. In our ase `treatment' is the fator of interest. Beause of the
unequal numbers of patients per treatment we onsider a model whih aounts for this
unbalaned design. In order to fous on the main aspets, we assume in this thesis that
treatment is the only inuening fator. The model presented below an be extended to
multiple fators and multiple ovariates as shown by Kirk (1995) and Winer et al. (1991).
To model the inuene of strategy as well as treatments on Y (e.g. a sore measuring
quality of life) use an unbalaned one-way lassiation or a so-alled one-way analysis
of variane with xed-eets. For the purpose of strategy omparison an alternative fa-
tor to use in our model would be `strategy' (with levels A and B). However, we are
also interested in omparing the patient-oriented and not patient-oriented deisions within
treatments. This an not be investigated by using the fator strategy. Additionally, it is
sensible to assume that dierent treatments within one strategy have a dierent inuene
on Y . Therefore, we prefer to use the fator treatment (with levels A1, . . . , Ak, B1, . . . , Bl).
This allows us to investigate dierenes between strategies as well as treatments by using
appropriate ontrasts (see Setion 5.3).
Denition 5.2.1 (Unbalaned one-way lassiation with xed-eets for a
PORk, l design). The model equation for an unbalaned one-way lassiation with
xed-eets for the PORk, l design is
Yji = µj + εji for i = 1, . . . , nj; j ∈ A ∪ B (5.1)
where
Yji is the response for subjet i in treatment level j (random variable with E[Yji] = µj).
µj is the treatment group mean of treatment j (parameter in R).
εji is the error assoiated with Yji (random variable).
nj is the number of patients treated with treatment j.
For the xed-eets model assumption, the model Equation (5.1) ontains all the soures
of variation that aet Yji. The treatment means µj for j ∈ A∪B are onstant. The only
soure of variation is the error εji. We assume that the εji are normally and indepen-
dently distributed with mean equal to zero and variane equal to σ2ε , i.e. εji
i.i.d.∼ N (0,σ2ε) ,
i = 1, . . . , nj and j ∈ A ∪ B, and σ2ε is referred to as error variane.
To express the eet of eah level we deompose the expeted value E[Yji] = µj into
µj = µ+ τj,
where
µ is the expeted value of the overall population.
τj is the treatment eet of jth treatment.
Additionally, for the uniqueness of the deomposition,
∑
j∈A∪B τj = 0 has to be fullled.
In this way, we have the following model
Yji = µ+ τj + εji for i = 1, . . . , nj ; j ∈ A ∪ B.
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Aording to this equation the realisations yji of the random variable Yji an be deomposed
yji = y¯..︸︷︷︸ + (y¯j. − y¯..)︸ ︷︷ ︸ + (yji − y¯j.)︸ ︷︷ ︸ (5.2)
yji
Sore
= µˆ
Grand mean
+ µˆj − µˆ
Treatment eet
+ eji
Residual eet
where
y¯j. :=
1
nj
nj∑
i=1
yji is the mean in treatment level j
y¯.. :=
1
N
∑
j∈A∪B
nj∑
i=1
yji is the grand mean
with N = nA1 + · · ·+ nAk + nB1 + · · · + nBl the total number of observations. Hene, we
obtain y¯j. − y¯.. for the estimation of τj and y¯.. as estimate for the expeted value of the
overall population µ. The deomposition of the realisations provide a deomposition of the
total sum of squares
SSTOT : =
∑
j∈A∪B
nj∑
i=1
(yji − y¯..)2
into the sum of squares between groups
SSBG : =
∑
j∈A∪B
nj (y¯j. − y¯..)2
and the sum of squares within groups
SSRES : =
∑
j∈A∪B
nj∑
i=1
(yji − y¯j.)2.
The desired partition of the total sum of squares
SSTOT = SSBG + SSRES∑
j∈A∪B
nj∑
i=1
(yji − y¯..)2 =
∑
j∈A∪B
nj (y¯j. − y¯..)2 +
∑
j∈A∪B
nj∑
i=1
(yji − y¯j.)2 (5.3)
is obtained by rearranging the terms in Equation (5.2). A proof an be seen for example in
Kirk (1995, pp. 8083). The partition of the total sum of squares in Equation (5.3) provides
an intuitive understanding of the soures of variation. The sum of squares between groups
shows the variation between patients treated with dierent treatments. Nevertheless, the
responses of patients in the same treatment level an vary due to the individual dierenes
of the patients. The sum of squares within groups shows the variation due to dierenes
among patients who reeive the same treatment. If the sum of squares within groups
is small in omparison to the sum of squares between groups, the total variation of the
responses of patients an be explained through the variation between groups treated with
dierent treatments rather than through the variation within groups due to the individual
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patients. If we assume that the treatment means within the strategies dier, then using the
fator `strategy' instead of `treatment', the variation between treatments would be at least
partially asribed to the variation within the strategies. This shows another advantage of
using treatments as fator in presene of heterogeneous treatment means within strategies.
The degrees of freedom df assoiated with SSTOT, SSBG and SSRES refer to the num-
ber of observations whose values are free to vary in this sum of squares. They are only
mentioned here, but not determined. The degrees of freedom assoiated with SSTOT
are dfTOT = N − 1, dfBG = k + l − 1 are assoiated with SSBG and with SSRES
dfRES = N − (k + l) are assoiated. Corresponding to the partition of the total sum
of squares in Equation (5.3), the degrees of freedom of SSBG and SSRES sum up to the
degrees of freedom of SSTOT, i.e.
dfTOT = dfBG + dfRES.
Dividing a sum of squares by its degrees of freedom gives mean squares (MSTOT, MSBG
and MSRES).
For the next onsiderations, we dene the parameter
σ2µ =
∑
j∈A∪B(µj − µ)2
k + l − 1
whih indiates the extent to whih the treatment eet diers between the groups. We
obtain for the expeted value of the mean squares within groups
E[MSRES] = σ
2
ε . (5.4)
For the expeted value of the mean squares between groups, it an be shown that
E[MSBG] = σ
2
ε +
N2 −∑j∈A∪B n2j
N(k + l − 1) σ
2
µ (5.5)
(Graybill, 1961, pp. 353354). The expeted value of the total mean square an be obtained
by the partition of the total sum of squares and Equations (5.4) and (5.5),
E[MSTOT] = σ
2
ε +
N2 −∑j∈A∪B n2j
N(N − 1) σ
2
µ.
Hene, for the ase of equal sample sizes, i.e. nj = n for all j ∈ A ∪ B, N = (k + l)n
and
∑
j∈A∪B n
2
j = (k + l)n
2
we obtain for the expeted value of the mean squares
E[MSBG] = σ
2
ε + nσ
2
µ,
E[MSRES] = σ
2
ε
and
E[MSTOT] = σ
2
ε +
n(k + l − 1)
n(k + l)− 1σ
2
µ.
The question that immediately arises is whether the dierenes in treatment eets are
due to the (randomly) seleted sample or due to the dierenes in treatments. The null and
the two-sided alternative hypotheses an be stated in terms of the population treatment
5.3 Contrast among treatment group means 73
group means as follows
H : µA1 = µA2 = · · · = µBl = 0 vs. K : µj 6= µj′ for some j and j′.
This null hypothesis is also alled omnibus hypothesis. Based on the null hypothesis, σ2µ
will be zero in Equation (5.5). If a treatment eet exists, then the expeted value of the
mean square between groups estimates the population error variane σ2ε plus a funtion of
squared treatment eets. We an asses the magnitude of the treatment eet by setting
the treatment eet in relation to the population error variane. Therefore, the statisti
F =
MSBG
MSRES
may be used to test the null hypothesis that the treatment eets are equal. If the null
hypothesis is true and if the assumption for the xed-eet model from Denition 5.2.1 are
tenable, the statisti F is entrally F -distributed with dfBG and dfRES degrees of freedom.
The deision rule is as follow: We rejet H if the value of the F -statisti is larger than the
(1−α)-quantile of the F -distribution with dfBG = k+l−1 and dfRES = N−(k+l) degrees of
freedom F1−α(dfBG,dfRES), otherwise we do not rejet H. If the null hypothesis of equality
of treatment eets is rejeted, we are usually interested in the problem of deiding whih
of the treatment eets are not equal respetively not equal to zero. For this analysis, the
onept of ontrasts may be used. If the assumptions of Denition 5.2.1 are not tenable,
the onsequenes of violation and other onepts are disussed extensively for example in
Kirk (1995, pp. 97103).
5.3 Contrast among treatment group means
Denition 5.3.1 (Linear ombination of treatment group means). A linear om-
bination of treatment group means µj is an expression of the form
ψ = c1µ1 + · · ·+ csµs =
s∑
j=1
cjµj ,
where the oeients cj are known onstants and s is the number of treatments.
Remark. In Setion 5.2, the index j runs from A1 to Bl and has s = k + l values.
Denition 5.3.2 (Linear ontrast or omparison). A linear ontrast or omparison
among treatment group means is a linear ombination of treatment group means for whih
1) at least one oeient is not equal to zero (∃j ∈ A ∪ B : cj 6= 0) and
2) the oeients sum to zero (
∑s
i=1 ci = 0).
Remark.
• Instead of treatment group means µj of the response, we an also use the treatment
eets τj in Denition 5.3.2, sine by ondition 2) together with µj = µ + τj , we
obtain
ψ =
s∑
j=1
cjµj = µ
s∑
j=1
cj +
s∑
j=1
cjτj =
s∑
j=1
cjτj .
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• The least-squares estimator of ψ is
ψˆ =
s∑
j=1
cj Y¯j. .
The variane of ψˆ is
σ2
ψˆ
=
s∑
j=1
c2jVar[Y¯j.] = σ
2
ε
s∑
j=1
c2j
nj
,
whih is estimated by
σˆ2
ψˆ
= MSRES
s∑
j=1
c2j
nj
.
Denition 5.3.3.
1. A linear ontrast ψ =
∑s
j=1 cjµj is alled
a) pairwise, if all of the oeients cj exept two are equal to zero. Otherwise, the
ontrast is alled non-pairwise.
b) normalised, if
∑s
j=1 c
2
j/nj = 1.
2. Two linear ontrasts ψ1 =
∑s
j=1 c1jµj and ψ2 =
∑s
j=1 c2jµj are alled
a) equivalent, if c1j = mc2j for all j = 1, . . . , s with m an arbitrary onstant
(m 6= 0).
b) orthogonal, if
∑s
j=1 c1jc2j/nj = 0. Otherwise, the ontrasts are alled non-
orthogonal. Two ontrasts ψ1 and ψ2 whih are non-orthogonal are said to be
orrelated with orrelation
ρ12 =
∑s
j=1
c1jc2j
nj√∑s
j=1
c2
1j
nj
∑s
j=1
c2
2j
nj
.
3. The ontrasts of a set of linear ontrast are alled
mutually orthogonal, if eah ontrast of the set is orthogonal to all other ontrasts
of the set.
Remark.
• It is reommended to use normalised ontrasts to avoid ambiguities due to the equiv-
alent ontrasts.
• If there are s treatments, the maximum number of mutually orthogonal ontrasts is
equal to s− 1.
Denition 5.3.4. Let s be the number of treatments in model (5.1). Then a set of s − 1
mutually orthogonal ontrasts is alled a omplete orthogonal set.
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Remark. There exists an innite number of omplete orthogonal sets. The ontrasts of
two omplete orthogonal sets need not neessarily be orthogonal. Furthermore, all other
ontrasts an be expressed as a linear ombination of the mutually orthogonal ontrasts of
a omplete orthogonal set.
Sum of squares for a ontrast
The variation due to a ontrast an be dened as a omponent of SSBG. The sum of
squares for a ontrast ψ among treatment eets is denoted by SSψ and is omputed as
SSψ =
ψˆ2∑s
j=1
c2j
nj
.
Sine the sum of squares for a ontrast has only one degree of freedom, it is equal to the
mean squares for this ontrast MSψ.
In general, the sum of squares between groups SSBG an be totally deomposed with a
omplete orthogonal set of ontrasts ψ1, . . . , ψs−1, i.e.
SSBG = SSψ1 + SSψ2 + · · · + SSψs−1 .
This holds for all omplete orthogonal sets of ontrasts. Sine the sum of squares between
groups has s−1 degrees of freedom and the sum of squares for a ontrast has one degree of
freedom, eah degree of freedom of SSBG may be assoiated with one ontrast of a omplete
orthogonal set. Using dierent omplete sets of orthogonal ontrasts, SSBG is partitioned
dierently. It is possible to onstrut a ontrast ψmax suh that SSBG = SSψmax . For
equal sample sizes a onstrution for ψmax an be found for example in Winer et al. (1991,
pp. 149-151).
Hypotheses, a priori and a posteriori ontrasts
For eah ontrast ψ there is a null hypothesis
Hψ : ψ =
s∑
j=1
cjµj = 0 (5.6)
assoiated with it. The alternative hypothesis an be formulated one-sided or two-sided.
In planning a linial trial, a researher has a spei set of ontrasts in mind, the
orresponding hypotheses of whih he wants to test (e.g. dierenes in treatment means).
With regard to inferenes on ontrasts among treatment means, we have to distinguish
whether the ontrasts are a priori or a posteriori. A priori or planned ontrasts are dened
before running the linial trial. These ontrast are usually related to the struture of the
data obtained. A posteriori or post ho ontrasts are derived from the struture of the
outome after the linial trial was run.
To test the hypothesis (5.6) for an a priori ontrast, we an use one of two following
test statistis. First, we onentrate on a two-sided alternative hypotheses and dene an
Fψ-statisti by following the onsiderations of the omnibus hypothesis
Fψ =
MSψ
MSRES
. (5.7)
Under the null hypothesis, and if the assumptions of Denition 5.2.1 are met, the statisti
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Fψ is F -distributed with dfψ = 1 and dfRES = N−s degrees of freedom. The deision rule is
to rejet the null hypothesis if the value of the statisti Fψ is larger than F1−α(dfψ,dfRES),
otherwise we do not rejet Hψ. The tψ-statisti with
tψ =
ψˆ√
σˆ2
ψˆ
=
∑s
j=1 cj Y¯j.√
MSRES
∑s
j=1
c2j
nj
(5.8)
may also be used to test the hypothesis, sine
t2ψ =
ψˆ2
MSRES
∑s
j=1
c2j
nj
=
MSψ
MSRES
= Fψ.
Under the null hypothesis, and if the assumptions of Denition 5.2.1 are met, tψ follows
a Student's t-distribution with dfRES = N − s degrees of freedom. The deision rule is
to rejet the null hypothesis if the value of |tψ| is larger than the 1 − α/2 quantile of the
t-distribution with dfRES degrees of freedom t1−α/2(dfres). The equation
t21−α/2(dfRES) = F1−α(1,dfRES).
holds for the quantiles of the t- and the F -distribution.
Seond, for the one-sided ase, the deision rules are hanged to rejet the null hypoth-
esis if the value of the statisti tψ is larger than t1−α(dfRES). The equivalent F -test would
rejet the null hypothesis if the value of the statisti Fψ is larger than F1−2α(1,dfRES).
Multiple testing
To test only one a priori ontrast, the probability of a type I error is equal to the level of
signiane α. If we onsider two or more ontrasts, the situation is more omplex and
depends on whether the ontrasts are orthogonal or not and whether they are a priori or
a posteriori. When testing multiple hypotheses simultaneously, the probability of a type I
error is larger than for testing one single hypothesis. If we onsider Z independent tests,
eah test an be evaluated on its own and its probability of not making a type I error is
1 − α. For independent tests, the probability of not making one ore more type I error is
the produt of the single probabilities (1− α)Z . Consequently the
probabily of making at least one type I error = 1− (1− α)Z > α
for Z > 1. For Z dependent tests, the probability of making one or more type I errors
is less than or equal to 1 − (1 − α)Z . Obviously, if the number of tests inreases, the
probability of one or more false positive deisions inreases also. The multiple tests of
ontrasts are not independent even if the ontrasts are orthogonal, sine the error variane
in the denominators of the orresponding t-tests is the same.
In most ases, the researh strategy is to ontrol the type I error at α for the set of
ontrasts that are tested. Therefore, an adjustment an be performed by omputing a
redued signiane level for eah hypothesis. To ontrol the type I error at α for a set
or family of ontrasts, dierent type I error rates are dened, e.g. the per-ontrast error
rate, the familywise error rate and the per-family error rate. For more information about
the dierent error rates and their relationship see for example Kirk (1995, pp. 119122)
or Dmitrienko et al. (2009, pp. 3639)). Sine we are interested in orthogonal and non-
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orthogonal as well as pairwise and non-pairwise ontrasts, we onentrate on ontrolling
the familywise error rate, whih is the probability of making at least one type I error in
the family.
Let Z ≥ 1 denote the number of null hypotheses Hψ1 , . . . ,HψZ to be tested with
alternative hypotheses Kψ1 , . . . ,KψZ . Eah of the tests Hψi , i = 1, . . . , Z, is assoiated
with a given ontrast ψi =
∑s
j=1 cijµj of interest. Let tψ1 , . . . , tψZ denote the orresponding
test statistis for eah ontrast. In the two-sided test problems the absolute values of the
individual test statistis are taken and larger values of tψi favour the rejetion of Hψi .
Then one natural approah for the multiple ontrast test uses the max-t test statisti with
tψmax = max{tψ1 , . . . , tψZ}.
Under the assumption from Denition 5.2.1 of model (5.1), it an be shown that under the
global null hypothesis H = ∩i∈IHψi , I = {1, . . . , Z}, the joint distribution of tψ1 , . . . , tψZ is
a multivariate t-distribution with orrelation matrix R = (ρij), where ρij is the orrelation
between the ontrasts ψi and ψj . The test rejets H if tψmax > q, where q denotes the
upper α ritial point of this distribution. For omputing the multivariate t probabilities,
see Genz and Bretz (2002, 2009). For testing all ontrasts, we use a step-down algorithm
based on max-t tests under the free ombination ondition. This means that for any subset,
the simultaneous truth of Hψi and falsehood of the remaining hypotheses is a plausible
event. The presented algorithm originates from Bretz et al. (2010).
Step 1: Let I1 = {1, . . . , Z}. The test of the global null hypothesis HI = ∩i∈IHψi with a
suitable max-t test results in a p-value pI .
• If pI ≤ α, then determine i1 := argmaxi∈I tψi and rejet Hψi1 with adjusted
p-value qi1 = pI . Proeed to the next step.
• Otherwise stop.
Step 2: Let I2 = I1 \ {i1}. The test HI2 = ∩i∈I2Hψi with a suitable max-t test results in
a p-value pI2 .
• If pI2 ≤ α, then determine i2 := argmaxi∈I2 tψi and rejet Hψi2 with adjusted
p-value qi2 = max{qi1 ,pI2}. Proeed to the next step.
• Otherwise stop.
.
.
.
Step j: Let Ij = Ij−1 \{ij−1}. The test HIj = ∩i∈IjHψi with a suitable max-t test results
in a p-value pIj .
• If pIj ≤ α, then determine ij := argmaxi∈Ij tψi and rejet Hψij with adjusted
p-value qij = max{qij−1 ,pIj}. Proeed to the next step.
• Otherwise stop.
.
.
.
Step Z: Let IZ = IZ−1 \ {iZ−1} = {iZ}. The test HIZ = ∩i∈IZHψi with a suitable max-t
test results in a p-value pIZ .
• If pIZ ≤ α, then determine iZ := argmaxi∈IZ tψi and rejet HψiZ with adjusted
p-value qiZ = max{qiZ−1 ,pIZ}. Proedure stops.
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Another popular proedure for testing any of the possible ontrast among eets is the
S-method whih has been developed by Sheé and is now better known as Sheé's test.
This approah uses a ondene interval on the maximum normalized ontrast. The idea
is the following: if this ondene interval holds for the maximum ontrast, it will hold
simultaneously for all ontrasts. However, for all ontrasts exept the maximum ontrast,
the ondene interval is onservative.
Theorem 5.3.5 (Sheé (1959)). The probability that the values of all ontrasts simul-
taneously satisfy the inequalities
ψˆ − Sσˆψˆ ≤ ψ ≤ ψˆ + Sσˆψˆ
is 1− α, where the onstant S is given by
S2 := (s− 1)F1−α(s− 1,N − s).
Remark.
• Sheé's test is robust with respet to violations of the assumptions of Denition 5.2.1
and it does not require equal sample sizes (f. Winer et al. (1991, pp. 191197)).
Sheé's test an be also used for an a posteriori test, whih means all ontrasts that
appear interesting from an inspetion of the data an be tested under ontrol of the
type I error. However, this test proedure is not as powerful as other ones (f. Kirk
(1995, pp. 126127, 154155)).
• If the F -test of the omnibus null hypothesis is signiant, at least one ontrast among
the treatment eets is not equal to zero. However, it ould happen that this ontrast
is not of any pratial interest. For more information about the relationship of the
Sheé's test to the F -test if the omnibus hypothesis see Sheé (1959, pp. 7072)
or Winer et al. (1991, pp. 191195).
• Computing the ondene interval is equivalent to omputing the F -statisti used
for individual ontrasts Fψ = MSψ/MSRES and rejeting the null hypothesis (5.6) if
the value of the test statisti is larger than S2 = (s− 1)F1−α(s− 1, N − s).
5.4 Contrasts among treatment group means in a PORk, l
design
5.4.1 Strategy omparison ontrast
The ontrasts whih are of interest in the ontext of a patient-oriented randomisation
design are presented in this setion. Primarily, we are interested in a ontrast omparing
the two dierent strategies. Sine the oeients of a ontrast have to be known onstants
and we assume that all treatments in eah strategy are equally probable. We onsider the
linear ombination
ψ =
1
k
µA1 + · · ·+
1
k
µAk −
1
l
µB1 − · · · −
1
l
µBl
=
1
k
k∑
i=1
µAi −
1
l
l∑
j=1
µBj
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to ompare both strategies. This linear ombination is a ontrast, sine
k+l∑
j=1
cj =
k∑
j=1
1
k
+
l∑
j=1
−1
l
= 1− 1 = 0.
Denition 5.4.1 (Strategy omparison ontrast). Let A1, . . . , Ak be treatments of
strategy A and B1, . . . , Bl be treatments of strategy B. The linear ontrast
ψ0 =
1
k
µA1 + · · ·+
1
k
µAk −
1
l
µB1 − · · · −
1
l
µBl (5.9)
among treatment means of two strategies A and B is alled strategy omparison ontrast
between A and B.
Remark.
• If we wish to test only the strategy omparison ontrast, we an use the presented
t-test (see Equation (5.8)) or the F -test (see Equation (5.7)).
• For the purpose of strategy omparison, it might be desirable for the ontrast to
aount for possible imbalanes in the sample size of the treatment groups. This
would lead to the oeients
cj = nj/
∑
i∈A
ni for j ∈ A (5.10)
and
cj = −nj/
∑
i∈B
ni for j ∈ B. (5.11)
for the ontrast. However, the atual sample sizes observed in a study might dier
from the pre-planned sample sizes and are in general unknown prior to the ondut
of the study. Therefore, the ontrast with the oeients from (5.10) and (5.11) is
not a priori and an thereby not be tested with the step-down proedure outlined in
Setion 5.3.
Nevertheless, it is possible to formulate an a priori ontrast that aounts for the
imbalanes when we use strategy as fator in ontrast to treatment as was done here,
the estimated strategy omparison ontrast
ψˆ = µˆA − µˆB
(where µˆA = 1/nA
∑
j∈A
∑nj
i=1 yji and µˆB = 1/nB
∑
j∈B
∑nj
i=1 yji are the mean re-
sponses in the two strategies and nA and nB are the sample sizes in both strategies)
is equivalent to the estimated ontrast with oeients from (5.10) and (5.11) in the
model with treatment as fator, sine
ψˆ =
∑
j∈A∪B
cj µˆj
=
∑
j∈A
cj µˆj +
∑
j∈B
cj µˆj
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=
∑
j∈A njµˆj∑
i∈A ni︸ ︷︷ ︸
=nA
+
∑
j∈B−nj µˆj∑
i∈B ni︸ ︷︷ ︸
=nB
=
∑
j∈A njY¯j.
nA
−
∑
j∈B nj Y¯j.
nB
=
∑
j∈A
∑nj
i=1 Yji
nA
−
∑
j∈B
∑nj
i=1 Yji
nB
= µˆA − µˆB.
5.4.2 Patient-oriented deision versus randomisation ontrast
In addition to the main hypothesis desribed by the strategy omparison ontrast (Deni-
tion 5.4.1) above, we are also interested in other questions onerning the patient-oriented
deision, e.g. whether it is possible to prove that the patient-oriented hoie results in a
more eetive treatment as opposed to pure randomisation. In the CUtLASS design, it
is not possible to answer this question beause there is no randomised referene popula-
tion. To see how the eet of patient-oriented treatment deisions an be investigated in a
PORk, l design and whih further information is needed, we onsider the following example.
Example. For our example POR2, 2, we onsider the two-pair ombinations of Table 5.1
and separate the treatments of both strategies aording to only randomised hoie treated
patients and patient-oriented hoie treated patients. Thereby the supersript R following
the treatments indiates that the patients reeived the treatment due to randomisation's
reasons. Similarly, the supersript P indiates that the patients reeived the treatment not
only due to randomisation, but due to a patient-oriented deision of the physiian. The
information whether the patient reeived the treatments of a two-pair ombination due to
patient-oriented deision or only due to randomisation reasons is marked with `X'.
No. of two-pair
ombination
T PC2, 2 Randomised Patient-oriented
treatmens treatmens
Pair 1 Pair 2 AR1 A
R
2 B
R
1 B
R
2 A
P
1 A
P
2 B
P
1 B
P
2
Clear deision between A1 ↔ A2
2 (A1,B1) (A2,B1) X X X X X
5 (A1,B2) (A2,B2) X X X X X
Clear deision between B1 ↔ B2
1 (A1,B1) (A1,B2) X X X X X
6 (A2,B1) (A2,B2) X X X X X
No lear deision
3 (A1,B1) (A2,B2) X X X X X X X X
4 (A1,B2) (A2,B1) X X X X X X X X
Table 5.1: Two-pair ombinations of the POR2, 2 design. Treatments separated aording
to patients reeiving this treatment due to randomisation (`R') or due to patient-
oriented hoie (`P') are marked with `X'.
5.4 Contrasts among treatment group means in a PORk, l design 81
As we desribed before, the physiian seleted one pair out of a randomly hosen two-
pair ombination. In four out of the six two-pair ombinations, we have one idential
pair. If the patient is randomised to the strategy with the idential pair in both two-pair
ombinations, the physiian's deision had no inuene on the treatment reeived. If the
randomisation in step 2 alloates the other strategy, the treatment follows the physiian's
deision. Hene in two-pair ombinations with a lear patient-oriented deision, we an
distinguish between a merely randomised patient and a randomised patient with a patient-
oriented deision. This lassiation is marked with a blak `X' in Table 5.1. For this
lassiation in TPCs 2, 5, 1 and 6, we assume a onsious deision of the physiian
between the two treatments of the mixed pair. However, it ould also happen that the
physiian favours no treatment of the mixed pair for a ertain patient and selets one of the
random pairs at random. Then the patients an be lassied as treated with a treatment
due to randomisation's reasons. This speial ase is marked with a red `X' in Table 5.1.
In the mixed ombinations without lear deision, we an not make this lassiation
diretly. The physiian may have hosen one of the pairs on the basis of one preferred
treatment of this pair and not of both. If the randomisation in step 2 alloates the patient
to the preferred treatment, the treatment would be lassied as patient-oriented treatment.
However, in ase that the randomisation in step 2 alloates the patient to the other treat-
ment, the treatment would be lassied as randomised treatment. Hene we see that we
need additional information about the preferred treatment of the physiian in eah strategy
of this two-pair ombination to lassify the treatments. Either this information is available
for eah patient and we an take this into aount, or the information is missing for some
patients. In this ase, we have two opportunities. Either we ignore this information by
disregarding all patients without lear deision, or we take this information into aount
under the assumption that the missing information is missing at random. That means
we use the data of all patients where we have the information whether the alloation was
purely random or due to a patient-oriented deision (omplete ase analysis). In the fol-
lowing part of this thesis, we assume that we have all required information available and
we an lassify eah patient to one of the two groups (P and R).
Due to the lassiation of the treatments into randomised and patient-oriented, we see
that our model 5.2.1 is no longer suient.
Denition 5.4.2. The set of all patient-oriented hoie treated patients is alled patient-
oriented group and the set of all random hoie treated patients is alled random group.
Notation. The supersript R following the treatments A1, . . . , Ak, B1, . . . , Bl indiates
that the patients reeived the treatment due to randomisation's reasons. Similarly, the
supersript P indiates that the patients reeived the treatment not only due to randomi-
sation, but due to a patient-oriented deision of the physiian. This leads to the following
notations
• AR = {AR1 , . . . , ARk } and AP = {AP1 , . . . , APk }
• BR = {BR1 , . . . , BRl } and BP = {BP1 , . . . , BPl }.
Denition 5.4.3 (Extended unbalaned one-way lassiation with xed-eets
for a PORk, l design). The model equation for an extended unbalaned one-way lassi-
ation with xed-eets for a PORk, l design is
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Yji = µj + εji for i = 1, . . . , nj (5.12)
and j ∈ AR ∪ AP ∪ BR ∪ BP
where
for j ∈ AR ∪ BR, µj is the treatment group mean of the randomised group.
for j ∈ AP ∪ BP , µj is the treatment group mean of the patient-oriented group.
For the xed-eets model assumption, the model Equation (5.12) ontains all the soures
of variation that aet Yji. The treatment group means µj for the jth fator level for
j ∈ AR ∪ AP ∪ BR ∪ BP are onstant. The only soure of variation is the error εji. We
assume that εji
i.i.d.∼ N (0,σ2ε ). σ2ε is referred to as error variane.
Remark.
1. Model (5.12) an equivalently be parametrised by
Yji = µ
R
j + 1{∆i=1}δj + εji (5.13)
with
j = A1, . . . , Ak, B1, . . . , Bl
i = 1, . . . , nj
∆i =
{
0, if patient i is in the random group.
1, if patient i is in patient-oriented group.
where
µRj is the treatment group mean of patients in the random group treated with
treatment j.
∆i is an indiator variable indiating whether the patient is in the random or
patient-oriented group.
δj is the treatment group mean dierene between the random or patient-oriented
group for the jth treatment.
Sine the two models (5.12) and (5.13) are equivalent, the same questions an be
answered. In the seond model, the eet of patient-oriented deisions is diretly
modelled by the δj . However, in the rst model, the ontrasts whih are of major
interest in this thesis are easier to formulate, whih is why we hose that parametri-
sation.
2. Model (5.12) has twie the number of levels ompared with model (5.1). The
degrees of freedom of the sum of squares within groups dereases to dfRES =
N − 2(k + l). The degrees of freedom of the sum of squares between groups in-
reases to dfBG = 2(k + l)− 1.
3. The strategy omparison ontrast from Denition 5.4.1 an also be formulated with
model (5.12) as
ψ0 =
1
k
k∑
i=1
1
2
(
µARi
+ µAPi
)
− 1
l
l∑
j=1
1
2
(
µBRj
+ µBPj
)
.
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However, the test statistis (5.7) and (5.8) hange slightly due to the number of
parameters to estimate and the assoiated hange in the sum of squares within groups
and their degrees of freedom.
Denition 5.4.4 (Patient-oriented deision versus randomised ontrasts). Let
(5.12) be the underlying model. Then the following ontrasts and their orresponding on-
trast tests are of interest.
1. The ontrast
ψ1 =
k∑
i=1
µARi
+
l∑
j=1
µBRj
−
k∑
i=1
µAPi
−
l∑
j=1
µBPj
ompares the treatment group means of the random group and the patient-oriented
group.
2. The ontrasts
ψ2 =
k∑
i=1
µARi
−
k∑
i=1
µAPi
ψ3 =
l∑
j=1
µBRj
−
l∑
j=1
µBPj
ompare the treatment group means of the random group and the patient-oriented
group by strategy.
3. The ontrasts
ψ3+i = µARi
− µAPi for i = 1, . . . , k,
ψ3+k+j = µBRj
− µBPj for j = 1, . . . , l.
ompare the treatment group means of the random group and the patient-oriented
group by treatment.
4. The ontrast
ψ4+k+l =
k∑
i=1
1
k
µARi
−
l∑
j=1
1
l
µBRj
ompares the treatment group means of the random group between both strategies and
the ontrast
ψ5+k+l =
k∑
i=1
1
k
µAPi
−
l∑
j=1
1
l
µBPj
ompares the treatment group means of the patient-oriented group between both strate-
gies.
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Remark. In total, there are 6+k+l ontrasts of interest. Eah ontrast onsiders an other
aspet of the PORk, l designs. ψ0, ψ4+k+l and ψ5+k+l ompare the dierenes between the
strategies. ψ0 desribes our main ontrast omparing the two dierent strategies. Due to
the ontrasts ψ4+k+l and ψ5+k+l, it is possible to prove the assumption of heterogeneous
patient-drug-interation. The senario where the PORk, l design is most advantageous
(ompared to other randomisation shemes), is one where there are dierenes in treatment
group means of the patient-oriented group between both strategies and no dierenes in the
treatment group means of the random group between both strategies. That means that the
heterogeneity of patient-drug-interation of the responders and non-responders may anel
eah other out in the blok design as we have seen in our example in the introdutory
setion. The eet in the treatment means between the strategy in the patient-oriented
group an only be seen beause of the physiian's deision.
Although the physiian's deision may result in a higher treatment group mean, it
ould happen that the higher group mean ours in both strategies equally strong, or that
not all deisions in all treatments lead to higher group mean. Therefore, the ontrasts
ψ1, ψ2, ψ3, ψ3+1, . . . , ψ3+k+l are of interest. These ontrasts ompare the treatment group
means between patient-oriented and random group in eah treatment, eah strategy and
overall and not the eets between the treatments of dierent strategies.
The k+ l ontrasts ψ3+1, . . . , ψ3+k+l are pairwise and mutually orthogonal. In addition
they are all orthogonal to the ontrast ψ0. The set of ontrasts ψ = {ψ0, ψ3+1, . . . , ψ3+k+l}
forms one possible base for all ontrasts whih we are interested in, sine all other ontrasts
ψ1, ψ2, ψ3, ψ4+k+l and ψ5+k+l an be derived via linear ombinations from elements of ψ:
ψ1 = ψ3+1 + · · ·+ ψ3+k+l,
ψ2 = ψ3+1 + · · ·+ ψ3+l,
ψ3 = ψ3+l+1 + · · · + ψ3+l+k
ψ4+k+l = ψ0 +
1
2
ψ3+1 + · · ·+ 1
2
ψ3+l − 1
2
ψ3+l+1 − · · · − 1
2
ψ3+l+k,
ψ5+k+l = ψ0 − 1
2
ψ3+1 − · · · − 1
2
ψ3+l +
1
2
ψ3+l+1 + · · ·+ 1
2
ψ3+l+k.
Other sets of ontrasts are also mutually orthogonal, e.g. {ψ0, ψ2, ψ3}, {ψ1, ψ4+k+l, ψ5+k+l},
{ψ2, ψ3+l+1, . . . , ψ3+l+k} and {ψ3, ψ3+1, . . . , ψ3+1+l}. However, the dimension of ψ is
largest with k + l + 1. The dimension of a set of mutually orthogonal ontrasts of model
(5.12) is at most 2(k+ l)−1. Therefore, the remaining k+ l−2 dimensions are not reahed
with the ontrasts of interest.
Depending on the partiular linial trial, some of the ontrasts may be more important
than others.
5.5 Sample size alulation
In this setion, we onentrate on the determination of the total sample size needed to test
the strategy omparison ontrast (5.9). We will further investigate how the alloation of
sample sizes in eah treatment inuenes the total sample size. To test the orresponding
null hypothesis (5.6),
Hψ0 : ψ0 =
1
k
µA1 + · · ·+
1
k
µAk −
1
l
µB1 − · · · −
1
l
µBl = 0,
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we use the tψ0-statisti with
tψ0 =
ψˆ0√
σˆ2
ψˆ0
=
∑
j∈A∪B cj Y¯j.√
σˆ2ε
∑
j∈A∪B
c2j
nj
(f. O'Brien and Muller (1993, pp. 297344)). Under the null hypothesis, and if
the assumption of Denition 5.2.1 are met, tψ0 follows a Student's t-distribution with
dfRES = N − (k + l) degrees of freedom. Under the alternative hypothesis Kψ0 , i.e if
∆ = ψ0 6= 0, and if ψˆ0 is distributed as N (∆,σ2ε
∑s
j=1 c
2
j/nj), we have
tψ0 =
ψˆ0 −∆√
σˆ2ε
∑
j∈A∪B
c2j
nj
+
∆√
σ2ε
∑
j∈A∪B
c2j
nj
√
σ2ε
σˆ2ε
= t′ψ0 + δ
√
σ2ε
σˆ2ε
,
where
δ =
∆√
σ2ε
∑
j∈A∪B
c2j
nj
(5.14)
and t′ψ0 follows a entral t-distribution with N − (k+ l) degrees of freedom. Consequently,
tψ0 follows a nonentral t-distribution with dfRES = N − (k + l) degrees of freedom and
nonentrality parameter δ. We denote this distribution by t(dfRES, δ). The nonentral
t-distribution permits us to alulate the power of the test with respet to the alternative
Kψ0 . In the two-sided test, the power is
P
(|t(dfRES, δ)| ≥ t1−α/2(df, 0))
= P
(
t(dfRES, δ) ≥ t1−α/2(df, 0)
)
+ P
(−t(dfRES, δ) ≥ t1−α/2(dfRES, 0))
= 1− P (t(dfRES, δ) ≤ t1−α/2(df, 0)) + P(t(dfRES, δ) ≤ −t1−α/2(dfRES, 0)︸ ︷︷ ︸
=tα/2(dfRES, 0)
)
= 1− P (t(dfRES, δ) ≤ t1−α/2(dfRES, 0)) + P(t(dfRES, δ) ≤ tα/2(dfRES, 0)) (5.15)
and for the one-sided test,
P
(
t(dfRES, δ) ≥ t1−α(df, 0)
)
= 1− P(t(dfRES, δ) ≤ t1−α(df, 0)). (5.16)
Equation (5.14) shows that the nonentrality parameter δ, whih determines power,
is a funtion of three parameters: the expeted eet between both strategies ∆,
the ommon within-group standard deviation
√
σ2ε and the treatments' sample sizes
nA1 , . . . , nAk , nB1 , . . . , nBl . To estimate ∆ and
√
σ2ε we an use pilot data or data of
previous studies. The alloation of the treatments' sample sizes an not be so easily deter-
mined, sine these numbers depend on the physiians' deisions in the study (f. Setion 3).
In order to enable an evaluation for the treatment sample sizes, we dene the treatments'
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sample sizes as proportion of the total sample size N , i.e.
nj = wj ·N for j ∈ A ∪ B,
with
∑
j∈A∪B wj = 1 and
∑
j∈Awj = pΨ = 1/2. With this notation, we obtain
δ =
∆
√
N√
σ2ε
∑
j∈A∪B
c2j
wj
=
∆
√
N√
σ2ε
√
η
,
where
η :=
∑
j∈A∪B
c2j
wj
.
The total sample size N depends linearly on η. If η beomes larger the total sample size N
inreases. Whih values we an assume for η will be disussed in more detail below. It an
easily be seen that in general, it it not possible to solve (5.15) or (5.16) for N . However,
we demand that the minimum aeptable power should be larger than or equal to 1 − β.
To determine the required N , we have to insert dierent values for N (in an inreasing
manner) in Equation (5.15) or (5.16) until the desired power is ahieved.
For the two-sided ase, the sample size onsideration an also be made on the basis
of the F -statisti (5.7), whih under Kψ0 follows a nonentral F -distribution with 1 and
dfRES degrees of freedom and the nonentrality parameter λ = δ
2
(f. O'Brien and Muller
(1993, pp. 297344)).
Now that we know how to determine the total sample size, we onsider dierent ηs and
the orresponding alloation of the treatments' sample sizes. The parameter η depends
only on the struture of the design. The proportions of the total sample size wj are
inluded inversely in the alulation of η with a weight c2j . This shows that imbalanes in
the strategy with more treatments weigh more heavily than in the other.
In the best ase situation, all treatments in eah strategy are balaned, i.e.
wj =
1
2k
for j ∈ A and wj = 1
2l
for j ∈ B (5.17)
and we reeive as minimum
η =
∑
j∈A
c2j
wj
+
∑
j∈B
c2j
wj
=
∑
j∈A
2k
k2
+
∑
j∈B
2l
l2
= 2 + 2 = 4.
To determine the maximum of η is not so easy, sine the treatments' sample sizes depended
on eah other.
However, the previous onsiderations of Chapters 2 and 3 are helpful to determine a
lower bound for the maximum of η in the PORk, l design. To be able to desribe the
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dierent distributions, we introdue the following denition.
Denition 5.5.1. Let Ci and Ci′ be two dierent treatments of strategy C.
1. The treatment Ci′ is alled preferred to Ci, if whenever Ci and Ci′ were present in
the mixed pair of one two-pair ombination, the physiian hoose the random pair of
the two-pair ombination with treatment Ci′.
2. The treatments Ci′ and Ci are alled equally preferred, if the physiians hose the
random pair of the two-pair ombinations with Ci′ equally often as the random pair
of the two-pair ombinations with Ci.
Notation. If Ci′ is preferred to Ci, we denote this with Ci′ ≻ Ci. If Ci′ and Ci are equally
preferred, we denote this with Ci′ ≍ Ci.
Remark. If there is more than one relation given and both an be used in one two-pair
ombination, the rst-mentioned should be prioritised, i.e. let Ai′ ≻ Ai and Bi′ ≻ Bi be
given, then the deision of the physiian prioritises the relationship in strategy A over that
in strategy B in all two-pair ombinations, where both deisions are possible. If there are
more than two relations given, we ontinue this sheme.
To get an idea of sensible value for wj , we look at the following example.
Example. To illustrate how the distribution of sample sizes in eah treatment inuenes
the total sample size, we return to the NeSSy study and look at the sample size alulation
in the POR2, 3 design. It was required to test the two-sided hypothesis
H0 : ψ0 =
1
2
µA1 +
1
2
µA2 −
1
3
µB1 −
1
3
µB2 −
1
3
µB3 = 0 vs. K0 : ψ0 6= 0
with type I error α = 0.025 and power 1 − β = 0.8 at ∆ = ±8 when the observations
have standard deviation σε = 20.28. For the sample size alulation, a worst ase senario
for treatment A1 in strategy A was assumed, sine treatment A1 was not so popular in
the past. Although the most side eets are aused by the high dosage and the treatment
was used in the study with lower dosage, it was assumed that physiians often deselet
treatment A1. Therefore the proportion wA1 was assumed to take the minimum alloation
probability 1/10 from Property 3.2.2, and the proportion wA2 then automatially takes the
maximum alloation probability 4/10 from Property 3.3.3. Together, wA1 and wA2 sum
up to pΨ = 1/2. The treatments' sample sizes of strategy B were assumed to be balaned,
i.e. wB1 = wB2 = wB3 = 1/6. With this assumption, we ompute η1 = 5.125 and a total
sample size N1 = 316.
In this example, we want to see how other assumptions on the alloation of treat-
ments' sample sizes inuene the total sample size. In Table 5.2, the proportions
wA1 , wA2 , wB1 , wB2 and wB3 as well as the orresponding η and the total sample size
for dierent senarios of alloations of treatments' sample sizes are presented. Case 0 de-
sribes the balaned senario, where the smallest total sample size was omputed. Case 1
omplies with the assumption of the NeSSy study, where it was assumed that treatment
A1 is always deseleted when possible. Case 2 desribes the distribution of the treatments'
sample sizes, when additionally to the ase 1, the treatments in strategy B are as unbal-
aned as possible. Case 3 assumes that treatment B1 is always deseleted when possible
and all other treatments are balaned. In addition, ase 4 also assumes that treatment
B1 is always deseleted when possible, but that the sample sizes of B2 and B3 are as
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Case
Proportions
η N
wA1 wA2 wB1 wB2 wB3
0  A1 ≍ A2, B1 ≍ B2 ≍ B3 14 14 16 16 16 4 247
1  A2 ≻ A1, B1 ≍ B2 ≍ B3 110 410 16 16 16 5.13 316
2  A2 ≻ A1, B3 ≻ B1, 110 410 330 530 730 5.38 332
B3 ≻ B2 ≻ B1
3  B2 ≻ B1, B3 ≻ B1, B2 ≍ B3, 14 14 130 730 730 6.29 387
A1 ≍ A2
4  B3 ≻ B1, B3 ≻ B2 ≻ B1, 14 14 130 530 930 6.37 392
A1 ≍ A2
5  B3 ≻ B1, B3 ≻ B2 ≻ B1, 110 410 130 530 930 6.45 397
A2 ≻ A1
6  B3 ≻ B2 ≻ B1 and A2 ≻ A1 110 410 130 530 930 7.50 461
simultaneously (not possible
in theory and pratie)
7  NeSSy 27149
42
149
25
149
23
149
32
149 4.17 258
Table 5.2: Proportions wA1 , wA2 , wB1 , wB2 and wB3 , η and the total sample size for dif-
ferent alloations of treatments' sample sizes in the NeSSy design POR2, 3.
unbalaned as possible. The sample sizes of ase 1 and ase 3 illustrate the fat that im-
balanes in the strategy with more treatments weight more heavily. Case 5 follows ase
4, exept that the treatments in strategy A are now as unequally represented as possible.
The dierene between ase 4 and 5 in the alulated total sample size is small ompared
to the dierenes from ase 0 to 5. Case 6 desribes a senario that is not possible in
theory and in pratie in a PORk, l design. The treatments in both strategies take their
maximal unbalaned ase in eah strategy. However, this ase shows what ould happen in
the CUtLASS design if not the strategy is used as fator in the one-way lassiation, but
the treatments together with a strategy omparison ontrast. The treatments with only
one patient would inrease the sample sizes enormously.
Case 7 in Table 5.2 shows the observed alloation in the NeSSy study with total sample
size lose to the balaned senario. This demonstrates that ase 1 to ase 5 inlude strong
assumptions on the distribution of the treatments' sample sizes. We an see that the
assumptions on the physiian's seletion behaviour have a large impat on the omputed
sample size. Therefore, those assumptions should be made with are and be well justied.
It may be advisable to do a realulation of the sample size after a ertain number of
patients are randomised. This way, one ould make use of the observed alloation of the
patients in order to gain a more orret sample size alulation. Figure 5.1 illustrates the
linearity between the dierent ηs for ase 0 to 7 of Table 5.2 and N in the POR2, 3 design
with the assumptions from Table 5.2 for ∆, σε, α and β.
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η
T
o
t
a
l
s
a
m
p
l
e
s
i
z
e
N
2 3 4 5 6 7 8 9 10
5
0
1
0
0
1
5
0
2
0
0
2
5
0
3
0
0
3
5
0
4
0
0
4
5
0
5
0
0
η0
η1
η2
η3η4
η5
η6
ηNeSSy
Possible values for η
in the NeSSy design
3
1
6
Figure 5.1: Dependene between total sample size N and alloation of sample sizes in all
treatments using the parameter η in the NeSSy design.
If the number of treatments in strategy A is smaller than the number of treatments
in strategy B, we an assume that ase 5 of Table 5.2 is a good lower bound for the
maximum of η for the POR2, 3 design. For k = l it is possible to nd an alloation
leading to a larger η than that of ase 5. For example in a POR3, 3 design, the weighting
fator c2j in the alulation of η is the same in both strategies. Therefore, we an take
the minimum proportion in one strategy, e.g. strategy B, and searh for the next smallest
possible proportion in both strategies. Our investigations show that this would be strategy
A. If we ontinue with minimisation for wj in both strategies, we obtain a larger η than
that the approah of ase 5 leads to.
For ase 1, 3 to 5, we determine general formulas for the proportions.
Property 5.5.2. Given a PORk, l design, the following statements are true.
1. If only treatment A1 is deseleted when possible and all other treatments' sample sizes
are balaned, i.e. Ai ≍ A1 for all i = 2, . . . , k and Bj ≍ Bj′ for j, j′ = 1, . . . , l, then
the following proportions are obtained
wA1 =
l − 1
2k(kl − 1)
wAi =
k2l − k − l + 1
2k(kl − 1)(k − 1) for i = 2, . . . , k
wBj =
1
2l
for j = 1, . . . , l.
2. Let the treatments of strategy A be seleted and deseleted with Ai′ ≻ Ai for i′ > i and
the treatments' sample sizes of strategy B be balaned (Bj ≍ Bj′ for j, j′ = 1, . . . , l).
90 5 Statistial analysis
Then the following proportions are obtained
wAi =
(2i− 1)l − 1
2k(kl − 1) for i = 1, . . . , k
wBj =
1
2l
for j = 1, . . . , l.
3. If only treatment B1 is deseleted when possible and all other treatments' sample sizes
are balaned, i.e. Bj ≍ B1 for all j = 2, . . . , l and Ai ≍ Ai′ for i, i′ = 1, . . . , k, then
we obtain the proportions
wAi =
1
2k
for i = 1, . . . , k
wB1 =
k − 1
2l(kl − 1)
wBj =
kl2 − k − l + 1
2l(kl − 1)(l − 1) for j = 2, . . . , l.
4. Let the treatments of strategy B be seleted and deseleted with Bj′ ≻ Bj for j′ > j and
the treatments' sample sizes of strategy A be balaned (Ai ≍ Ai′ for i, i′ = 1, . . . , k).
Then the proportions
wAi =
1
2k
for i = 1, . . . , k
wBj =
(2j − 1)k − 1
2l(kl − 1) for j = 1, . . . , l
are obtained.
5. Let the treatments of strategy B be seleted and deseleted with Bj′ ≻ Bj for j′ > j and
afterwards, let the treatments of strategy A be seleted and deseleted with Ai′ ≻ Ai
for i′ > i. Then the following proportions are obtained
wAi =
kl − k + 2(i− 1)
2k(kl − 1) for i = 1, . . . , k
wBj =
(2j − 1)k − 1
2l(kl − 1) for j = 1, . . . , l.
Proof.
1. If treatment A1 is deseleted when possible, the proportion wA1 takes the minimum
alloation probability from Property 3.2.2. Sine
∑k
i=1 wAi = pψ, we have that∑l
j=2wAi = pψ − wA1 . Furthermore, we have that wAi = wAi′ for i, i′ ≥ 2, and
onsequently
wAi =
pΨ −wA1
k − 1
=
(
1
2
− l − 1
2k(kl − 1)
)
1
k − 1
=
k2l − k − l + 1
2k(kl − 1)(k − 1)
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for i = 2, . . . , k. For the treatments of strategy B we split 1 − pΨ = 1/2 in l equal
proportions
wBj =
1
2l
for j = 1, . . . , l.
2. We reeive as before
wA1 =
l − 1
2k(kl − 1)
for the proportion of A1. For wA2 , the proportion takes also the minimum alloa-
tion probability, but, in addition, in all two-pair ombinations with a mixed A-pair
[A1, A2], we prefer the random pair with treatment A2. From Equation (2.7), we
know that the probability for mixed A-pairs is qA = 2l/k(kl − 1). Taking into a-
ount that it is possible to randomise in strategy B with a probability of pΨ = 1/2,
we obtain
wA2 =
l − 1
2k(kl − 1) +
1
2
2l
k(kl − 1)
=
3l − 1
2k(kl − 1) .
In the same way we have for the proportion of treatment Ai (i ≤ k xed but arbitrary)
i − 1 distint mixed A-pairs [Ai′ , Ai] (i′ = 1, . . . , i − 1) with the same probability
pΨpA as before. Hene, we obtain
wAi =
l − 1
2k(kl − 1) +
1
2
2l
k(kl − 1)(i− 1)
=
(2i − 1)l − 1
2k(kl − 1) .
The onsiderations for the proportions of strategy B are the same as before under
point 1.
3.-4. Follows form 1. and 2. by symmetry.
5. The proportions of patients per treatment in strategy B are the same as in 4. If we
hoose all random pairs in the two-pair ombination due to preferenes in strategy
B, we only have the A-informative ombinations to take the preferenes of strategy
A into aount. In eah A-informative ombination, treatment A1 an be deseleted.
Therefore, we have to determine the number of two-pair ombinations in whih treat-
ment A1 is possible after deisions in strategy B. These two-pair ombinations are
the B-informative ombinations with idential A-pair [A1, A1] and the mixed om-
binations. In the B-informative ombinations, the physiian's hoie in strategy B
does not matter if the seond randomisation step randomises the patient to strat-
egy A. In the mixed ombinations, the physiian's deision in strategy B leads to
equally often presented treatments in strategy A in the hosen random pairs. To
determine the total number of mixed ombinations, we subtrat the number of lear
patient-oriented deisions from the number of two-pair ombinations
|T PCk,l| − |PODk, l| = kl(kl − 1)
2
− kl(l + k − 2)
2
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=
kl(kl − l − k + 1)
2
=
kl(k − 1)(l − 1)
2
.
Summing up the l(l−1)/2 B-informative ombinations with idential A-pair [A1, A1]
and the l(k − 1)(l − 1)/2 mixed ombinations with treatment A1 in the remaining
random pair after physiian's deisions in strategy B, we have
l(l − 1)
2
+
l(k − 1)(l − 1)
2
=
l(l − 1)(k − 1 + 1)
2
=
kl(l − 1)
2
two-pair ombinations, where treatment A1 is present in the hosen random pair.
Hene the proportion of these two-pair ombinations is
kl(l − 1)
2
2
kl(kl − 1) =
l − 1
kl − 1 .
Sine strategy A is randomised with probability pΨ = 1/2 the proportion of patients
reeiving treatment A1 after the seletion of random pairs due to the preferenes in
strategy B is given by
wA1 =
1
2
l − 1
kl − 1
=
l − 1
2(kl − 1) .
Obviously, wA2 is equal to wA1 plus the proportion of ases where we have the mixed
A-pair [A1, A2] in the A-informative ombinations multiplied with pΨ = 1/2. Eah
A-informative ombination appears l times (one with eah of the l distint idential
B-pairs). Hene we have
wA2 = wA1 +
l
kl(kl − 1)
=
l − 1
2(kl − 1) +
l
kl(kl − 1)
=
kl − k + 2
2k(kl − 1) .
In the same way, we have for the proportion of treatment Ai (i ≤ k xed but
arbitrary) i− 1 distint mixed A-pairs [Ai′ , Ai] (for i′ = 1, . . . , i − 1) with the same
probability l/kl(kl − 1) as before. Hene, we obtain
wAi =
l − 1
2(kl − 1) +
l
kl(kl − 1)(i− 1)
=
kl − k + 2(i− 1)
2k(kl − 1) . 
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Example. Table 5.3 shows η for the ve ases of alloation of treatments'
sample sizes from Property 5.5.2 in the patient-oriented randomisation designs
k Alloation of treatments' sample sizes l 2 3 4
2
1. A2 ≻ A1, Bj ≍ Bj−1 for j = 2, . . . , l 5.60 5.13 4.97
2. A2 ≻ A1, Bj ≍ Bj−1 for j = 2, . . . , l 5.60 5.13 4.97
3. B2 ≻ B1, Bj ≻ B1, Bj ≍ Bj−1 for j = 3, . . . , l, A2 ≍ A1 5.60 6.29 6.67
4. Bj′ ≻ Bj for j = 1, . . . , l − 1 and 5.60 6.37 6.86
j′ = 2, . . . , l with j′ > j, A2 ≍ A1
5. Bj′ ≻ Bj for j = 1, . . . , l − 1 and 5.85 6.45 6.90
j′ = 2, . . . , l with j′ > j, A2 ≻ A1
3
1. A3 ≻ A1, A2 ≻ A1, A3 ≍ A2, Bj ≍ Bj−1 for j = 2, . . . , l - 5.64 5.42
2. A2 ≻ A1, A3 ≻ A1, A3 ≻ A2, Bj ≍ Bj−1 for j = 2, . . . , l - 5.71 5.50
3. B2 ≻ B1, Bj ≻ B1, Bj ≍ Bj−1 for j = 3, . . . , l, - 5.64 5.93
A3 ≍ A2 ≍ A1
4. Bj′ ≻ Bj for j = 1, . . . , l − 1 and - 5.71 6.11
j′ = 2, . . . , l with j′ > j, A3 ≍ A2 ≍ A1
5. Bj′ ≻ Bj for j = 1, . . . , l − 1 and - 5.80 6.15
j′ = 2, . . . , l with j′ > j, A2 ≻ A1, A3 ≻ A1, A3 ≻ A2
Table 5.3: Parameter η for dierent alloations of treatments' sample sizes in dierent
PORk, l designs.
POR2, 2, POR2, 3, POR2, 4, POR3, 3 and POR3, 4. Thereby, only the ηs of one design an be
ompared against eah other, sine the assumptions for∆, σε for the sample size alulation
as well as the number of terms in η hange between dierent designs.
For the POR2, l designs, l = 2, . . . , 4, we see that the rst and the seond alloation of
the treatments' sample sizes are the same, likewise the third and the fourth alloation of
POR2, 2. We also see that the rst and the third and the seond and the fourth alloation
of designs with the same number of treatments in both strategies lead to the same η due
to symmetry. However, the fth alloation has the largest η in all designs.
Remark. We also an use Model (5.1) and the strategy omparison ontrast (5.9) for the
CUtLASSk, l and Blockk, l designs. For the power alulation, only the assumptions on the
eet between both strategies ∆ and η hange. For the Blockk, l design, the proportions
oinide with the balaned ase of the PORk, l design (see Equation (5.17)) and lead to
η = 4. For the CUtLASSk, l design, it is not as simple to determine η as in the Blockk, l
and the PORk, l designs. In the best ase, the treatments' sample sizes are balaned in
eah strategy and we also obtain η = 4. In the worst ase, eah treatment exept one is
represented with one patient in eah strategy. Then, the proportions depend inversely on
the total sample size N and lead to a large η. In order to prevent a large sample size or
a derease in the power, the CUtLASSk, l design should use Model (5.1) with strategy as
fator. The assumption for the eet between both strategies ∆ may be hanged between
the three design types, in the following setion we will see why.
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5.6 Strategy omparison in POR, CUtLASS and Blokan
example
When allowing for a patient-oriented deision in the randomisation proess (as is done in
the CUtLASS and the POR design) the observed treatment eets also depend on the
physiians' deision. In this setion, we will investigate how the randomisation design, the
physiian's deisions (i.e. the frequeny of `optimal' deisions as dened below) and the
heterogeneity of the study population (f. the example of Setion 1.3) aet the treatment
eet under onsideration. Furthermore, we investigate the dierene in treatment eets
when using strategy instead of treatments as fator in model (5.1).
Example. Let us onsider a hypothetial linial trial omparing two dierent strategies
A and B. Eah strategy onsists of two dierent treatments: A1, A2 ∈ A and B1, B2 ∈ B.
We also suppose that we have two dierent population types P1 and P2, not neessarily of
similar size. The proportion of population type P1 in the total population is speied by
κ with κ ∈ [0,1] and the proportion of population type P2 with (1− κ). In pratie, we do
not know whih patient belongs to whih population and how large the groups are.
To simplify the example, we assume that patients of populations P1 and P2 respond
dierently to the treatments of strategy A, but similar to the treatments of strategy B.
We also assume that the error variane σ2ε is the same for all patients independent from
treatment and population. The treatment means in strategy A of the dierent populations
are denoted by µA1P1 , µA1P2 , µA2P1 and µA2P2 and the treatment means in strategy B by
µB1P1 , µB1P2 , µB2P1 and µB2P2 where µB1P1 = µB1P2 = µB2P1 = µB2P2 = µB. We assume
that patients in P1 have a better response to A1 than to A2 and onversely patients in P2
have a better response to A2 than to A1, i.e. µA1P1 > µA2P1 and µA2P2 > µA1P2 .
Additionally, we dene ρ as the probability that a physiian hooses the most suitable
random pair from a two-pair ombination for a given patient whenever possible. In the set-
up onsidered here, this means seletion of a random pair with the A-treatment whih has
a higher treatment mean in the population the patient belongs to, whenever mixed A-pairs
are present. Of ourse, there an be no `best' or `worst' deision when the given two-pair
ombination has an idential A-pair, beause the treatment means for the B-treatments
are assumed to be equal for all patients. We assume that ρ is equal for all physiians.
Obviously, we have ρ ∈ [0,1], where ρ = 1 means that the physiians deisions are always
optimal and ρ = 0 desribes the ase where the random pair with the best treatment is
never seleted. Sine the physiians do not know whih sub-population a spei patient
belongs to, we expet ρ ∈ (0,1) in pratie. However, this is not an assumption made here.
It is easy to see that for ρ = 0.5, the POR and the CUtLASS design lead to the
same distribution of patients to the treatment groups and thereby to the same expeted
treatment eets.
Block2, 2 design
The probability that a given patient in the study is in population Pi, i = 1, 2, and reeives
treatment A1, A2, B1 or B2 is κ/4 or (1 − κ)/4 depending on population and treatment
(see Table 5.4). The treatment mean of treatment j onsists of the proportions of patients
with the jth treatment in the populations P1 and P2 as well as the treatment means of the
jth treatment in these populations, i.e.
µBlockA1 =
1
4κ
1
4
µA1P1 +
1
4(1− κ)
1
4
µA1P2 = κµA1P1 + (1− κ)µA1P2 .
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Strategy Treatment
Probability distribution in Cumulative frequenies
population type in
P1 P2 Treatment Strategies
A A1
1
4κ
1
4(1− κ) 14 1
2
A2
1
4κ
1
4(1− κ) 14
B B1
1
4κ
1
4(1− κ) 14 1
2
B2
1
4κ
1
4(1− κ) 14
Cumulative frequenies κ 1− κ 1 1
Table 5.4: Probability distribution for a patient to belong to population Pi, i = 1, 2, and
to reeive one of the four treatments A1, A2, B1 and B2 in the Block2, 2 design.
Similiarly, we obtain
µBlockA2 = κµA2P1 + (1− κ)µA2P2 ,
µBlockB1 = κµB1P1 + (1− κ)µB1P2 = µB,
µBlockB2 = κµB2P1 + (1− κ)µB2P2 = µB,
µBlockA =
1
2
κµA1P1 +
1
2
(1− κ)µA1P2 +
1
2
κµA2P1 +
1
2
(1− κ)µA2P2 ,
µBlockB =
1
2
κµB +
1
2
(1− κ)µB + 1
2
κµB +
1
2
(1− κ)µB = µB.
The omponents of the strategy omparison ontrast are then given by
1
2
µBlockA1 +
1
2
µBlockA2 =
1
2
(κµA1P1 + (1− κ)µA1P2) +
1
2
(κµA2P1 + (1− κ)µA2P2) = µBlockA
and
1
2
µBlockB1 +
1
2
µBlockB2 = µB.
In the ase of balaned sample size in all treatments in eah strategy suh as in the Block2, 2
design, the dierene in strategy means oinides with the strategy omparison ontrast,
i.e.
ψBlock0 =
1
2
µBlockA1 +
1
2
µBlockA2 −
1
2
µBlockB1 −
1
2
µBlockB2 = µ
Block
A − µBlockB .
POR2, 2 design
As for the Block2, 2 design we are interested in the probabilities that a patient entering the
study will be in a spei population (P1 or P2) and reeives a spei treatment in the
POR2, 2 design. Unlike in the Block2, 2 design the physiians deision has now inuene on
there probabilities.
As desribed above, we assume a dierent response behaviour for the subjets of P1
and P2 to the treatments of strategy A (µA1P1 > µA2P1 and µA2P2 > µA1P2). Further-
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more, we assume that the physiian hooses the random pair of a two-pair ombination
whih inludes the A-treatment with better response for eah patient (depending on the
population Pi) with probability ρ whenever possible (see above).
The probability that a patient entering the study will be in a spei population (P1
or P2) and reeive a spei treatment an be deomposed in the onditional probability
of reeiving the treatment given the population and the randomised strategy and the joint
probability of being in the spei strategy. The latter probability is κ/2 for population
P1 and (1 − κ)/2 for population P2. To determine the mentioned onditional probability
we have a look at Table 5.5. In this table, we nd the onditional probability of reeiving
a spei treatment given the two-pair ombination, the population and randomisation
to the orresponding strategy. In the last row (`relative frequenies'), we nd the desired
onditional probability mentioned above. The numbers in Table 5.5 are the result of the
following onsiderations. In two-pair ombination 1 and 6, the physiian an not deide
between the treatments of strategy A. Sine we assume that treatments B1 and B2 are
equally preferred, in half of the ases the patient will reeive treatment B1 and otherwise
B2 independent of the population of the patient. For two-pair ombinations 2 to 5, the
physiian should deide for a patient of population P1 for treatment A1 and otherwise for
a patient of population P2 for treatment A2. This is done with probability ρ. Summing
up over all two-pair ombinations we obtain the umulative frequenies. Dividing them by
the number of two-pair ombinations leads to the relative frequenies. Combining there
with the probabilities κ/2 respetively (1 − κ)/2 leads to the probability distribution in
Table 5.6.
TPC T PC2, 2
Patient-oriented deision in strategy
A for a patient in B for a patient in
P1 P2 P1 P2
A1 A2 A1 A2 B1 B2 B1 B2
1 [(A1,B1),(A1,B2)] 1 0 1 0
1
2
1
2
1
2
1
2
2 [(A1,B1),(A2,B1)] ρ 1− ρ 1− ρ ρ 1 0 1 0
3 [(A1,B1),(A2,B2)] ρ 1− ρ 1− ρ ρ ρ 1− ρ 1− ρ ρ
4 [(A1,B2),(A2,B1)] ρ 1− ρ 1− ρ ρ 1− ρ ρ ρ 1− ρ
5 [(A1,B2),(A2,B2)] ρ 1− ρ 1− ρ ρ 0 1 0 1
6 [(A2,B1),(A2,B2)] − 1 0 1 12 12 12 12
Cumulative frequenies 1 + 4ρ 5− 4ρ 5− 4ρ 1 + 4ρ 3 3 3 3
Relative frequenies
1+4ρ
6
5−4ρ
6
5−4ρ
6
1+4ρ
6
1
2
1
2
1
2
1
2
Table 5.5: Probability to reeive a spei treatment, given the two-pair ombination, the
population and randomisation to the orresponding strategy in the POR2, 2 de-
sign.
This shows the probability distribution for a patient to belong to population Pi, i = 1, 2,
and to reeive one of the four treatments A1, A2, B1 and B2. We see that this distribution
depends on the quality of physiians' deision measured by ρ (see Table 5.6).
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Strategy Treatment
Probability distribution in Cumulative frequenies
population type in
P1 P2 Treatment Strategies
A A1
1+4ρ
12 κ
5−4ρ
12 (1− κ) 5−4ρ−4κ+8κρ12 1
2
A2
5−4ρ
12 κ
1+4ρ
12 (1− κ) 1+4ρ+4κ−8κρ4
B B1
1
4κ
1
4(1− κ) 14 1
2
B2
1
4κ
1
4(1− κ) 14
Cumulative frequenies κ 1− κ 1 1
Table 5.6: Probability distribution for a patient to belong to population Pi, i = 1, 2, and
to reeive one of the four treatments A1, A2, B1 and B2 in the POR2, 2 design.
Similar to the Block2, 2 design, the treatment mean of treatment j onsists of the pro-
portions of patients with the jth treatment in the populations P1 and P2 as well as the
treatment means of the jth treatment in these populations. Sine the probabilities of
treatments of strategy B do not hange ompared to the Block2, 2 design, we only onsider
the treatment means of strategy A,
µPORA1 =
(1 + 4ρ)κ
5− 4ρ− 4κ+ 8κρµA1P1 +
(5− 4ρ)(1 − κ)
5− 4ρ− 4κ+ 8κρµA1P2 ,
µPORA2 =
(5− 4ρ)κ
1 + 4ρ+ 4κ− 8κρµA2P1 +
(1 + 4ρ)(1 − κ)
1 + 4ρ+ 4κ− 8κρµA2P2
and
µPORA =
(1 + 4ρ)κ
6
µA1P1 +
(5− 4ρ)(1 − κ)
6
µA1P2
+
(5− 4ρ)κ
6
µA2P1 +
(1 + 4ρ)(1 − κ)
6
µA2P2 .
The A omponent of the strategy omparison ontrast results in
1
2
µPORA1 +
1
2
µPORA2 =
(1 + 4ρ)κ
10− 8ρ− 8κ+ 16κρµA1P1 +
(5− 4ρ)(1− κ)
10− 8ρ− 8κ + 16κρµA1P2
+
(5− 4ρ)κ
2 + 8ρ+ 8κ− 16κρµA2P1 +
(1 + 4ρ)(1− κ)
2 + 8ρ+ 8κ− 16κρµA2P2 .
Hene we see that in the POR2, 2 design, the dierene in strategy means does generally not
oinide with the strategy omparison ontrast. An exeption is the ase of ρ = 1/2, where
all treatment means are the same for the POR2, 2 and the Block2, 2 design. In partiular,
the dierene of the strategy means and the strategy omparison ontrast are the same.
CUtLASS2, 2 design
Similar to the POR2, 2 design, the assumption on the dierent response of patients from
dierent populations (µA1P1 > µA2P1 and µA2P2 > µA1P2) have to be taken into aount to
determine the probability distribution for a patient to belong to population Pi, i = 1, 2, and
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to reeive one of the four treatments A1, A2, B1 and B2 in the CUtLASS2, 2 design. The
orresponding values an be found in Table 5.7. The physiian hooses with ρ treatment
A1 for patients from population P1 as well as treatment A2 for patients of population P2.
The fator 1/2 in the probabilities of strategy A are due to the design, sine the probability
of the patient to be randomised to strategy A is pΨ = 1/2.
Strategy Treatment
Probability distribution in Cumulative frequenies
population type in
P1 P2 Treatment Strategies
A A1
1
2ρκ
1
2 (1− ρ)(1− κ) 1−κ−ρ+2κρ2 1
2
A2
1
2(1− ρ)κ 12ρ(1− κ) κ+ρ−2κρ2
B B1
1
4κ
1
4 (1− κ) 14 1
2
B2
1
4κ
1
4 (1− κ) 14
Cumulative frequenies κ 1− κ 1 1
Table 5.7: Probability distribution for a patient to belong to population Pi, i = 1, 2, and
to reeive one of the four treatments A1, A2, B1 and B2 in the CUtLASS2, 2
design.
Similar to the Block2, 2 and the POR2, 2 design, the treatment mean of treatment j onsists
of the proportions of patients with the jth treatment in the populations P1 and P2 as well
as the treatment means of the jth treatment in these populations. Sine the probabilities
of treatments of strategy B do not hange ompared to the other designs, we only onsider
the treatment means of strategy A,
µCUtLASSA1 =
ρκ
1− ρ− κ+ 2κρµA1P1 +
(1− ρ)(1 − κ)
1− ρ− κ+ 2κρµA1P2 ,
µCUtLASSA2 =
(1− ρ)κ
ρ+ κ− 2κρµA2P1 +
ρ(1− κ)
ρ+ κ− 2κρµA2P2
and
µCUtLASSA = ρκµA1P1 + (1− ρ)(1 − κ)µA1P2
+ (1− ρ)κµA2P1 + ρ(1− κ)µA2P2 .
The A omponent of the strategy omparison ontrast results in
1
2
µCUtLASSA1 +
1
2
µCUtLASSA2 =
ρκ
2− 2ρ− 2κ+ 4κρµA1P1 +
(1− ρ)(1− κ)
2− 2ρ− 2κ+ 4κρµA1P2
+
(1− ρ)κ
2ρ+ 2κ− 4κρµA2P1 +
ρ(1− κ)
2ρ+ 2κ− 4κρµA2P2 .
The means µCUtLASSA and 1/2µ
CUtLASS
A1
+ 1/2µCUtLASSA2 are not the same. Hene, we see
that in a CUtLASS2, 2 design, the dierene in strategy means does generally not oinide
with the strategy omparison ontrast. An exeption is the ase ρ = 1/2, where all
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treatment means are the same for the CUtLASS2, 2 and the Block2, 2 design. In partiular,
the dierene of the strategy means and the strategy omparison ontrast are the same.
Example
As further ondition, we assume that µA = µB. In this ase, we have an eet neither
between the strategy means nor in the strategy omparison ontrast in the Block2, 2 de-
sign. Obviously, for ρ = 1/2, this also applies for the POR2, 2 and CUtLASS2, 2 designs.
Furthermore, we onsider the means of strategy A relative to those of strategy B, i.e. for
a, b, c, d ∈ [0, 1], we dene
µA1P1 = µB(1 + a), µA1P2 = µB(1− b),
µA2P1 = µB(1− c), µA2P2 = µB(1 + d).
To full the ondition µBlockA = µB in the Block2, 2 design with
µBlockA =
1
2
κµA1P1 +
1
2
(1− κ)µA1P2 +
1
2
κµA2P1 +
1
2
(1− κ)µA2P2 ,
we need to have a + b − c − d = 0 and d − b = 0, hene a = c and d = b. With these
onditions, we obtain
µPORA = µB
(
1 +
4ρ− 2
3
(aκ+ b(1− κ))
)
, (5.18)
1
2
µPORA1 +
1
2
µPORA2 = µB
(
1 +
12κ(1 − κ)(2ρ − 1)
16κ(1 − κ)(2ρ− 1)2 + 16ρ(1− ρ) + 5(a+ b)
)
(5.19)
for the means of the POR2, 2 design and
µCUtLASSA = µB (1 + (2ρ− 1) (aκ+ b(1− κ))) , (5.20)
1
2
µCUtLASSA1 +
1
2
µCUtLASSA2 = µB
(
1 +
κ(1− κ)(2ρ − 1)
2κ(1 − κ)(2ρ − 1)2 + 2ρ(1 − ρ) (a+ b)
)
(5.21)
for the CUtLASS2, 2 design means. All means of strategy A are multiples of µB. When
determining the strategy dierenes, respetively the strategy omparison ontrast, we
subtrat µB from (5.18)(5.21) and obtain a multiple of µB itself. The orresponding
fator (i.e. the seond summand in the brakets) is alled relative eet and is denoted by
∇ for the relative eet of the strategy mean dierenes and ∇SCC for the relative eet
of the strategy omparison ontrast. The relative eets of the strategy mean dierenes,
respetively the strategy omparison ontrast, depend on κ, ρ, a, b and the type of design.
We see that the size of the populations (κ) and the relative eet size in these populations
(a and b) are inluded together in the relative eets of the strategy omparison ontrasts
of both designs and annot be separated. However, in the relative eet of the strategy
omparison ontrast, they are separated in both designs. Therefore, the behaviour of ∇
and ∇SCC are dierent in eah design. For the parameters a, b, we onsider two dierent
models.
• Model 1: a = b = 0.5, i.e. treatments A1 and A2 dier in eay in the dier-
ent populations, the eet of the more suitable A-treatment is the same in both
populations.
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• Model 2: a = 0.5, b = 0, i.e. treatments A1 and A2 dier in eay in the dierent
populations, but the eet is the same in population P2.
In Panels a)f) of Figure 5.2, the results of the relative eets ∇ and ∇scc depending on
κ and ρ are presented. Panel a) of Figure 5.2 ompare the strategy omparison ontrast
of the three randomisation designs in model 1. We see that the CUtLASS2, 2 design has
a larger relative eet than the other designs for ρ > 0. If we hange the size of a and b,
only the height of plans will hange, not the position to eah other, beause the sum of a
and b works in Equations (5.19) and (5.21) suh as saling fator.
Panel b) of Figure 5.2 ompares the dierenes in strategy means in the three designs in
model 1. The position of three planes to eah other is the same in model 2. Furthermore,
the relative eet is larger in the CUtLASS2, 2 than in the POR2, 2 design for ρ > 0.5.
Panels )d) of Figure 5.2 show the strategy dierene and the strategy omparison
ontrast of the POR2, 2 design for the two models. We see that the ourse of the relative
eet of the dierene in strategy means depends on the model and on the omposition of
the populations. The piture is almost the same in the Panels e)f) for the CUtLASS2, 2
design.
a) Strategy omparison ontrast of
Block2, 2, POR2, 2 and CUtLASS2, 2
in model 1 (a = b = 0.5)
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b) Strategy dierene of
Block2, 2, POR2, 2 and CUtLASS2, 2
in model 1 (a = b = 0.5)
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) Strategy omparison ontrast
and strategy dierene of POR2, 2
in model 1 (a = b = 0.5)
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d) Strategy omparison ontrast
and strategy dierene of POR2, 2
in model 2 (a = 0.5, b = 0)
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e) Strategy omparison ontrast
and strategy dierene of CUtLASS2, 2
in model 1 (a = b = 0.5)
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f) Strategy omparison ontrast
and strategy dierene of CUtLASS2, 2
in model 2 (a = 0.5, b = 0)
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Figure 5.2: Relative eets ∇ and ∇SCC of the POR2, 2, CUtLASS2, 2 and Block2, 2 design
depending on the quality of physiian's deision ρ and the heterogeneity κ
between populations P1 and P2.
We see in all pitures that the relative eet in the POR2, 2 and the CUtLASS2, 2
design is positive if the quality of physiians' deisions fulls ρ > 0.5. If the physiian
deided in more than the half of the patients ases for the not optimal treatment (i.e.
ρ < 0.5), the relative eets beome negative. Therefore, besides the main hypothesis, the
other hypotheses presented in Subsetion 5.4.2 are very important to assess the quality
of patient-oriented deisions. If the quality of patient-oriented deisions is worse than the
Block design, the results of the study an hange in the wrong diretion. This is one of
the largest points of ritiism of the CUtLASS design: We an not evaluate the results of
suh a trial and we do not know about the quality of the physiians deision.

CHAPTER 6
Disussion and outlook
In this thesis we dealt with the general properties of a new trial design, the patient-oriented
randomisation design, whih was developed to ounter problems of `lassial' RCTs fa-
ing the high omplexity of therapeuti situations due to the presene of heterogeneity of
patient-drug-interations. The heterogeneity of patient olletives in medial are makes
strategy omparison with dierent treatments ontained in eah strategy espeially di-
ult. In the patient-oriented randomisation design, the patient-oriented seletion of treat-
ment was inorporated in a RCT-like design.
We started by investigating the basi properties of the patient-oriented randomisation
design to understand whih onsequenes are to be expeted due to the numbers of treat-
ments in eah strategy as well as the physiian's deision within the design. We have seen
that there are two main groups of two-pair ombinations (informative and mixed ombina-
tions) whih dier in the number of dierent treatments the physiians have to deide be-
tween. The informative ombinations oer the opportunity to asses physiians' preferenes
in the treatment hoie. If it is assumed that the physiians make onsious hoie (i.e.
no random hoie) in the presene of informative ombinations, a lear patient-oriented
deision for one of the two treatments (in one strategy) presented in that ombination
an be dedued. Analysing all lear patient-oriented deisions it may be derived that the
physiians prefer ertain treatments over others. Moreover, the informative ombinations
ensure that eah study treatment ours in a known minimum number of treated patients.
Therefore, we onsidered the alloation probability of all treatments in eah strategy in
the patient-oriented randomisation design ompared to the alloation probabilities in the
balaned blok randomisation design for two strategies and in the CUtLASS design. In
ontrast to the blok randomisation design, the alloation probability of eah treatment is
not xed a priori but depends on the physiians' deisions in the patient-oriented designs.
However, the range of the alloation probabilities in the CUtLASS design is larger than
that in the patient-oriented randomisation design. The minimum alloation probability in
the CUtLASS design is zero, whereas the minimum alloation probability in the patient-
oriented randomisation design is larger than zero. `Hene, we are able to ompute the
number of patients needed to avoid poorly represented and poorly powered omparisons'
(Shulz et al., 2016b). However, in ase that patients are intolerant of a single treatment
they have to be exluded from the study, sine one treatment an not be totally deseleted
suh as in the CUtLASS design.
Although the main fous in this thesis was on the properties of the new study design, the
important question onerning the feasibility of the implementation was also dealt with. We
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have a look at the implementation of the new design in the performed NeSSy study. `Even
though the study design used in [the℄ NeSSy [study℄ looks more ompliated [than ordinary
designs℄ due to the integration of a linial deision, the study was not so inonvenient
for physiians and study nurses that they had diulty following the proedures or were
unwilling to ollaborate. On the ontrary, the personnel feedbak shows that they felt
themselvestheir onerns for the patient and their expertiseto be taken more seriously'
(Shulz et al., 2016a). The patient-oriented randomisation design `has been evaluated very
positively by the physiians at the trial entres. Physiians found the design suitable and
pratial in its benets. [...℄ Furthermore, patients partiipate more readily in the study
design beause they feel that their individual experiene and needs are being taken into
aount' (Shulz et al., 2016a). The demonstrated feasibility of this new biometri design
is an important result. However, the NeSSy study also pointed out that the probability of
imbalanes in strategies in a patient-oriented randomisation design is large beause of the
large minimum blok length (number of two-pair ombination multiplied with the number
of strategies) in the randomisation list. Additional investigations assessed the probability
of imbalanes in strategies as well as in the two-pair ombination frequenies. It turned out,
that minor modiations in the randomisation list derease the probability of imbalanes
without hanges in the implementation of the study design.
With respet to pratial appliation we presented a statistial model to evaluate nor-
mally distributed endpoints in an unbalaned one-way lassiation with xed eets and
the onept of ontrasts whih an be extended independent of the design used. We have
seen that not only the main strategy omparison ontrast is of partiular interest but also
hypotheses dealing with onsequenes from the patient-oriented deisions. `Paradoxially,
the main limitation of this design emerges from the issue it solves: it is the physiian's
experiene and knowledge that make strategy omparison in a heterogeneous patient group
possible.' (Shulz et al., 2016a) Yet patient-oriented designs suh as the CUtLASS design
and the patient-oriented randomisation design only work as well as the physiians seleting
the treatments. In ontrast to the CUtLASS design, in the patient-oriented randomisa-
tion design, it is possible to prove whether the patient-oriented hoie results in a more
eetive treatment due to the spei random design. Therefore, we distinguished (some-
times with supplementary information from the physiian) between patients reeiving the
treatment not only due to randomisation but due to a patient-oriented deision of the
physiian (patient-oriented treated patients) and patients reeiving the treatment due to
randomisation's reasons (randomised hoie treated patients). After that we were able
to test the dierene in treatment means between patient-oriented treated patients and
randomised hoie treated patients in eah treatment, eah strategy, or overall. In parti-
ular, the possibility to analyse the dierene between strategies for subgroups onsisting
of only randomised hoie treated patients or only patient-oriented hoie treated patients
may help to test the assumptions about the heterogeneity of patient-drug-interation in
the patient-oriented randomisation design. Furthermore, we have seen that in a blok
randomisation design under ertain onditions there is no treatment eet observable, no
matter how many patients are reruited, while using a patient-oriented randomisation de-
sign would lead to observable treatment eets. The results of the CUtLASS design may
go in the `wrong' diretion without one even notiing it due to the non-optimal physiian's
deision. Therefore, both study designs the CUtLASS design and the blok design are
ethially questionable if strategies are ompared in presene of heterogeneity in patient-
drug-interations.
The patient-oriented randomisation design bridges the gap between methodologial re-
stritions of evidene-based mediine and daily linial impressions of physiians in the
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presented set-up and responds to the need for a next step in evidene-based mediine, that
of `integrating individual linial expertise with the best available external linial evidene
from systemati researh'(Sakett et al., 1996).
We onlude with an outlook on potential subjets of future researh based on the trial
design presented in this thesis. First of all, it seems natural to expand the theory to more
than two strategies. In this ase, the presented formulas and theories have to be adjusted.
Furthermore, our investigations showed that the sample size alulation depends parti-
ularly on the unknown alloation of treatments' sample sizes in ase of balaned strategies'
sample sizes. However, the onsiderations from Chapter 4 on imbalanes in strategies per-
mit more extreme values of η than we observed in Chapter 5. For large imbalanes in
strategies and for dierent modiations of the randomisation list the theory involving η
has to be adjusted.
`Additionally, the design provides the opportunity to learn more about therapeuti
deisions in heterogeneous patient populations. Here, the diering individual medial his-
tories, risk fators, and soial and ultural perspetives are aounted for through analysing
the doumented reasons for therapeuti deisions based on these patient harateristis'
(Shulz et al., 2016a). In this ontext, it is important to reate a good ase-report-form,
whih douments the reasons for the physiian's hoie systematially. Additionally, it
would also be interesting to know whih treatment the physiian presumes the patient to
be alloated to after a ertain time and the reasons for the presumption.
Further researh an be performed on the question of how to implement patient-oriented
deisions in other study designs. One approah would be to let the physiian hoose the
treatment most suitable in his opinion and in parallel to randomly hoose a treatment and
then to randomise between these two treatments. This design inorporates the patient-
oriented approah and allows for treatment omparison as well as omparison between
patient-oriented deision and random deision.

APPENDIXA
R programs
The following R programs an be found on the appended CD:
Chapter 4: Balane behaviour and pratial implementation
Overview of the programs.
−→ 00_Overview_programs.R
Figures of frequenies of patient per entre and per two-pair ombination (f. Figures
4.3, 4.2 and 4.7).
−→ 01_Figures_frequenies.R
Simulation study basi program for a PORk, l designs, whih determines the strategy
imbalane.
−→ 02_Simulationstudy_basi.R
Simulation studies with NeSSy study onditions inluding the same distribution of
patients per entre. Results are shown in histograms of imbalanes in strategies and
two-pair ombinations (f. Figures 4.5, 4.6 and 4.8).
−→ 03_Histogram_imbalanes.R
Simulation studies with NeSSy study onditions inluding the same distribution of
patients per entre, but using a randomisation list with sub groups (modiation I).
The result is shown in one histogram of imbalane in strategies (f. Figure 4.9).
−→ 04_Histogram_strategy_imbalane_mod_I.R
Simulation studies with NeSSy study onditions inluding the same distribution of
patients per entre, but using a randomisation list with sub groups (modiation
I). The result is shown in one histogram of imbalane in two-pair ombination (f.
Figure 4.10).
−→ 05_Histogram_TPC_imbalane_mod_I.R
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Simulation studies with NeSSy study onditions inluding the same distribution of
patients per entre, but using a randomisation list with sub groups and a Latin square
(modiation II). Results are shown in histograms of imbalanes in strategies and
two-pair ombinations (f. Figure 4.11).
−→ 06_Histogram_imbalane_mod_II.R
Chapter 5: Statistial analysis
Sample size alulation for the NeSSy study for dierent ηs (f. Figure 5.2).
−→ 07_Sample_size.R
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